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ABSTRACT 
 
Oesophageal squamous cell carcinoma (OSCC) has a high prevalence in the Asiatic belt and 
areas of Africa. In South Africa (SA), the incidence of this cancer in the Eastern Cape is one of 
the highest in the world. The molecular carcinogenesis of this disease remains unresolved. 
Single nucleotide polymorphism (SNP) array technology provides a high resolution 
technique to determine DNA copy number imbalances across the whole genome. DNA copy 
number changes can affect oncogenes and tumour suppressor genes, contributing to 
carcinogenesis. The aim of this study was to map common chromosomal break points 
previously identified in five SA OSCC cell lines by multi colour fluorescence in situ 
hybridisation (FISH) and to characterise copy number changes in  these cell lines and OSCC 
patient’s specimens using  SNP array technology. Genome wide copy number analysis was 
performed on the cell lines and 51 OSCC retrospective samples from the Eastern Cape 
region using Affymetrix® 500K SNP arrays. A number of genes were significantly affected by 
copy number changes across specimens. The copy number status of some of these 
candidate genes identified by arrays, were verified by (FISH) in a subset of the samples. 
Expression of the EPHA3, FGF3, FGF4, FGF19 and C-MYC candidate genes was assessed in 
the cell lines and four fresh samples. The common translocation break point previously 
detected in 5 cell lines involving chromosome 3p11.2 correlated with deletions affecting the 
EPHA3 gene in 4 of the 5 cell lines and was deleted in 74% of the OSCC cohort. EPHA3 is an 
ephrin A3 receptor tyrosine kinase that has been shown to have both oncogenic and tumour 
suppressor functionality. In addition, significant regions of amplification and deletion 
identified genes (CCND1, C-MYC, FHIT, SFRP1, SFRP2, FGF3, FGF4, FGF19, SMAD4, SMAD6 
and FBXW7) involved in the Wnt, TGF-β and FGF. Deletion of the genes, WRN, ATM, RAD18 
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and XRCC4 involved in DNA repair pathways, may contribute to genetic instability that is 
characteristic of OSCC. This study has highlighted some molecular pathways that may 
contribute to better understanding carcinogenesis of OSCC in South Africa. 
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1.1 Oesophageal Squamous Carcinoma: Epidemiology and risk factors 
Overview 
Oesophageal squamous cell carcinoma (OSCC) is a major cause of cancer death worldwide 
and has been linked to geographically endemic regions including Northern Iran, China, 
Japan, Central Asia, South America, African Americans in the US and Northern France (Islami 
et al., 2009). In South Africa, it has one of the highest incidences in the world, in particular it 
is endemic to the Eastern Cape and to a lesser extent, Johannesburg and the Western Cape 
regions (Denver Hendricks & M Iqbal Parker 2002.; van Rensburg 1987). According to the 
most recent cancer registry operating in the Eastern Cape alone, OSCC is the leading cancer 
affecting men and second most common cancer in woman residing in the region, with a 
prevalence of 31.3 and 18 per 100 000 individuals respectively (Somdyala et al., 2010).  
Tumours are diagnosed at very advanced stages of the cancer and thus these patients have 
a poor survival rate (Khushalani, 2008). Surgery has low cure rates due to this factor, as the 
disease has in most cases metastasized. The aetiology of this cancer is unresolved and while 
the most common risk factors associated with OSCC include smoking and alcohol 
consumption, these factors are surprisingly lacking in areas of high incidence such as in Iran 
and northern parts of China (Islami et al., 2009).  Additional risk factors have been proposed 
to play a role in some regions. In particular, exposure to fumonisin, a Fusarium fungi toxin 
that grows on maize, is reported in South Africa and China (W. F. Marasas et al., 1979; G. 
Sun et al., 2007) as well as human papillomavirus (HPV) infection (Sitas et al. 2007; Yao et al. 
2006). Poor nutrition is associated with OSCC in most parts of the world (Pacella-Norman et 
al., 2002; Islami et al., 2009) and chronic inflammation was described in endemic parts of SA 
(Matsha et al., 2006). The respective part played by environmental risk factors and a 
potential genetic susceptibility remains unclear and it is possible that different combinations 
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of factors may be at play in different areas of the world. In the USA, the incidence of OSCC is 
48% higher in Hispanic males than non-Hispanic white males and the incidence in African –
American males is 70% higher than that of Hispanic males (Wu et al., 2007). Similarly, white 
South Africans smoke more than black South Africans, including those residing in the 
Eastern Cape region, however smoking is strongly associated with OSCC but the incidence of 
OSCC in white individuals is much lower (Sammon, 2007). These facts would suggest that 
there might be an ethnic predisposition to this form of cancer. The risk of OSCC is certainly 
linked to the socioeconomic status, with poorer populations being the most affected (Islami 
et al., 2009; K. M. De Groot, 2006).  
Although numerous studies on OSCC have been done, which have highlighted the genetic 
complexity of this disease, very little has been translated into clinical, prognostic and 
treatment practices. Resection was the main mode of OSCC treatment in the past. However, 
the failure rates were high with survival not exceeding 18 months (Khushalani, 2008). Now 
the common practice internationally is neoadjuvant chemoradiation therapy, i.e. 
administration of radiation-sensitising chemotherapeutic drugs and radiation prior to 
resection. The 5 year survival rate, which is rarely above 25%, is poor no matter what mode 
of treatment is currently used (Khushalani, 2008). This highlights the need for a better 
understanding of the underlying mechanisms involved in the development and progression 
of this disease. Some of the main risk factors and molecular markers associated to OSCC are 
discussed below. Despite the numerous studies, no clear genetic aberrations that are linked 
to common molecular pathways have been identified in OSCC.  
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Maize consumption and OSCC 
In the past sorghum was the staple diet in South African regions endemic for OSCC; however 
this changed to maize since the onset of the 20th century, similarly to the onset of the OSCC 
epidemic (Isaacson 2005). Maize is now the dietary staple of populations residing in rural 
and subsistence farming regions of Africa and in particular the Eastern Cape region of South 
Africa is known as a high maize consuming area with high levels of fumonisin contamination 
(G S Shephard et al., 2007). The fumonisin mycotoxins are produced in maize by the 
Fusarium verticilliodes and Fusarium moniliforme fungi. These toxins have been associated 
with the risk of acquiring OSCC (W. F. Marasas et al., 1979). Even though maize used for 
consumption is visibly separated out from mouldy maize in households, the estimated 
fumonisin exposures were detected to be higher than the provisional maximum tolerable 
daily intake for fumonisin B1 and B2 of 2ugkg-1body weight day-1 (G S Shephard et al., 2007).  
Fumonisins can be present in maize beer and could be a significant additional source of 
toxin. This beer, along with non-alcoholic lactic acid fermented beverage made from local 
maize, could contribute to fumonisin intake (Gordon S Shephard et al., 2005; G S Shephard 
et al., 2007). Despite these mycotoxins being shown to be hepatocarcinogenic and 
nephrocarcinogenic in rats (Howard et al., 2001; W C Gelderblom et al., 1991), these studies 
could not detect changes to the oesophageal epithelium in these rats. There is still a need to 
determine a direct relationship between Fumonisin toxin and OSCC carcinogenesis.  
Another mechanism proposed for OSCC risk associated with maize consumption is that 
maize meal is high in linoleic acid content, a precursor of prostaglandin E2 (PGE2) (A M 
Sammon & Iputo, 2006). The consumption of maize and a low fat diet are associated with 
elevated PGE2 production (Sammon & A. Morgan 2002). Elevated PGE2 production causes 
lower gastric acid production and causes relaxation of the lower oesophageal sphincter. 
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Lowered gastric acid production and reflux due to a relaxed sphincter has been associated 
with a risk to develop OSCC (A M Sammon & Iputo, 2006). However, the authors show no 
experimental evidence to support their hypothesis that elevated PGE2 levels are directly 
linked to reflux of gastrointestinal juices into the oesophagus.  
Perhaps a more solid implication for elevated PGE2 is that PGE2 itself has been implicated in 
tumour cell growth. PGE2 stimulates G-protein coupled receptors (EPs), which are proposed 
to mediate over expression of C-MYC through protein kinase C and extracellular signal 
regulated kinase (ERK) thereby stimulating tumour growth (L. Yu et al., 2009). Over 
expression of EPs is also detected in 43.4% of OSCC cases (n=226), which was detected by 
immunohistochemical analysis and verified with western blotting (Kuo et al., 2009).  
Additional studies to corroborate these results would strengthen PGE2 as a candidate 
involved in OSCC.  
An additional factor at play in prostaglandin synthesis is Cyclooxygenase-2 (COX-2), which is 
a rate limiting enzyme in prostaglandin synthesis. COX-2 is often over expressed in many 
cancers (M. Sahin et al., 2009). COX-2 over expression is detected in 34-40% of OSCC 
tumours (n=68 and 108 respectively for the two studies) (N. Hashimoto et al., 2007; Boone 
et al., 2009). COX-2 inhibition with aspirin has been proposed as therapy for OSCC due to 
the observed COX-2 over expression (Umar & Fleischer, 2008). 
Smoking, alcohol consumption and OSCC 
Smoking and alcohol consumption are established risk factors associated with the 
development of OSCC and have a combined effect as well as acting independently with a 
dose-response relationship (Ganesh, Talole, & Dikshit, 2009; Pacella-Norman et al., 2002; 
A.H. Wang et al., 2004). Smoking is thought to contribute to the early and late stages of 
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OSCC carcinogenesis while alcohol consumption may only be associated with a later stage of 
carcinogenesis (Vos, Adams, Victor, & van Helden, 2003).  
Generally in the Eastern Cape region the tobacco is home grown and is said to be more 
carcinogenic than commercial cigarettes, possibly due to the higher content of N-
Nitrosamine compounds (Vos et al., 2003).  Cigarette carcinogens can cause a number of 
DNA lesions such as apurinic/apyramidinic (AP) sites, modified bases, adducts, cross links 
and DNA strand breaks (Hang et al. 2010). N-nitrosamine compounds are one of more than 
60 known carcinogenic compounds in cigarette smoke and react with DNA to form DNA 
adducts. DNA adducts are regions of the DNA that are covalently bonded to a chemical, 
these affect the helical structure of DNA and lead to defective DNA pairing and synthesis 
(Hang et al., 2010). DNA adducts are known to be elevated in smokers and increase the risk 
for development of cancer (Hang et al., 2010). In addition to being a risk factor to develop 
OSCC, smoking is found to affect the outcome of patients on treatment. Patients with a 
history of heavy smoking had significantly lower 3 and 5 year survival rates compared to 
non-smokers or light smokers (Shitara et al., 2010). The exact mechanism is not known but 
likely, over expression of DNA repair enzymes may affect the efficacy of chemoradiation 
therapy (Shitara et al., 2010). 
Alcohol can act as a carcinogen through various mechanisms, including the DNA damaging 
effects of the alcohol metabolite, acetaldehyde, which causes oxidative stress (Millonig et 
al., 2011). Several enzymes are involved in metabolising alcohol, which have been 
implicated in the production of reactive oxygen species associated with alcohol induced 
carcinogenesis. A few of these enzymes are discussed later in this chapter. Alcohol 
consumption also aggravates mineral deficiencies, for example folate and folate deficiency 
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is another factor associated with the incidence of OSCC (van Rensburg, 1987). Folate (a 
water soluble vitamin B) is required for DNA synthesis, repair and methylation by donation 
of one carbon units, which are involved in cellular metabolism (Bailey 2003). Alcohol 
contributes to folate deficiency by inhibiting its absorption and increasing its excretion 
(Bailey, 2003). It can also impair folate metabolism by inhibiting folate metabolising 
enzymes, e.g. Methylenetrahydrofolatereductase (MTHFR) (van Rensburg, 1987; Bailey, 
2003). MTHFR is responsible for the conversion of folate to 5-methyltetrahydrofolate (5-
methyl THF), which is required for methionine production. The 5-methyl THF compound is 
metabolised by thymidylate synthase (TS), which uses the methyl group to convert 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). 
Depletion in folate causes a lack of this process and accumulation of dUMP, which is mis-
incorporated into DNA in place of thymidine (Duthie, 2010). DNA repair enzymes excise the 
dUMP, which results in single stranded breaks and if folate remains at low levels, this cycle 
continues leading to chromosomal aberrations (Duthie, 2010). In addition to high levels of 
alcohol consumption, rural endemic regions do show dietary nutrient deficiencies, including 
folate (van Rensburg, 1987). Alcohol may therefore aggravate this deficiency and in this 
way, amongst other mechanisms, add to the risk of developing OSCC.  
Human Papillomavirus infection and OSCC 
Human Papillomavirus (HPV) infection has been associated with a number of cancers, 
especially cervical cancer (Matsha et al., 2002). The high risk HPV subtypes (higher risk 
association for development of cancer) are HPV16 and 18 while HPV6, 11 and 13 are lower 
risk types (McCabe & Dlamini, 2005). HPV has been linked to the aetiology of OSCC (P. F. Yao 
et al., 2006) but the reported prevalence of HPV in OSCC varies considerably. The frequency 
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ranges from 3.6% (n= 222) to, 30% (n=82) to, 56.1% (n= 435) in Western and Chinese 
populations (Antonsson et al., 2010; P.F. Yao et al., 2006; Xueqian Wang et al., 2010) and 
one Chinese study did not detect HPV in 272 OSCC cases analysed (Koshiol et al., 2010).  The 
discrepancy in reports is thought to be attributed to the difference and accuracy of 
detection methods, different sample types and the regions where samples are collected 
(Xueqian Wang et al., 2010). In SA, HPV subtype 11 is found to be the predominant subtype 
associated with OSCC, with 46% (n=50) and 44.7% (n=114) of cases being positive by PCR 
detection in two studies (Matsha et al., 2007; Matsha et al., 2002). Only 4.3% of cases were 
positive for the high risk subtype 16 (Matsha et al., 2002). These findings would suggest that 
HPV infection may be associated with OSCC incidence, although this is unlikely as the low 
risk subtype 11 is predominant in SA. 
The mechanisms proposed for HPV in carcinogenesis is through the E6 and E7 proteins. 
Expression of the HPV16 oncoproteins, E6 and E7, was observed to induce chromosomal 
aberrations (H. Zhang et al., 2006) and the expression of proteins such as telomerase, c-myc, 
ras, bcl-2 and p53 are altered in the presence of HPV18 oncoproteins E6 and E7 (Z. Y. Shen 
et al., 2001). The de-regulated expression of these proteins results in loss of apoptosis and 
uncontrolled cell growth (Z. Y. Shen et al., 2001). Oesophageal cells immortalised by HPV16 
also showed gain of chromosome 20q, which suggested that this aberration was an early 
event in the process of oesophageal squamous cell immortalisation (Zhang et al., 2006). 
There is still no evidence of HPV directly causing OSCC. 
Chronic inflammation and OSCC 
Chronic inflammation can be induced by biological, chemical and physical factors and 
induces oxidative stress and lipid peroxidation (Bartsch & Nair, 2006). These processes can 
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lead to the production of reactive oxygen species and DNA reactive aldehydes, which cause 
DNA damage (Helmut Bartsch & J. Nair, 2006). Chronic inflammation is proposed to be 
associated to, or to act as a precursor to the development of OSCC (Matsha et al., 2006). 
The endemic area of South Africa, the Eastern Cape, is populated by a majority of Xhosa 
speaking people who follow a cultural tradition of self–induced vomiting.  This ritual is 
considered as either a biological cleansing or spiritual cleansing and the most common 
mode of induction is through the consumption of sea water or salt water (Matsha et al., 
2006).  Only one study showed that self induced vomiting is strongly associated with chronic 
inflammation of the oesophagus, however the methodology used in the study by Matsha et 
al (2006) did not differentiate between other possible causes of inflammation such as 
infection or exposure to irritants such as smoking and alcohol, which could have affected 
their results (Matsha et al., 2006). Additional studies on chronic inflammation in OSCC are 
still required to establish if self-induced vomiting has a direct impact on OSCC development.  
 
1.2 OSCC  Molecular biology 
OSCC is difficult to stage on pathological features alone and the heterogeneous nature of 
the tumours presents a problem using standard methods (Nair et al., 2005). Patients with 
lymph node metastases and organ infiltration do poorly in comparison to those patients 
with minimal tumour invasion (Nair et al., 2005). It would be of great benefit to identify 
molecular markers related to tumour invasion in the interest of using them as prognostic 
and diagnostic indicators.  Many studies have investigated various molecular factors 
involved in tumour development and progression such as, factors of cell adhesion, repair 
genes, chemokines, gene polymorphisms, oncogenes and tumour suppressor genes. Most 
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studies have been done abroad and a few studies were done in SA. Some of the most 
important molecular factors that emerged in these studies are discussed below and the 
details of publications describing these factors from multiple studies are summarised in 
Table 1.1. 
Adhesion molecules 
The first step for cancer cells to metastasize is for them to detach from the tumour, which 
can occur when there is de-regulation of cell-cell adhesion and cell-matrix interactions (K. S. 
Nair et al. 2005). The cell adhesion molecules (CAMS) are critical in this process. There are 
several families of CAMS involved in adhesion, which include integrins, cadherins, 
immunoglobulins and selectins.   
The integrins are transmembrane glycoproteins that are important in the control of 
attachment, migration, cell division and apoptosis. They exist as alpha or beta heterodimers 
at focal adhesion sites and have extracellular domains (acting as receptors in the 
extracellular matrix) and intracellular domains, which bind to the actin cytoskeleton (K S 
Nair et al., 2005). Under normal conditions, integrins are stimulated by the extracellular 
matrix to mediate adhesion and inactivation of integrins prevents adhesion at inappropriate 
times. It only was shown by one study in SA that α2 and β1 integrin subunits were under 
expressed, suggesting that there is decreased adhesion in OSCC (S. E. Miller & Veale, 2001). 
In another study, alpha4-integrin was hypermethylated in 21% of OSCC tumours (n=251) (E. 
J. Lee et al., 2008). This study only assessed the methylation status of the gene promoter 
and did not show whether gene expression was affected by the methylation status although 
methylation was associated with disease recurrence and a poor survival (E. J. Lee at al., 
2008). The β1 integrin subunit was also shown to have low expression in 71 OSCC lymph 
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node metastases in Japan (Takayama et al., 2003). These three independent studies have 
not been repeated and provide little evidence to support a role for decreased expression of 
integrins in OSCC.  
Increased expression of some integrins has been associated with the ability of cancerous 
cells to adhere to the vascular endothelium, which is required in the process of migration. 
One study showed strong expression of the α5 integrin in tumour samples and not in the 
normal epithelium, this is likely to allow for the adhesion to endothelial vessels required for 
migration and as a result this may increase the metastatic potential of OSCC cells (S. E. 
Miller & Veale, 2001). In another study, α2β1 and α3β1 integrins were similarly over 
expressed in OSCC cells cultured with endothelial cells and the authors observed in culture 
that this enhances migration of cells to extravascular tissues (M Sato et al., 1996).  
The cadherins are a family of membrane glycoproteins that are required for cell-cell 
adhesion in normal cells. E-cadherin is one of the most important cadherins in epithelial 
cells and has been the most extensively studied in OSCC. Reduced expression of E-cadherin 
results in OSCC cells having a higher metastatic potential (K S Nair et al., 2005; Kriebashne S 
Nair et al., 2006). E-cadherin was found to be absent in 57% of SA OSCC tumours (n=100) 
(Kriebashne S Nair et al., 2006), however expression was assessed by immunohistochemical 
analysis and could not be directly related to prognosis. A mechanistic role for reduced E-
cadherin in OSCC carcinogenesis was shown by one study, where exposure of cells to 
endothelial proteins (e.g. SHEAR) resulted in internalisation of E-cadherin in an OSCC cell 
line, which increased invasiveness of the cells (Lawler et al., 2009). Methylation of the CDH1 
gene (encoding E-cadherin) was detected in 43% (n=251) and 42.3% (n=71) of OSCC tumours 
(E. J. Lee et al., 2008, Chung et al., 2007). Two studies showed that the methylation status of 
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the CDH1 gene in stage I OSCC was strongly associated with a high risk of recurrence (E. J. 
Lee et al., 2008) and lymph node metastasis (Takayama et al., 2003.). These studies all 
applied immunohistochemistry to establish the expression levels of E-cadherin and only one 
study (Lawler et al., 2009) looked at the functional impact of E-cadherin expression in a cell 
line.   
Catenins are cytoplasmic proteins closely related to the cadherins that bind cytoplasmic 
domains of cadherins to the cytoskeleton. One study showed that reduced expression of E-
cadherin correlated with lower levels of β-catenin in the cytoplasm (Takayama et al., 2003). 
It was found that in 46 primary OSCC tumours, 56% of cases had similar expression of E-
cadherin and α-catenin while 46% had expression of E-cadherin in some of the tumour cells 
and no α-catenin expression (Kadowaki et al., 1994). Kadowki et al (1994) showed that α-
catenin was only expressed when normal E-cadherin was present, suggesting that E-
cadherin is required for α-catenin stability. Regardless, there are no functional studies to 
corroborate this hypothesis and it is only based on one method, immunohistochemistry. 
Forty eight percent of tumours showed no expression of α-catenin while E-cadherin was still 
expressed; suggesting that α-catenin is downregulated earlier in metastasis than E-cadherin. 
Reduced expression of α-catenin was correlated with invasion and lymph node metastasis 
(Kadowaki et al., 1994). 
CD44 is a transmembrane glycoprotein which binds ligands in the extracellular matrix and is 
involved in cell-matrix adhesion. CD44 has a variable affinity to bind hyaluronic acid, which 
allows for binding to other ligands. The down regulation of CD44v2 is associated with a poor 
prognosis in OSCC (K S Nair et al., 2005). Two studies detected lowered expression of 
CD44v6 in OSCC (Roye et al., 1996; Takayama et al., 2003). One study showed that low 
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expression of CD44v6 had a significant correlation with lymph node metastasis (n=71) 
(Takayama et al., 2003). CD44v3 and CD44v6 expression patterns differed from normal, 
dysplastic, moderately differentiated carcinoma and poorly differentiated tumours with the 
highest expression of these variants observed in the normal epithelium (Roye et al., 1996), 
suggesting that the lowered expression of these variants is associated with disease 
progression.  In contrast, three studies showed that CD44v6 was over expressed in 64.6% of 
OSCC (n=82) cases, 71.43% of cases (n=21) and 46.9% of cases (n=38), which had a 
correlation with lymph node metastasis (Wen-Kang Liu et al., 2009; DM. Li et al., 2005; 
Nozoe et al., 2004). All these studies were performed using the subjective method, 
immunohistochemistry, which could account for the contradictory results and highlight the 
need to clarify the exact role of CD44 and its isoforms in OSCC.  
A newer candidate gene being investigated in OSCC is cortactin (CTTN), a cytoplasmic 
protein also involved in cell adhesion and cytoskeletal structure. This gene is on 
chromosome 11q13.3, a region frequently amplified at the DNA level in OSCC (Man-Li Luo et 
al., 2006). CTTN is highly over expressed in 43.5% of OSCC cases (n=46) and 47.8% had high 
expression but at a lower level (K. F. Hsu et al., 2009). Over expression of CTTN has been 
detected in pre-malignant lesions, suggesting its involvement in carcinogenesis (N. Y. Hsu et 
al., 2008). Another study studied the expression of CTTN by immunohistochemical analysis, 
reverse transcriptase PCR (RT-PCR) and gene amplification by PCR and fluorescence in situ 
hybridisation (FISH) analysis. Fifty percent of primary tumours (n=16) had CTTN gene over 
expression by PCR analysis, 68.8% (n=125) had a strong immunohistochemical staining, 
which correlated with tumour stage and lymph node metastasis while amplification (as 
detected by FISH and PCR) was detected in 70% of samples (n=20) (Man-Li Luo et al., 2006). 
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This study showed that gene amplification correlated with over expression in 70% of 
tumours and over expression of CTTN was associated with lymph node metastasis, a strong 
indication that CTTN has a role in OSCC.  Luo et al (2006) also performed RNA interference 
(RNAi) experiments in EC9706 cells (OSCC cell line), which were inoculated into nude mice. It 
was found that knock down of CTTN resulted in these cells growing slower in nude mice 
than in mice inoculated with EC9706 cells without RNAi against CTTN (Man-Li Luo et al., 
2006). They concluded that CTTN is an independent marker for lymph node metastasis and 
promotes tumour invasiveness in OSCC (Man-Li Luo et al., 2006). CTTN expression was 
correlated with activation of the PI3K/Akt pathway, which is proposed to facilitate 
resistance to anoikis (programmed cell death initiated by cell detachment), which may allow 
survival of cells in circulation (X. L. Du et al., 2009; Man-Li Luo et al., 2006). These studies 
show good evidence to highlight CTTN as a promising marker for further investigation in 
OSCC as it appears to be functionally relevant in OSCC carcinogenesis.  
It is evident from the literature that E-cadherin is the adhesion molecule with the most 
corroborative data to show that it is involved in the metastasis of OSCC. However the 
studies are not supported with functional analyses. On ther other hand, CTTN has good 
evidence to show a functional role in OSCC. It is unclear from the work on the other 
molecules in the adhesion network whether they are of real importance. More information 
and a comprehensive understanding of the interactions and impact of all these adhesion 
molecules are required to see if they can be used as markers of diagnosis and prognosis. 
Studies involving more samples, alternative methods and a collective effort on the adhesion 
molecule network could help in this regard. Specifically, whole genome studies could show 
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aberrations in multiple molecules involved in adhesion, which could facilitate identifying 
those that may work in combination.  
Repair genes 
The mismatch repair genes are important for the detection and correction of errors in DNA 
sequence that arise during cell division. Mutation of both alleles of mismatch repair genes 
results in DNA mismatch repair being defective and consequently, the accumulation of 
mutations occurs in the DNA (Vasavi et al. 2010). The mismatch repair gene most well 
studied in oesophageal cancer is hMLH1. Most studies have been performed in China and 
India assessing the methylation status and microsatellite instability (MSI) of this gene. A 
series of studies show methylation of the hMLH1 gene in 27-85.7% of OSCC cases (case 
numbers ranged from 30 to 125) with this frequency increasing with disease progression. 
Methylation of hMLH1 is therefore associated with a poor prognosis (Mohan Vasavi et al., 
2006; Uehara et al., 2005; M Vasavi et al., 2010). Fifty percent of pre-cancerous lesions 
(n=13) in one study had methylation of hMLH1 with MSI (M Vasavi et al., 2010), the authors 
suggest that hMLH1 inactivation may occur early in oncogenesis, but due to the small 
number studied, this would need to be analysed in a larger sample size to prove that hMLH1 
inactivation is an early event. None of these studies were verified by an alternative 
technique to establish whether expression of hMLH1 is affected and whether this does 
indeed result in defective DNA repair in patients with OSCC. This gene has been studied in 
SA in one study. Microsatellite instability (MSI) analysis of 6 markers located at mismatch 
repair gene loci (hMLH, hPMS1, hPMS2, hMSH2, HMSH3 and hMSH6) showed a low 
frequency of aberrations in 100 OSCC patients in South Africa. Loss of heterozygosity (LOH) 
was found more frequently than MSI in the microsatellite loci analysed and specifically in 
chromosome 3 (D3S659 and D3S1255, hMLH1), which was detected in 40% of the cases (R 
16 | P a g e  
 
Naidoo et al., 2005). Naidoo et al (2005) concluded that no predisposition could be 
associated with any of these loci in OSCC and that the molecular pathway for OSCC is 
something involving genes other than the mismatch repair genes (R Naidoo et al., 2005). 
However, the study only investigated 100 tumours and normal epithelium, it is unclear if the 
normal epithelium was obtained from the same patients or not and only a clear case control 
study could determine whether MSI at these loci contributes to a predisposition for OSCC or 
not.  
Chemokines 
Chemokines and their receptors stimulate the recruitment of leukocytes through chemo 
attraction and CXC chemokines (chemokines with a C-X-C motif) play a role in inflammatory 
responses (B. Wang et al., 2006). They have also been linked to cancer and tend to show 
over expression in various cancer types for example, the CXC chemokine family member, 
Growth-related oncogene alpha (GROα) and its receptor chemokine receptor 2 (CXCR2) act 
as growth factors and are over expressed in melanoma and prostate cancer cells (B. Wang et 
al., 2006). In South Africa, one study examined the chemokine GROα and the receptor 
CXCR2 in OSCC. Only 4 tumours and matching normal epithelium were studied and a two to 
five fold increase in expression of GRO α and β was found in these tumours (B. Wang et al., 
2006). RNA interference against GROα and GROβ in the South African OSCC cell line 
WHCO1, resulted in 20% and 50% decrease in cell proliferation respectively. The authors of 
this study suggested that GROα-CXCR2and GROβ-CXCR2 signalling pathways contribute to 
OSCC proliferation and may be involved in OSCC development (Wang et al., 2006). These 
studies are too small to show real significance of these proteins in OSCC and their results 
need to be corroborated by larger studies.  
17 | P a g e  
 
Wang et al (2009) investigated expression of the EGR-1 (early growth response-1) gene, 
which they reported to be over expressed in 80% of OSCC tumours (n=65) and four OSCC 
cell lines (WHCO1, WHCO5, WHCO6 and KYSE 450) (B. Wang et al., 2009). EGR-1 protein 
knockdown in the WHCO1 cell line resulted in a 50% reduction in cell proliferation, 50% 
reduction in Cdkn-4 levels and mediated GRO/CXCR2 proliferative signalling (Wang et al., 
2009). Wang et al (2009) suggested that this protein could be a therapeutic target in OSCC. 
This study also needs to be corroborated with additional research by other groups.  
Five studies from China and Japan investigated the expression of CXCL12 and its receptor 
CXCR4. All three studies found that both CXCL12 and CXCR4 were strongly expressed in 
OSCC primary tumours (numbers were 86 to 214 samples) and two of the studies found that 
CXCL12 expression correlated with lymph node metastasis while CXCR4 did not (Lu et al. 
2010; D.F. Wang et al. 2009; K. Sasaki et al. 2008; K. Sasaki et al. 2009; Gockel et al. 2007).  
Again, these studies are lacking in additional methods to support their 
immunohistochemistry results. There is still not enough evidence to say that chemokines 
are clinically relevant to OSCC. 
Genetic polymorphisms associated with risk of OSCC development. 
Metabolic enzymes responsible for metabolism of carcinogenic compounds, such as those in 
cigarette smoke and alcohol, have been investigated due to risk association to develop OSCC 
with smoking and alcohol consumption. Genetic polymorphisms in these genes are thought 
to contribute to this risk of developing OSCC.  
Sulfate conjugation is involved in pathways responsible for the metabolism of carcinogenic 
compounds such as catecholamines, aromatic amines and certain drugs. This sulfation is 
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carried out by sulfotransferases, encoded by the SULT gene family (Glatt et al. 2001). The 
enzyme is important in the metabolism of heterocyclic amines and polycyclic aromatic 
hydrocarbons, components of cigarette smoke (Glatt et al. 2001). SULT1A1 polymorphisms 
are associated with a higher risk to develop breast cancer and colorectal cancer (M.T. Wu et 
al., 2003; Cleary et al., 2010) and specifically the G--→A transition at codon 213 (SULT1A1*2 
allele) confers a reduced enzyme activity and stability (Glatt et al., 2001; Weinshilboum et 
al., 1997). Only two studies have looked at these genes in OSCC, one in Taiwan and one in 
South Africa. The SULT1A1*2 allele was found in 27.8% of OSCC cases (n=187) in Taiwan, 
which was significantly higher than controls (n=308). This allele (SULTA1*2) was associated 
with a 3.53 fold higher risk of developing OSCC in Taiwanese men (M.T. Wu et al., 2003). The 
SULT1A1*2 allele was investigated in the black and mixed ancestry populations in SA. The 
polymorphism in a homozygous state (SULT1A1*2/*2) was detected with a frequency of 
32% in blacks and 31% in mixed ancestry individuals with OSCC compared to 20% (n=245) 
and 14% (n=288) in controls respectively. The presence of this homozygous genotype was 
associated with an increased risk for OSCC development in smokers (Dandara et al., 2006). 
Additional studies to corroborate this data are required.  
Alcohol dehydrogenases (ADH) metabolise alcohol into acetyldehyde, which is further 
metabolised into acetic acid by aldehyde dehydrogenase (ALDH).  Acetyldehyde is a known 
carcinogenic compound in this pathway (Jelski et al., 2009). Highly active ADH enzymes are 
associated with alcohol intolerance and low active ADH enzymes are associated with an 
increased risk for cancer development (Brooks et al., 2009). Three meta-analyses of ADH1B 
and ALDH2 gene polymorphisms in China and Japan from several studies, collectively 
looking at over 1000 patients and controls, showed that ADH1B (Arg/Arg) and ALDH2 
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(Lysine) genotypes have an increased risk to develop OSCC and interact significantly with 
alcohol consumption (G. H. Zhang et al., 2010; F. Tanaka et al., 2010; S. J. Yang et al., 2010). 
These particular genes have not been investigated in SA apart from ALDH2 polymorphisms. 
The Alcohol dehydrogenase 2 (ADH2) gene has two polymorphisms (ADH2*2 and ADH2*3) 
associated with increased activity of the enzyme. The ADH2*2 allele was associated with an 
increased risk to develop OSCC in a Chinese study of 221 cases and 191 controls (J. hua Ding 
et al., 2010). A case control study in 238 patients and 268 controls from South African black 
(n=125) and mixed ancestry (n=268) populations investigated frequencies of ADH2, ADH3 
and ALDH2 genotypes. The ADH2*1, ADH3*2, ADH3*2/*2 and ALDH2*2 alleles were 
significantly associated with an increased risk to develop OSCC in the black individuals, while 
the ADH2*2 and ADH2*3 alleles were only associated with increased production of 
acetaldehyde and a higher intolerance to alcohol (D. P. Li et al., 2008). Li et al (2008) suggest 
that the mechanism by which the ADH2*1 and ADH3*2 alleles may increase the risk for 
OSCC development could be due to a higher tolerance to alcohol. The higher tolerance of 
individuals for alcohol may result in prolonged consumption and high volumes of alcohol 
could act as a solvent for other carcinogenic compounds such as those from cigarettes and 
lead to induction of other carcinogen metabolising enzymes such as cytochrome p450 (D. P. 
Li et al., 2008). Interactions between polymorphisms in the ADH and ALDH enzymes with 
those polymorphisms in the cytochrome p450’s may add to the risk of OSCC development.  
The cytochrome p450 2E21 (CYP2E1) enzyme in particular, metabolises ethanol as well as 
nitrosamines, and may bio activate these potential carcinogens (D. P. Li et al., 2008). The 
gene contains several polymorphisms with contradicting reports on the effects on the 
expression of the gene and its protein function. CYP2E1 was recently shown to be induced in 
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a dose dependant manner in the oesophagus by ethanol (Millonig et al., 2011) and various 
studies in Chinese and Japanese populations show that the CYP2E1*5 polymorphism 
(1293G→C) is associated with an elevated risk to develop OSCC (X. M. Lu et al., 2005; W. Tan 
et al., 2000; J. M. Qin et al., 2008; Y. M. Guo et al., 2008; R. Liu et al., 2007). CYP2E1 has not 
been extensively studied in the SA population. One study investigated three polymorphisms 
and have conflicting reports on the effects on expression and function of the gene, 
1053CT, 1293GC and 7632TA. The study was performed on 189 patients with OSCC 
and 198 controls from black and mixed ancestry populations (D. Li et al., 2005). The 
polymorphism with the highest frequency was the 7632TA polymorphism, detected in 
18% of patients (n=189) as opposed to 7% (n=198) in control individuals. The CYP2E1*6 
polymorphism was associated with an increased risk of developing OSCC in SA as opposed to 
the more frequent CYP2E1*5 polymorphism detected in Chinese and Japanese populations 
(D. Li et al., 2005). A second study performed in SA, on 331 black individuals (70 cancers and 
261 controls), reported a higher frequency (95%) of the CYP2E1*1 polymorphism 
(1053C→T) also in contrast to the Chinese and Japanese studies (Chelule et al., 2006). 
However both these studies in SA have relatively small numbers and the first being on both 
black and mixed ancestry individuals does not clarify the frequency of these alleles in the 
black population where OSCC has the highest incidence. 
Overall, studies of genetic polymorphisms related to disease susceptibility require large 
numbers of subjects with and without disease to determine the significance of these alleles 
in specific populations. Although some of these genes involved in chemical metabolism 
maybe convincing in the Chinese and Japanese populations, further work is required to 
establish their role in the South African population affected by OSCC.  
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Oncogenes and tumour suppressor genes implicated in OSCC 
Oncogenes can be categorised into several classes including growth factors, growth factor 
receptors, nuclear factors and signal transducers all of which have been implicated in 
carcinogenesis.  
The growth factors and growth factor receptors stimulate cells to enter into the cell cycle. 
Growth factors have not been extensively studied in OSCC, however vascular endothelial 
growth factor (VEGF) has been implicated in OSCC in China and Japan by 
immunohistochemical anlaysis (summarised in Table 1.1). The growth factor, VEGF, is 
important in angiogenesis, an important process for tumour survival.  The VEGF gene is over 
expressed in a high number of tumours (43-100%) and is associated with tumour 
progression (Y Shimada et al., 1999; Okazawa et al., 2008.; P. Liu et al., 2009; Gholamin et 
al., 2009; Bedoya et al., 2009). These studies could only show a prognostic value for VEGF, 
no functional studies are available to show the direct impact of VEGF expression on OSCC 
carcinogenesis.  
The epidermal growth factor receptor (EGFR gene) is a tyrosine kinase transmembrane 
receptor and is often over expressed in lung and colorectal cancers (Ding et al. 2008; 
Dragovich & Campen, 2009). This receptor has sparked interest due to the development of 
targeted therapies against EGFR protein in the form of small molecule tyrosine kinase 
inhibitors and monoclonal antibodies (Dragovich & Campen, 2009). It is a promising gene in 
OSCC however, most studies only looked at over expression with immunohistochemistry 
and so should be evaluated using an alternative method as there is variation in the reported 
data. Over expression of EGFR is detected in OSCC as evidenced by a few studies from 
Japan, China, the Netherlands and France (summarised in table 1.1). Over expression was 
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detected at frequencies ranging from 34-75.8% (Gotoh et al., 2007; Hoshino et al., 2007; 
Gongyuan Zhang et al., 2010; Boone et al., 2009; Gibault et al., 2005).  Hoshino et al (2007) 
specified that 71.2% of OSCC specimens (n=52) show EGFR protein localisation at the cell 
surface and only 36.5% showed phosphorylated EGFR in the nucleus and the latter was 
correlated with a poor prognosis (Hoshino et al., 2007). Zhang et al (2010) detected EGFR 
mRNA by in situ hybridisation in 75.8% of cases (n=62), which correlated with tumour grade, 
invasion and lymph node metastasis (Gongyuan Zhang et al., 2010). Over expression of EGFR 
in primary OSCC was also correlated with the response of patients to chemoradiation 
therapy (Gotoh et al., 2007). The activation of EGFR protein is thought to contribute to 
transformation of oesophageal epithelium to squamous carcinoma under inflammatory 
conditions (Parthasarathy et al., 2010). EGFR gene amplification has also been reported, 
which is associated with over expression in 85-88.7% of the OSCC cases that had gene 
amplification (Hanawa et al., 2006; Carneiro, Isinger, Karlsson, J. Johansson, Jönsson, et al. 
2008). The sensitivity of patients to treatment using EGFR targeted therapies is still unclear 
and further work is required on the mechanisms by which EGFR acts in carcinogenesis in 
order to establish reliable molecular predictors of patient responses to this kind of therapy 
(Dragovich & Campen, 2009).  
The nuclear factor Cyclin D1 (encoded by CCND1) forms complexes with the cyclin 
dependent kinases, CDK4 and CDK6, which control the transition of cells from G1 to the S 
phase of the cell cycle. Over expression of the CCND1 gene results in deregulated cell 
division. A study looking at the effects of cigarette smoke extracts on the expression of 
CCND1 in an OSCC cell line (EC109), showed an increase in proliferation and CCND1 protein 
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levels in a dose responsive manner (H. Hu et al., 2009). The cyclin D1 protein levels reduced 
upon treatment with aspirin and resulted in decreased cell proliferation (H. Hu et al., 2009).  
CCND1 over expression and gene amplification with over expression, have been well 
documented in OSCC in more than 10 studies mostly conducted in USA, Japan and China 
(summarised in Table 1.1). CCND1 gene amplification and over expression is detected in 22-
73% of OSCC tumours and cell lines and several of these studies show a correlation with 
lymph node metastasis and a poor survival (S. Zhu et al., 1998; S. Fujii et al., 1998; H. Suzuki 
et al., 1998; Takeuchi et al., 1997; Roncalli et al., 1998; Shamma et al., 1998; Inomata et al., 
1998; R Chetty & S. Chetty, 1997; Sheyn et al., 1997; J. Zheng et al., 1996; Shinozaki et al., 
1996; Kitahara et al., 1996; H Nakagawa et al., 1995; W Jiang et al., 1993; W Jiang et al., 
1992; De-Chen Lin et al., 2010). One study from South Africa reported a minority of cases 
(29%, n=80) to have over expression by immunohistochemical analysis and over expression 
could not be correlated with histological grade (R Chetty & S. Chetty, 1997). This gene 
requires further investigation in the SA setting with only one study to date however, the 
CCND1 gene is a significant gene involved in OSCC pathogenesis and appears to be a useful 
prognostic marker.  
Over expression of the CCND1 gene can also occur through deregulation of the Wnt 
pathway as CCND1 is a transcriptional target of the TCF/β-catenin complex. The 
Adenomatosis Polyposis Coli (APC) gene is a tumour suppressor gene that is involved in 
antagonising the Wnt pathway. Loss of the APC protein contributes to accumulation of non-
phosphorylated β-catenin in the nucleus, which leads to deregulated cell division through 
transcription of target genes by the TCF/β-catenin complex. APC can be inactivated by 
hypermethylation of its promoter or by LOH/deletion (studies are summarised in Table 1.1). 
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Hypermethylation was found in 44.4% (n=45) and 46% (n=50) of OSCC tumours in two 
studies, however it is unclear whether this correlates with metastasis or a poor survival as 
each of these studies reports a different finding in this regard (Zare et al., 2009; Y. T. Kim et 
al., 2009). Expression of APC was lost in 30.4% (n=199) of late stage OSCC according to a 
study in China. Indeed APC expression decreases with undifferentiated tumours; therefore 
nuclear β-catenin levels increase (H. Peng et al., 2009).  APC has not been well studied in SA, 
only one study evaluated MSI in the APC gene in 100 cases of OSCC. Nair et al (2006) 
showed an overall LOH frequency of 62.48% and 41.27% MSI for at least one of the 4 
markers analysed (Kriebashne S Nair et al., 2006). APC gene expression and methylation 
could still be investigated in the South African setting using more than one method to verify 
the international findings. 
In addition to APC, the fragile histidine triad (FHIT) gene was also shown to inhibit the 
oncogenic TCF/β- catenin complex (Weiske et al., 2007) and several studies (summarised in 
table 1.1) show that loss of FHIT by deletion or methylation occurs in OSCC at a frequency of 
14-89% and correlates with loss of expression of the gene (X. Q. Guo et al., 2007; M. Morita 
et al., 2006; Kuroki et al., 2003; Noguchi et al., 2003; Kitamura et al., 2001; Y Shimada et al., 
2000; M Mori et al., 2000; Menin et al., 2000; H. Tanaka et al., 1998). These studies showed 
varying degrees of FHIT involvement (from 14% to 89%). This variation in frequency is likely 
due to the differing methodologies used to detect FHIT deletions, never the less, FHIT seems 
to be an important tumour suppressor in OSCC.  
The well known oncogene, C-MYC encodes a transcription factor involved in transcription of 
numerous genes involved in cell division, apoptosis and transformation. The C-MYC gene is 
deregulated through amplification or translocation in many cancers. C-MYC amplification 
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was detected in 39% (n=41) and 45% (n=20) of OSCC samples (J. He et al., 1995; H. Arai et 
al., 2003) while two other studies on 20 and 46 OSCC samples did not show a significant 
amplification or over expression of C-MYC and report that C-MYC may not be important for 
OSCC carcinogenesis (S. Miyazaki et al., 1992; X.P. Huang et al., 2006). Only one study was 
done on C-MYC expression in four South African OSCC cell lines using one technique, 
western blot analysis, which showed over expression of C-MYC in two of the cell lines (G. J. 
Jones et al., 1993). The limited study of C-MYC in OSCC would not suggest a role for C-MYC 
in the disease pathogenesis, however these studies had relatively small samples sizes and 
further study of this oncogene may clarify its role. 
Additional tumour suppressor genes inactivated, either by mutation, LOH or deletion that 
are also important in the deregulation of the cell cycle and apoptosis in cancer cells are the 
TP53 and CDKN2A genes, both previously investigated in OSCC (Metzger et al. 2004). 
Although p53 is usually active in oncogenesis by deletion, mutations of the TP53 gene have 
also been correlated with abnormal over expression of this protein (Wagata et al., 1993), 
which accumulates in the nucleus (von Brevern et al., 1996) and possibly inhibits apoptosis 
(Hamada et al., 1996), although there has not been experimental data to support this 
hypothesis. Expression analysis of p53 has mostly been conducted by 
immunohistochemistry, a limitation to these studies. These studies show over expression of 
p53 in 39 to 88% of tumours (K Y Lam et al., 1995; Casson et al., 1998; Wagata et al., 1993; 
von Brevern et al., 1996; Muro et al., 1996; K Y Lam, S Law, et al., 1997). Mutated p53 is 
suggested to have a longer half life and accumulates in less differentiated cells (A. K. Lam, 
2000; K Y Lam et al., 1995). Patients with abnormally expressed p53 were suggested to have 
a shorter survival (K Y Lam, S W Tsao, et al., 1997; Casson et al., 1998).  
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TP53 gene missense mutations (mostly correlating with p53 over expression) have been 
described in OSCC in more than 20 studies, 2 of which were from South Africa (summarised 
in table 1.1) (K Y Lam et al., 1995; Casson et al., 1998; Wagata et al., 1993; Montesano et al., 
1996; W. P. Bennett et al., 1997; Hamada et al., 1996; Muro et al., 1996; Seta et al., 1998; 
Matsha et al., 2007; Vos et al., 2003; R Chetty & Simelane, 1999; Gamieldien et al., 1998; 
Jaskiewicz & K. M. De Groot, 1994). Overall, from these studies, at least 50% of tumours 
have TP53 gene aberrations internationally, with most mutations occurring within exons 5-8 
(A. K. Lam, 2000).  
Two SA studies investigated TP53 mutation status; the first analysed exons 5-8 and the 
second the flanking regions of exons 5-8. Gamieldien et al (1998) detected a relatively low 
mutation frequency of 17% (n=76) (Gamieldien et al., 1998). The second study by Vos et al 
(2003), on 73 tumours, only detected 2 mutations in the exon 5-8 flanking regions (Vos et 
al., 2003). These studies do not suggest a role for TP53 mutation in OSCC. However, more 
comprehensive analysis of the TP53 gene is required in SA. Additional TP53 mutations in the 
intronic sequences or TP53 expression may be affected by other mechanisms, which were 
not addressed in these studies. Three SA studies showed that expression of p53 was absent 
in 30-40% of OSCC tumours (n=50 to 155) (Matsha et al., 2007; R Chetty & Simelane, 1999; 
Jaskiewicz & K. M. De Groot, 1994). These studies did not report any association with 
tumour grade or depth of tumour invasion, which may be due to the limitation of only using 
one technique, immunohistochemistry. Overall, p53 overexpression appears to be the major 
mode of action in carcinogenesis however, the molecular basis for p53 involvement in OSCC 
carcinogenesis needs clarification with functional studies. 
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The p16 protein (encoded by CDKN2A) is an inhibitor of the cyclin dependant kinases and 
inactivation of this protein facilitates the transition of cells into S-phase. The expression of 
p16 is often lost in OSCC and deletions and/or mutations are not frequently detected 
suggesting that other mechanisms of p16 inactivation occur in OSCC (A. K. Lam, 2000). One 
of the mechanisms reported is hypermethylation of the CDKN2A gene, which correlates with 
loss of expression in 60%-80% of OSCC tumours (studies are summarised in table 1.1) 
(Taghavi et al., 2010; Salam et al., 2009; X. Q. Guo et al., 2007; Jianming Wang et al., 2008; 
Fukuoka et al., 2006; M. Guo et al., 2006). Only one study was performed on CDKN2A in SA, 
the mutation status of exons 1 and 2 was investigated. Seventy six OSCC samples were 
analysed and mutations were found in 28% of the samples (Gamieldien et al., 1998). These 
mutations resulted in missense mutations, deletions, stop codons and insertions, which 
would result in loss of functional protein (Gamieldien et al., 1998).  
Overall, from the published data, genes that play a role in oncogenesis have been identified. 
Most of these studies focused on association with prognosis. However, the results from 
these studies are difficult to apply in a clinical setting and the understanding of the 
molecular pathways underlying carcinogenesis in OSCC is still not clarified. As mentioned 
before, the tumours are difficult to stage, which may contribute to the variation in results 
obtained.  
In South Africa specifically, the focus of research on OSCC, as described above, has been on 
gene polymorphisms linked to the risk of developing disease, mutations in the TP53, 
CDKN2A and APC genes, expression of some of the adhesion molecules and the association 
of HPV with the disease.  These studies have not yet elucidated clear pathways for the 
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molecular carcinogenesis of OSCC in South Africa. Whole genome studies could help to 
identify genes linked to key pathways, which collectively contribute to OSCC carcinogenesis. 
 
Table 1.1 Summary of studies done on molecular markers in OSCC 
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Author and country Number of 
samples 
Aberration Method Findings/comments 
ADHESION 
β1 integrin 
(S. E. Miller & Veale 2001), SA ? Under expressed (?) ? Could only obtain an abstract. Increased 
metastasis 
(Takayama et al.2003), Japan 71 Under expressed (?) immunohistochemistry Could only obtain an abstract. Correlated 
with lymph node metastasis 
CD44 
(Takayama et al. 2003), Japan 71 Reduced expression of CD44 and CD44v6 (?) immunohistochemistry metastasis 
(Roye et al. 1996), USA 50 Over expressed CD44 (100%) immunohistochemistry OSCC development 
(W-K Liu et al. 2005), China 40 CD44v6 over expressed (65%) immunohistochemistry Increased expression linked to HPV16 
infection 
(D.-M. Li et al. 2005), China 42 CD44v6 over expressed (71.43%) immunohistochemistry  
(Nozoe et al. 2004), Japan 81 Over expressed (46.9%) immunohistochemistry  
E-Cadherin 
(Kriebashne S Nair et al. 2006), SA 100 Low or no expression (81%) immunohistochemistry  
(Lawler et al. 2009), Ireland Oc-1 cell line Showed shear induced internalisation of E-cadherin Cell culture experiments Endocytosis of E-cad associated with 
invasiveness 
(E. J. Lee et al. 2008), China 251 Methylated (43%) Methylation specific PCR  
(Chung et al. 2007), China 71 Under expressed (42.3%) immunohistochemistry  
(Takayama et al. 2003.), Japan 71 Decreased expression immunohistochemistry  
(Kadowaki et al. 1994), Japan 46 Reduced expression (46%) immunohistochemistry  
Table 1.1 Summary of studies done on molecular markers in OSCC 
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ONCOGENES 
VEGF 
(Y Shimada et al. 1999), Japan 116 Over expressed (68.9%) immunohistochemistry Tumour invasion 
(Gholamin et al. 2009), Iran 49 Over expressed (44.9%) mRNA detection  
(Bedoya et al. 2009), Spain 29 Over expressed (100%) immunohistochemistry  
(P. Liu et al. 2009), China 73 Over expressed (53.4%) immunohistochemistry  
(Okazawa et al. 2008.), Japan 100 Over expressed (43%) immunohistochemistry  
EGFR 
(Gotoh et al. 2007), Japan 62 Over expressed (34%) immunohistochemistry Predicts response to chemoradiation 
therapy 
(Hoshino et al. 2007), Japan 52 36% over expression of p-EGFR in nucleus immunohistochemistry p-EGFR associated with a poor prognosis 
(Gongyuan Zhang et al. 2010), China 62 Over expressed (75.8%) in situ hybridisation  
(Boone et al. 2009), Netherlands 108 Over expressed (40%) immunohistochemistry  
(Gibault et al. 2005), France 107 Over expressed (68.2%) immunohistochemistry  
(Hanawa et al. 2006), Japan 106 Over expressed (50%) immunohistochemistry  
(Carneiro, Isinger, Karlsson, J. 
Johansson, Jönsson, et al. 2008), 
Denmark 
30 Amplified (46.6%) CGH array (32K BAC array)  
CCND1 
(S. Zhu et al. 1998), China 104 Over expressed (62.5%) immunohistochemistry  
(S. Fujii et al. 1998), Japan 26 cell lines Over expressed (65.4%) Flow cytometry  
(H. Suzuki et al. 1998), Japan 4 Amplified (100%) Fluorescence in situ hybridisation 
(FISH), differential PCR 
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(Takeuchi et al. 1997), Japan 111 Over expressed (25%) immunohistochemistry  
(Roncalli et al. 1998), Italy 74 Amplified and over expressed (31%) FISH, immunohistochemistry  
(Shamma et al. 1998), Japan 66 Over expressed (42%) immunohistochemistry  
(Inomata et al. 1998.), Japan 45 Over expressed (31.2%) Southern, northern, western blotting & 
immunohistochemistry 
 
(R Chetty & S. Chetty 1997,), SA 80 Over expressed (29%) immunohistochemistry  
(Sheyn et al. 1997), USA 20 Amplified (65%), over expressed (75%) FISH, immunohistochemistry Correlation between amplification and 
over expression 
(J. Zheng et al. 1996), China 21 Amplified and Over expressed (57%) Northern blot, immunohistochemistry  
(Shinozaki et al. 1996), Japan 122 Amplified (23%) Slot blot  
(Kitahara et al. 1996), Japan 8 cell lines Over expressed (67.5%) ? Could only obtain abstract 
(H Nakagawa et al. 1995), USA ? Over expressed (50%) ? Could only obtain abstract 
(W Jiang et al. 1992), USA 20 Amplified (25%) ? Could only obtain abstract 
(W Jiang et al. 1993), USA 50 Amplified and over expressed (32%) immunohistochemistry  
(De-Chen Lin et al. 2010), China 148 Over expressed and amplified (45.5%) Immunohistochemistry, array CGH  
C-MYC 
(J. He et al. 1995), China 41 Amplified (39%) PCR  
(H. Arai et al. 2003), Japan 20 Amplified (45%) Array CGH  
(S. Miyazaki et al. 1992.), Japan 20 Expression  not significant Northern blot  
(X.-P. Huang et al. 2006), China 46 Amplified (100%) Over expression (8.6%) FISH, immunohistochemistry, RT-PCR C-MYC not target of amplification 
TUMOUR SUPPRESSORS 
TP53 
Table 1.1 Summary of studies done on molecular markers in OSCC 
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(Wagata et al. 1993), Japan 32 Mutations (47%) PCR, sequencing  
(von Brevern et al. 1996), Germany 62 Mutation and nuclear over expression (88%) PCR, immunohistochemistry  
(W. P. Bennett et al. 1997), USA 29 Mutations (69%) PCR, sequencing  
(Hamada et al. 1996), Japan 25    
(K Y Lam, S W Tsao, et al. 1997), 
China 
42 Over expressed (67%) immunohistochemistry  
(K Y Lam et al. 1995), China 99 Over expressed (50%) immunohistochemistry  
(Casson et al. 1998), UK 61 Over expressed (39%)   
(Montesano et al. 1996),      
(Muro et al. 1996), Japan 18 Over expressed (56%) immunohistochemistry  
(Seta et al. 1998), Japan 15 Over expressed (33%) immunohistochemistry  
(Matsha et al. 2007), SA 114 Over expressed (70%) PCR  
(Vos et al. 2003), SA 74 2 mutations (flanking regions to exon 5-8) PCR, sequencing  
(R Chetty & Simelane 1999), SA 50 Over expressed (42%) immunohistochemistry  
(Gamieldien et al. 1998), SA 76 Mutations (17%) PCR, HEX SSCP, sequencing  
(Jaskiewicz & De Groot 1994), SA 155  immunohistochemistry  
CDKN2A 
(Taghavi et al. 2010), Iran 50 Methylation (62%) Methylation specific PCR  
(Salam et al. 2009), India 69 Methylation (67%) Methylation specific PCR, 
Immunoblotting 
Correlated with loss of expression 
(Jianming Wang et al. 2008), China 125 Methylation (88%) Methylation specific PCR  
(Fukuoka et al. 2006.), Japan 35 Methylation (80%) Methylation specific PCR  
Table 1.1 Summary of studies done on molecular markers in OSCC 
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(Gamieldien et al. 1998), SA 76 Mutations (32%) Sequencing, HEX SSCP  
APC 
(Zare et al. 2009), Iran 45 Methylated (44.4%) Methylation specific PCR Poor survival 
(Y. T. Kim et al. 2009), Korea 50 Methylated (46%) Methylation specific PCR Good prognosis 
(H. Peng et al. 2009), China 199 Low expression (30.4%) Immunohistochemistry  
(Kriebashne S Nair et al. 2006), SA 100 LOH (62.48%), MSI (41.27%) MSI and LOH analysis  
FHIT 
(X. Q. Guo et al. 2007), China 95 No expression (81.62%) Methylation specific PCR, 
immunohistochemistry 
 
(Morita et al. 2006.), Japan 55 Loss of protein Immunohistochemistry  
(Kuroki et al. 2003), USA 47 Methylated (45%) Methylation specific PCR, LOH  
(Noguchi et al. 2003), Japan 36 Deleted (69.41%) Methylation specific PCR  
(H. Tanaka et al. 1998), Japan 35 Methylated (14%) Methylation specific PCR  
(M Mori et al. 2000), Japan 46 No expression (70%) Immunohistochemistry  
(Menin et al. 2000), Italy 21 LOH (80%), aberrant proteins (77%) LOH and RT-PCR  
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1.3 Chromosomal aberrations and OSCC 
OSCC is reported to be a genetically complex cancer (Carneiro, et al., 2008). The high 
number of genetic aberrations detected is likely due to genetic instability, which could be 
due to one or more of several mechanisms that lead to complex chromosomal aberrations. 
It is widely accepted that recurrent chromosomal aberrations seen in malignancies pinpoint 
the genes involved in the initiation and progression of cancer (Felix Mitelman et al., 2007). 
Gene fusions in solid tumours have not been studied in depth previously due to the 
difficulties in obtaining metaphase chromosomes from solid tumours, but increased access 
to better analysis tools has shown that translocations do occur more frequently in solid 
tumours than previously thought and contribute to cancer morbidity at an approximate rate 
of about 17% (Mitelman et al., 2007). In addition to chromosomal rearrangements, 
amplifications and deletions are frequent events in cancer. These events often lead to over 
expression of oncogenes and inactivation of tumour suppressor genes. 
Mechanisms of chromosomal aberrations 
Genetic instability is defined as an excess of structural or numerical chromosomal 
abnormalities. Intra-tumour heterogeneity is common amongst cancers, probably as a result 
of genetic instability due to the dysfunction of genes responsible for maintaining the 
integrity of the genome (D Gisselsson et al., 2000). 
Chromosomal rearrangements can be generated by the formation of double-stranded 
breaks (DSB) in the DNA, which are normally repaired by two main DNA repair mechanisms, 
non homologous end joining (NHEJ) and homologous recombination (HR) (Ferguson & Alt 
2001). Double stranded breaks are usually initiated by various DNA damaging agents such 
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as, ionising radiation and oxidative reactive species. Defects in the repair pathways can lead 
to rearrangements, LOH and deletions (Ferguson & Alt, 2001).  
NEJH involves the maintenance of DNA ends in close proximity, removal of 5’ and 3’ 
overhangs, fill in synthesis and ligation of the DNA strands (Lieber et al., 2003). NHEJ may 
create a perfect repair of a DSB or there can be loss of material surrounding the lesion, 
which often occurs at the sites of translocation break points (Lieber et al. 2003). HR on the 
other hand, can fill in gaps of DNA by copying missing information from a sister chromatid or 
homologous chromosomes, avoiding the formation of deletion (Lieber et al. 2003). This 
process increases the chance of generating LOH by gene conversion (base mismatch repair 
during recombination) or gene rearrangements by filling in DNA sequences that are similar 
but are not from homologous chromosomes (Ferguson & Alt, 2001). There is interplay 
between these pathways in maintaining the genome integrity and preventing 
tumourigenesis, with each of these pathways predominating in different phases of the cell 
cycle (Ferguson & Alt, 2001).  
Animal models have shown that when there is a deficiency of one or more of the proteins 
required for NHEJ, radiation sensitivity occurred mainly in the G1 and early S-phase while 
RAD54 inactivation, leading to disruption of the HR pathway, affects the survival of cells 
irradiated in late S phase and G2 (Takata et al. 1998; Sonoda et al. 1998). In addition, 
deletion of RAD51 lead to cells in the G2/M phase with numerous single chromatid breaks 
and lack of HR repair prior to DNA replication (Takata et al., 1998; Sonoda et al., 1998). The 
loss of these and other enzymes in the NHEJ and HR pathways can lead to higher levels of 
chromosome aberrations (Takata et al., 1998). 
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Another mechanism involved in genetic instability and the major mechanism for the 
formation of amplifications is the breakage-fusion bridge cycle. This mechanism was first 
described by Barbara McClintock in 1938 and 1940 and represents one of the most 
described mechanisms of variability in chromosome structure (McClintock, 1941). Breakage-
fusion-bridge (BFB) cycles can be described as a break forming within a single chromatid of a 
chromosome and a subsequent fusion forming between the two sister chromatids during 
the anaphase stage of cell division (McClintock 1941). This results in the inability for these 
two chromatids to separate during the following mitotic anaphase and a bridge is formed as 
the two centromeres migrate to opposite poles of the nuclei (Figure 1.1). Breakage will 
occur at the point of tension (McClintock, 1941). This results again in broken ends resulting 
in fusions and bridge formation in subsequent anaphases. The position of the breakage 
during successive cycles can vary, thus giving rise to the heterogeneity of aberrations seen in 
cancer cells (Selvarajah et al., 2006; D Gisselsson et al., 2000).  
Gisselsson et al (2000) showed that BFB’s were frequently detected in tumours with highly 
heterogeneous abnormalities i.e. unspecific patterns of chromosome rearrangements while 
BFB’s were less frequent in tumours with more specific and recurrent patterns of 
rearrangement.  This suggests that there are possibly several mechanisms of development 
of chromosomal aberrations in solid tumours (Gisselsson et al., 2000). In healthy cells, those 
carrying chromosomal damage are usually forced into apoptosis. In tumours, the 
mechanisms responsible for DNA damage checkpoint, repair and induction of apoptosis are 
often defective (Bayani et al., 2007).  
BFBs are also associated with telomere length, where excessive shortening of telomeres and 
loss of telomere capping function lead to BFB cycles (Bayani et al., 2007; David Gisselsson, 
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2005).  BFB cycles definitely contribute to genomic instability and promote the formation of 
complex rearrangements and homogenously staining regions (HSRs) (A. W. I. Lo et al., 2002; 
Bayani et al., 2007). Lo et al (2002) demonstrated that BFB formation was associated with 
amplification of small regions and can continue into at least 20 cycles of cell division (Lo et 
al., 2002).  
 
Figure 1.1. Diagrammatic representation of the BFB cycle adapted from Lo et al (2002). 
The blue squares indicate the telomeres and red dots, the centromeres. The stars indicate 
the region of initial break, which is copied and amplified in subsequent cell divisions.  
 
Another mechanism associated with genomic instability is the genomic architecture itself, 
where GC rich regions have been linked to translocations and AT rich regions with deletion 
events (Abeysinghe et al., 2003). Frequent translocation events at pericentric regions would 
also suggest that repetitive sequences facilitate translocation events with the sequence 
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homology of these regions across chromosomes acting as sites to receive and donate in 
translocation events and jumping translocations (Bayani et al., 2007). 
Fragile sites are chromosomal regions expressed as gaps or breaks appearing under specific 
culture conditions such as folate deficiency or aphidicolin treatment (Yunis & Soreng, 1984). 
They are prone to breakage under replication stress and exposure to clastogenic 
compounds. They are also prone to translocation events, deletions and viral integration and 
have been shown to coincide with amplicon boundaries (Myllykangas et al., 2007). Common 
fragile sites include FRA3B, FRA6E, FRA8C and FRA16D, which harbour the tumour 
suppressor genes FHIT, WWOX, PACRG and the oncogene C-MYC respectively, all known to 
be potentially involved in cancers (Toma et al., 2008). Amplification patterns seem to 
correspond to tissue-specific lineage, however tissues exposed to similar environmental 
conditions have similar patterns of amplification suggesting their link to environmental 
carcinogen exposure (Myllykangas et al., 2007).  
Chromosomal aberrations detected in OSCC 
A whole genome view would allow patterns of copy number change to be detected in 
tumours and since the detection of amplifications and deletions could help identify the key 
genes involved in the carcinogenic process, a newer approach to study cancers has evolved. 
The methodology of comparative genomic hybridisation (CGH) was developed for this 
purpose. In this method, hybridising labelled tumour DNA comparatively with normal 
labelled DNA to normal metaphases allows for detection of copy number changes at a 
resolution of 10Mb (Albertson & Pinkel, 2003). Large regions of deletions or amplifications 
can be detected but smaller regions (< 10Mb) will be missed by conventional CGH. 
Conceptually based on the same principle as CGH, array CGH has been developed. In array 
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CGH, tumour and control DNA are co-hybridised to slides printed with either BACs (Bacterial 
Artificial Chromosomes) or oligonucleotide sequences, either covering the whole genome or 
spanning it at regular intervals (Pinkel & Albertson, 2005). Depending upon the type of 
‘array CGH’, the resolution can range from 1 Megabase to a few hundred bases.  Small 
regions of gene imbalances can be detected and the delineation of critical regions of 
deletion and/or amplification can be refined (Pinkel & Albertson, 2005). SNP (single 
nucleotide polymorphism) array technology has provided a platform, which can be used to 
analyse the whole genome at high resolution and allow DNA copy number analysis by 
evaluating the signal intensities over a given genomic window for cancer samples by 
comparing them to the signal intensities of a normal reference set of samples (G. R. Bignell 
et al., 2004). The Affymetrix® 500K assay consists of two microarray chips covering 
approximately 500 000 SNPs. The features are 5µm in size and each SNP has 24 to 40 probes 
(matched and mismatched probes for the sense and anti-sense strands) at a mean spacing 
of 5.8kb.  This technique is now widely used to identify common DNA copy number 
aberrations across samples and identify genes that may be targeted by these amplicons or 
deletions. 
Regarding whole genome analysis of oesophageal cancer, to date, 15 studies have been 
performed analysing copy number changes, one of which was performed in the South 
African population using conventional CGH. Eight of these studies used conventional CGH 
and the other 7 have utilised various types of higher resolution array CGH from 10K SNP 
arrays, 32K BAC arrays to the highest resolution of 250K SNP arrays. Two studies scrutinised 
specific gene loci i.e. 766 known cancer genes and another specifically investigated 386 
markers on chromosome 3p. There is much variation in the results from study to study, 
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possibly due to the varying resolutions of the techniques or it may be that different 
geographic, ethnic or etiologic factors that contribute to this variation. One theory, 
suggested by Chattopadhyay et al (2010), was that the disease arises from mutations in 
genes involved in maintaining genetic stability. As a result, genomic instability increases as 
the tumours progress and different clones expand by selection of those cells with 
abnormalities that provide a growth advantage (Chattopadhyay et al., 2010).  
The most common aberrations across these studies were amplicons affecting chromosomes 
1p36.32-p36.13, 2q31-32, 3q28, 5p15.2, 6p25.3, 7p14, 8q24, 11q12.3, 20p11.1, 20q13.1 and 
deletions affecting 1p, 4p14-p15.3, 3p14.2, 3p26.3, 3p24.2, 5q33, 8p23.2, 9p21.3 and 
18q21.2-22 (C. C. Yen et al., 2001; C. C. Yen et al., 2005; Xu Zhang et al., 2008; J. Chen et al., 
2008; Y. R. Qin et al., 2008; Du Plessis et al., 1999; N. Hu et al., 2006; Carneiro, et al., 2008; 
Chattopadhyay et al., 2010). Aberrations that are consistently found include 3q 
amplification (8 studies) and 3p deletion (8 studies), which is not exclusive to OSCC but also 
common to other epithelial cancers. Abnormalities of chromosome 3 may therefore be 
pivotal in the carcinogenesis of epithelial tissues (Chattopadhyay et al., 2010).   
Chromosome 3q26 amplification is the most commonly detected 3q aberration in OSCC. The 
SOX2 gene, on chromosome 3q26, encodes a transcription factor and is amplified in primary 
OSCC’s at a rate of 15% (Bass et al., 2009; Gen et al., 2010) but over expression is detected 
in 70% of tumours and is found to promote proliferation (Gen et al., 2010), suggesting that 
SOX2 expression is not only activated by gene amplification and other genes may be the 
primary targets of 3q26 amplification.  
Chromosome 8q24 amplification and 8p deletions are also consistently detected in 8 
different studies, highlighting these regions as important for OSCC carcinogenesis. 
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Chromosome 8q24 amplification may target the C-MYC oncogene. However other genes on 
8q24 are proposed to be the targets for amplification due to a lack of over expression of C-
MYC in 59 cases analysed (X. P. Huang et al., 2006).  Huang et al (2006) suggested that the 
FAM84B gene was the probable target since 66% of the cases had over expression of this 
gene, which correlated with gene amplification (X. P. Huang et al., 2006). 
One study analysed both copy number aberrations and the expression of genes affected by 
copy number aberrations but the analysis was restricted to amplicons (T. Sugimoto et al., 
2007). The study was performed in 10 OSCC cell lines using oligo-array CGH and Acegene 
human oligo Chip 30K for the expression analysis. Correlations were detected for 97 genes, 
(i.e. the DNA copy number correlated with expression of genes within the aberrant region), 
in the top ranked region, namely 11q12-14. Twenty four of these genes were selected for 
verification of amplification and expression with quantitative PCR. Twenty of the genes in 
the 11q12-14 region are significantly over expressed (SSRP1, MS4A7, LOC51035, HRASLS2, 
LOC144097, MEN1, EHD1, CFL1, BANF1, SF3B2, SUV420H1, FGF19, PPFIA1, PDE2A, STARD10, 
RAB6A, WDR71, NEU3, SERPINH1 and PCF11), correlating with gene amplification (T. 
Sugimoto et al., 2007). 
The variation from these studies makes it difficult to identify genes that may be targets of 
the aberrations and apart from one (Chattopadhyay et al., 2010), these studies did not 
attempt to link the genes in aberrant regions to common biological pathways that may be 
implicated in OSCC. Recurrent chromosomal amplifications and deletions need clarification 
in OSCC with the varying results that have been highlighted in the literature and specifically, 
a high resolution analysis of such aberrations in SA OSCC could be valuable in assisting in the 
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unravelling of OSCC pathogenesis through identification of affected genes and their specific 
pathways.  
1.4 Project Rationale 
Hypotheses 
Previous work on five oesophageal squamous cancer cell lines developed in SA (Bey et al., 
1976; R Veale, 1989) were analysed for the presence of deletions at fragile sites  (Willem et 
al., 2006) and for the presence  of common translocations using Multicolour fluorescence in 
situ hybridisation (M-FISH) (J Brown, MSc thesis, WITS, 2005). Chromosomal aberrations 
were detected across cell lines, specifically a t(1;3), t(1;15), t(1;14), t(3;22), 7q deletion, and 
20q deletion, which could target common breakpoints on chromosome 1p, 3p, 7q and 20q. 
These common chromosomal rearrangements may target novel genes involved in 
carcinogenesis and further investigation of these breakpoints is required. As previously 
mentioned, only one study analysing copy number patterns in OSCC has been performed in 
SA and this study used low resolution conventional CGH. There is a need to look at common 
copy number aberrations at high resolution in OSCC patients in SA. 
It is hypothesised that breakpoints detected in the cell lines and common regions of 
amplifications and deletions in cell lines and patient samples will pin point genes and 
pathways involved in OSCC carcinogenesis.  
Aim 
The project aim is to map common rearrangements detected in five SA OSCC cell lines and 
establish the gene copy number profile of these 5 cell lines and 50 OSCC clinical specimens 
in order to identify the most common loci undergoing copy number changes.  
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Specific Objectives 
1. To map the common 1p11 and 3p11 breakpoints in the OSCC cell lines, which may 
reveal a common oncogene/s non-randomly involved in OSCC. 
2. To establish the DNA copy number profiles of the five OSCC cell lines and combine 
the results with the M-FISH data to characterise their cytogenetics and molecular 
profile. 
3. To assess the expression levels of candidate genes in the 5 OSCC cell lines to verify 
if copy number amplification/deletion correlates with expression levels of genes at 
these loci. 
4. To compare and identify regions of amplification and deletion in the genome of 50 
clinical specimens. Compare the patterns of abnormality to that of the 5 OSCC cell 
lines and to the findings of other studies. 
5. To validate the copy number microarray results using an alternative method. Here, 
being fluorescence in situ hybridisation (FISH). 
 
The project is broken into 3 major chapters; chapter 2 describes the work done on the 5 cell 
lines for objectives 1 and 2 combining molecular cytogenetic techniques. Chapter 3 deals 
with objective 3, the expression of some candidate genes identified in the cell line study and 
the fourth chapter describes objectives 4 and 5, the in depth copy number analysis in a 
patient cohort. These chapters are linked together in the final concluding chapter.  
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CHAPTER 2 
 
 
 
 
 
 
Characterisation of common chromosomal aberrations in 5 OSCC 
cell lines 
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2.1 Introduction 
It is widely accepted that recurrent chromosomal breakpoints in malignancies often 
pinpoint genes involved in the initiation and progression of cancer (Felix Mitelman et al., 
2007). A major limitation to assess the chromosome complement in OSCC specimens is the 
difficulty to obtain metaphases from fresh tumours and established cell lines provide a 
unique resource for such investigations. The number of OSCC cell lines that have been 
reported to date remains limited and they were all established in China (Y. C. Hu et al., 2002; 
Y. P. Wu et al., 2006; S. Xiao et al., 1991) and Japan (K. Tada et al., 2000). These cell lines 
have been investigated with one or several low resolution molecular cytogenetic techniques 
including cytogenetics, fluorescence in situ hybridization (FISH), multicolor FISH or spectral 
karyotyping (SKY) and conventional comparative genomic hybridization (CGH). Various 
clonal aberrations have been identified and the most common abnormalities across studies 
involved over representation of chromosomes 1q, 3q, 11q and 8q as well as breakpoints in 
the centromeric or near centromeric regions of chromosomes 1, 3 and 8 (Y. C. Hu et al., 
2002; Y. P. Wu et al., 2006; S. Xiao et al., 1991; H. Zhang et al., 2006).  
Five cell lines have previously been established from South African OSCC patients (Bey et al., 
1976; R Veale, 1989) but apart from cell line SNO, which was karyotyped, these cell lines 
were never characterized for their genetic constitution. Conventional cytogenetics, 
fluorescence in situ hybridization (FISH), and multicolor fluorescence in situ hybridization 
(M-FISH) were used to identify common chromosome structural abnormalities in these five 
cell lines. Affymetrix 250K SNP arrays were performed to investigate DNA copy number 
changes and interrogate the common aberrations previously detected by M-FISH (results 
from MSc work) and conventional cytogenetics. Here clonal aberrations shared by these cell 
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lines and highlighted preferential targets for chromosomal rearrangements and copy 
number changes are described. These are the first OSCC cell lines from Africa genetically 
characterized. 
2.2 Materials and Methods 
Cell lines  
Five oesophageal carcinoma cell lines were isolated from moderately differentiated OSCCs 
as previously described (Bey et al., 1976; R Veale, 1989). These cell lines are designated 
WHCO1, WHCO3, WHCO5, WHCO6 and SNO (Table 2.1). The five cell lines were cultured at 
37°C, 5% CO2 in Dulbecco's Modified Eagles medium (DME): HAMS F12 (3:1) (GIBCO®) 
containing 10% fetal calf serum (FCS) (GIBCO®), and 100ug/ml streptomycin (ICN) and 100 
IU/ml of penicillin (ICN).  
Table 2.1. Cell lines and their patho-clinical information 
 
 
CELL LINE SEX RACE AGE 
GRADE 
SOURCE YEAR Passage 
WHCO1 M Black 47 Moderately 
differentiated 
SSC  
Professor R Veale 
(WITS University) 
1986 141 
WHCO3 M Black 71 Moderately 
differentiated 
SSC 
Professor R Veale 1987 51 
WHCO5 M Black 47 Moderately 
differentiated 
SSC 
Professor R Veale 1988 66 
WHCO6 M Black 39 Moderately 
differentiated 
SSC 
Professor R Veale 1989 77 
SNO M Black 62 Well 
differentiated 
SSC 
Bey et al. (Virus Cancer 
Research Unit, 
Johannesburg) 
1976 Unknown 
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Isolation of cell lines for metaphase preparation 
The cell lines were cultured as above. When the cultures were half confluent, the cells were 
incubated with a final concentration of 0.44μg/ml of Karyomax® Colcemid® (Invitrogen 
Corporation) for 4 hours.  Cells were harvested using Nunc radiation sterilised scrapers 
(Thermo Fisher Scientific Incorporated) and poured into tubes for centrifugation at 900rpm 
for 10 minutes (Eppendorff centrifuge 5810R, A-4-62 rotor). The supernatant was removed 
and 8ml of 0.075M KCl and 1ml of Foetal Calf Serum (GIBCO®) was added. The cells were 
incubated for 30 minutes at 37⁰C. Five drops of fixative (3:1 methanol: acetic acid) was 
added prior to centrifugation at 900rpm for 10 minutes (Eppendorff centrifuge 5810R, A-4-
62 rotor). The supernatant was discarded and the cells re-suspended in 5ml of fixative and 
placed at -20⁰C for 1 hour. Two more fixative changes were performed and the cells were 
transferred to 1.5ml centrifuge tubes. Subsequent fixative changes were performed and 
centrifugation was performed at 6000rpm for 2 minutes (Eppendorff centrifuge 5810R, 
CL021 rotor). This was done until the pellets were clean in appearance. The cells were 
stored at -20⁰C until slides were prepared either for FISH or conventional cytogenetics. 
Isolation of cell lines for DNA  
When the cultures were confluent, the cells were isolated for DNA by scraping the cells from 
the plate and centrifuging at 900rpm (Eppendorff centrifuge 5810R, A-4-62 rotor) for 10 
minutes to remove the supernatant. The cells were washed in 1X PBS (Appendix A) and 
centrifuged again at 1500rpm for 10 minutes (Eppendorff centrifuge 5810R, A-4-62 rotor). 
New PBS was added to cover the cells and the cells were then frozen at -20⁰C until DNA 
isolation.  
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Conventional Cytogenetics  
Slides were prepared for conventional cytogenetics by dropping 30µl of the cell suspension 
onto clean glass slides flooded with 3:1 Methanol: Acetic acid. The slides were steamed for 
30 seconds to spread the metaphase chromosomes sufficiently. The slides were dehydrated 
in an alcohol series (70, 90 and 100%) for 5 minutes each. The slides were aged overnight in 
an oven at 60⁰C in preparation for GTW banding. Slides were placed in trypsin (Appendix A) 
for 1 minute and stained with Wright’s stain (Appendix A), rinsed with water and air dried. 
CytoVision 3.0 software (Applied Imaging Corporation San Jose, California, USA) was used 
for image acquisition and karyotypic analysis.  
Preparation of metaphase slides for Fluorescence in situ hybridisation (FISH) 
Slides were prepared, for metaphase analysis by FISH, by standard procedure. Slides were 
prepared a day prior to FISH experiments by dropping three drops of the cell suspension 
onto a glass slide and steaming for an appropriate amount of time to spread the metaphase 
chromosomes appropriately. The slides were dehydrated in an alcohol series 70, 90 and 
100% ethanol for 5 minutes each and then aged overnight at room temperature.  
FISH procedures 
FISH was performed on metaphase chromosomes from all cell lines in order to confirm or 
refine translocation derivatives’ breakpoints and composition. Probes specific for the short 
and long arms of chromosome 3, the short arm of chromosome 1 and the long arm of 
chromosome 22 (Qbiogene) as well as the Vysis ® Cep 3 Alpha and Cep 1 Alpha 
SpectrumOrange probes (Abbott Molecular Inc) were hybridized to further map 
translocation breakpoints in all cell lines. The Vysis® LSI IGH and Vysis® LSI RARA, both dual 
colour break apart rearrangement probes (Abbott Molecular Inc) were used to confirm the 
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involvement of chromosomes 14 and 15 in translocation derivatives seen in cell lines 
WHCO1 and WHCO3 respectively. FISH was also performed on interphase nuclei from all the 
cell lines using the Vysis® LSI C-MYC SpectrumOrange probe (Abbott Molecular Inc) and the 
Vysis® LSI t(11;14) dual colour probe (Abbott Molecular Inc). These probes target the MYC 
gene (Spectrum Orange) on 8q24 and the CCND1 and FGF4 genes (Spectrum Orange) on 
chromosome 11 respectively and were used to confirm SNP array copy number results. A 
hundred interphase nuclei were analyzed in all the cell lines. All FISH experiments were 
performed according to the manufacturer’s instructions and analyzed on an Olympus BX41 
fluorescent microscope equipped with appropriate fluorescence filters. The Genus™ 
CytoVision 3.0 software (Applied Imaging Corporation) was used for image acquisition and 
analysis.  
The slides were denatured at 76˚C for 5 minutes in denaturing buffer (Appendix A) and then 
dehydrated in ice-cold 70, 90 and 100% ethanol for 5 minutes each. The slides were air-
dried and the 10µl of probe was applied to the slides. Hybridisation was overnight or at least 
15 hours at 37˚C. Washing was done at 42˚C, three washes in 50% formamide (Appendix A) 
for 10 minutes each, one wash in 2X SSC (Appendix A) for 10 minutes and one wash in 2X 
SSC with Tween® 20 (Appendix A) for 5 minutes. The slides were then stained in DAPI 
(Appendix A) for 15 minutes and washed in DAPI wash solution (Appendix A) for 2 minutes. 
The slides were mounted with Vectashield (Vecta Laboratories) and a coverslip. Analysis was 
performed on a fluorescent microscope and all images were captured using the Genus™ 
CytoVision 3.0 program from Applied Imaging.  
BAC probe development and FISH analysis for the EPHA3 gene deletions 
This section of the work was done by an honours student supervised by myself. 
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The bacterial artificial chromosome is based on the fertility plasmid of bacteria. This cloning 
vector is an artificial, self-replicating chromosome, which can accept an insert of about 
300kb. The vector carries an antibiotic resistance marker allowing for the selection of those 
clones carrying the insert. E. Coli serves as the host cells for the generation of BAC clones. 
The BAC clones chosen for assessment of EPHA3 deletions are shown in figure 2.1 (Obtained 
from BACPAC resource centre, Children’s Hospital Oakland Research Institute, CA, USA). The 
BAC clone, RP11-598N21, maps to exons 1, 2 and 3. The BAC clone, RP11-535I05 maps 
telomeric to the EPHA3 gene and the RP11-547K2 clone maps from exons 11-17.  BAC clone 
RP11-784B9 was mapped to EPHA3, however, in these experiments, the clone we received 
mapped to a distant locus on chromosome 3p and was used as a 3p internal control for 
hybridisation of RP11-598N21 (Figure 2.2). 
Two hundred millilitres of BAC growth medium, LB top agar (Appendix A), was aliquoted into 
autoclaved flasks. 12.5μg/ml of chloramphenicol (Sigma®) was added to the growth 
medium. Five millilitres of the 200ml volume was aliquoted into 50ml Nunc® tubes for 
inoculation with BACs from frozen glycerol stock cultures (Appendix A). The inoculated 
medium was incubated at 37˚C, orbiting at 200rpm for 2-6 hours. When the medium was 
turbid, the cultures were transferred to the flasks containing 195ml of medium. If they were 
not turbid they were left overnight. The 200ml cultures were incubated at 37˚C, orbiting at 
180rpm overnight. 
The cultures were harvested by aliquoting into 50ml Nunc® tubes and centrifuging at 5000 
rpm for 15 minutes (Eppendorff centrifuge 5810R, F34-6-38 rotor). DNA extraction was done 
using the Qiagen® Plasmid Purification Kit. Utilisation of the QIAfilter™ Plasmid Midi 
procedure resulted in very pure, protein and RNA free insert DNA with no chromosomal 
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DNA. The protocol for the kit was strictly followed. The lysate was cleared through the 
Qiagen®-tip 100. Plasmid DNA is bound to the anion- exchange resin, while RNA, proteins 
and other impurities are removed by low salt washing. The high salt buffers then elute the 
DNA. The DNA is precipitated to remove the salt by adding isopropanol (Merck) and 
centrifuging at 12000xg for 30 minutes at 4˚C (Eppendorff centrifuge 5810R, CL021 rotor). 
Washing with 70% ethanol followed and then centrifugation at 12000xg for 10 minutes at 4˚ 
C (Eppendorff centrifuge 5810R, CL021 rotor). The pellets were air dried and re-suspended 
in an appropriate volume of 1X TE buffer (Promega) for the size of the DNA pellet. 
The concentration and purity of DNA extracted needs to be clarified for the efficient 
labelling of DNA in probe production. This was achieved by 2% agarose (Bioline) gel 
electrophoresis. The spectrophotometer was found to be inaccurate for BAC DNA 
estimation, the readings given, were 2 fold that given by estimation on gel electrophoresis 
and so the latter was used instead. 
To estimate the concentration of DNA, the sample DNA was compared to a control DNA 
with known concentration. Lambda DNA (Sigma®) was diluted to a 1/10 dilution, which was 
approximately 17.5ng/μl of DNA. 1μl of BAC DNA was loaded into a 2% agarose gel along 
with 17.5ng, 35ng and 70ng of Lambda DNA. The gel was run for 10 minutes at 100V. The 
electrophoresis tank contained 1X TAE buffer (Appendix A) in which the agarose had also 
been dissolved. DNA integrity could be determined by the presence of a high molecular 
weight band of DNA or a smear, in which case the DNA would be degraded.  
The BAC DNA was directly labelled using the nick translation method. BAC clones, RP11-
535IO5 and RP11-784B9, were labelled with SpectrumOrange-dUTP (Abbott Laboratories). 
The BAC clones RP11-598N21 and RP11-547K2 were labelled with SpectrumGreen-dUTP 
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(Abbott Laboratories). The reaction was made up to a final volume of 100μl, which consisted 
of final concentrations of 1x nick translation buffer (Appendix A), 0.01M β-mercaptoethanol 
(BDH), 0.8X nucleotide stock, which contained the fluorescent nucleotides (the fluorescent 
nucleotides were kept in a 1:1 ratio to thymine nucleotides to minimise steric hindrance 
(Appendix A),  210u/ml of DNA Polymerase (Promega), 1μl of a 3μl/1000μl dilution of DNase 
I solution (Appendix A) and 1μg/100μl of DNA. The reaction was incubated at 15˚C for 2 
hours in the Eppendorf Mastercycler. The optimum probe size is 200-500bp for efficient 
penetration of the nucleus and hybridisation. The probe size and fluorescence incorporation 
was evaluated by 2% agarose gel electrophoresis with a 100bp ladder (Fermentas Ruler™) 
(Appendix A). 
The probe was purified to remove unincorporated nucleotides by co-precipitation with 20μg 
of Cot1-Human DNA (Roche). To precipitate the labelled DNA, 1/10 volumes of 3M-sodium 
acetate and 2, 5 volumes of ice-cold 100% ethanol were added and then incubated at -70°C 
for 30 minutes and centrifuging at 13000xg for 30 minutes (Eppendorff centrifuge 5810R, 
CL021 rotor). The precipitated DNA was then washed in 70% ethanol to remove salts by 
centrifuging at 13000xg for 10 minutes (Eppendorff centrifuge 5810R, CL021 rotor). The 
probes were air dried and re-suspended in hybridisation buffer (Appendix A), usually 160ng 
of DNA per 10μl of hybridisation buffer. Ten microlitres of probe was hybridised to slides, 
with denaturing hybridisation and washing all done as above for FISH procedures. One 
hundred cells per cell line were analysed. Each probe was hybridised to normal metaphase 
and interphase cells to confirm the correct chromosomal location and interphase pattern 
(Figure 2.2 and 2.3). 
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Figure 2.1 Schematic representations of the EPHA3 gene locus and the BAC clones selected 
for FISH experiments. The red and green delineate the colour of the fluorescent label for 
each clone. The blue blocks represent each of the 17 exons that make up the EPHA3 gene. 
The black cross indicates that this clone did not map to this location. 
 
 
Figure 2.2. Normal metaphase and interphase FISH for RP11-598N21 and RP11-784B9. 
DAPI stained metaphase image showing the confirmed position of RP11-598N21 at 3p11.2 
(green arrow) (A).  The red arrow indicates RP11-784B9, which is not positioned in 3p11.2 
but on a distant band on chromosome 3p. DAPI stained interphase nuclei (B) showing the 
pattern of hybridisation for RP11-598N21 (green) and RP11-784B9 (red) in normal nuclei. 
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Figure 2.3. Normal metaphase and interphase FISH for RP11535I05 and RP11-547K2. DAPI 
stained metaphase image, showing the location of RP11-535I05 (red) and RP11-547K2 
(green) clones at 3p11.2 (A). DAPI stained interphase nuclei (B) showing the FISH pattern of 
two fusion (yellow) signals in normal nuclei.   
 
DNA isolation 
The cells were thawed and centrifuged at 1500rpm for 10 minutes (Eppendorff centrifuge, 
A-4-62 rotor), the supernatant was removed and 4ml of lysis buffer (Appendix A) was added 
to the pellets. One hundred micro litres of Proteinase K (10mg/ml) (Roche Diagnostics) was 
added to the samples and incubated at 55⁰C until homogenous. Four millilitres of phenol 
(Sigma®) and chloroform (Fluka® Analytical) were added and the samples were vortexed 
and spun at 6000rpm for 10 minutes (Eppendorff centrifuge 5810R, F34-6-38 rotor). The 
aqueous phase was transferred to a new tube and 2ml of phenol and chloroform were 
added to the samples. They were vortexed before centrifugation at 6000rpm for 10 minutes 
(Eppendorff centrifuge 5810R, F34-6-38 rotor). The aqueous phase was again transferred to 
a new tube and 4ml of chloroform was added. The samples were vortexed and centrifuged 
at 6000rpm for 10 minutes. The aqueous phase was transferred to a new tube and 2.5 
volumes of ice-cold, 100% ethanol was added to each sample. The samples were inverted to 
mix and then centrifuged at 6000rpm for 15 minutes at 4⁰C (Eppendorff centrifuge 5810R, 
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F34-6-38 rotor). The ethanol was decanted off and the pellets were washed in 200µl of 70%, 
ice-cold ethanol. The samples were centrifuged at 6000rpm for 10 minutes (Eppendorff 
centrifuge 5810R, F34-6-38 rotor). The DNA pellets were allowed to air-dry and then re-
suspended in 1XTE buffer (Promega).  
Assessment of DNA integrity 
All the DNA samples were assessed by gel electrophoresis and run on a 2% agarose gel at 
100mV for 45 minutes in 1X TAE buffer (Appendix A) to assess the DNA integrity. 
DNA Quantification 
The samples were quantified by spectrophotometry using the ND-1000 spectrophotometer 
(Nanodrop® Technologies). The A260/280 and A260/230 ratios were recorded. 
Sample preparation 
The DNA samples were diluted in a separate aliquot to 50ng/µl using molecular grade water 
(Accugene®, Lonza). They were assessed on the Nanodrop to check the concentration. 
Affymetrix 250K Genotyping assay for the assessment of DNA copy number changes in the 
five cell lines 
The 250K Nsp chips were used to assess copy number changes in the five cell lines. DNA 
extracted from blood of 6 normal male black individuals was used as a reference group for 
estimation of the copy numbers in the cell lines. 
Two hundred and fifty nanograms of DNA was used and the Affymetrix® GeneChip® 500K 
assay manual (P/N 701930 Rev. 3) was followed strictly for the Nsp part of the assay. The 
assay involves a restriction enzyme digest with Nsp I (New England Biolabs® Inc), adaptor 
ligation, PCR amplification using a universal primer, fragmentation and labelling. The 
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restriction enzyme digest, PCR amplification and fragmentation require quality assessment 
by gel electrophoresis before proceeding to the next step (full details on the 500K assay can 
be seen in Appendix C). Once the samples were labelled they were mixed with a 
hybridisation buffer and hybridised to the chips. Hybridisation took place overnight in an 
Affymetrix hybridisation chamber for 18 hours. Post hybridisation washing was performed 
using the Affymetrix fluidics station 450. Scanning was performed by the Affymetrix® 
Genechip scanner 7G. Quality control for the assay is done by generating the call rates for 
the genotyping calls in Genotyping Console™ (Affymetrix®).  
250K data analysis  
The Affymetrix®, Genotyping Console™ 2.0 was used for data analysis. The algorithm used 
for copy number estimation was the copy number analysis tool (CNAT 4.0) program 
(Affymetrix®). Subsequently the data was analyzed with third party software, Genepattern 
(Reich et al., 2006). The signal intensities from the CEL files were normalized by the PM-MM 
(perfect match minus mismatch) probe intensity and invariant set normalization against the 
median intensity of the controls. The raw copy number was then estimated from the signal 
intensities of the normals and smoothed by GLAD (Gain and Loss analysis of DNA) (Hupé et 
al., 2004).  
To determine the significant common regions of amplification and deletion (i.e. driver 
aberrations as opposed to random passenger aberrations) amongst the five cell lines, the 
GISTIC (Genomic Identification of Significant Targets in Cancer) algorithm (Beroukhim et al., 
2007) was applied to the smoothed data. The algorithm first scores the regions of copy 
number change according to their frequency and amplitude, which indicates the likelihood 
of it being a driver aberration (G-score). The statistical significance of each G-score is 
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calculated by comparison of these scores against a null model of random aberrations. This 
significance is represented as a q-value (False discovery rate), which represents the 
likelihood that the data was generated by chance. The aberrations that occur frequently and 
are highly aberrant are therefore considered to most likely contain driver aberrations. The 
most likely locations for oncogenes or tumour suppressors are identified by calculating the 
minimal common regions of aberration, which are most significantly altered i.e. high 
amplitude change. It also distinguishes broad aberrations (can be the length of a 
chromosome arm) from focal aberrations. The aberrations with high G-scores and minimal 
q-values (less than 0.25) are more likely to contain target genes. It also identifies possible 
overlapping aberrations that are statistically significant but independent. Each sample is 
then classified, according to its copy number status at each of these peak regions, as 
aberrant or not. The samples are classified as high or low level amplification with the 
thresholds: where low level amplification is greater than 0.1 but smaller than 0.9. High level 
amplification is >0.9 (0.9 corresponds to at least 3.7 copies per diploid cell). Similarly low 
level deletions (hemizygous) were -0.1 and high level deletions were <-1.3 (-1.3 corresponds 
to less than 0.9 copies per diploid cell). For further information refer to the publication and 
supplementary data from Beroukhim et al, 2007.  
2.3 RESULTS 
Cytogenetics and M-FISH 
Cytogenetic analysis revealed complex numerical and structural chromosome aberrations in 
all cell lines with a high variability observed between cells from the same cell line (Figures 
2.4 and 2.5). The G-banded karyotype of cell line WHCO1 and a corresponding M-FISH 
karyotype are shown in figure 2.4 that illustrates the degree of variation from one 
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metaphase to another (Figure 2.4). The M-FISH data confirmed the complexity of the 
karyotypes and revealed the genetic composition of recurrent chromosome markers that 
could not be identified on G-banded metaphases (Figure 2.5); some of these markers are 
further discussed below. The detailed composite karyotypes obtained from twenty 
metaphases in each cell line are summarized in Table 2.2. All cell lines were near diploid 
except for cell line WHCO5 which was near tetraploid (Figure 2.5). Across the five cell lines a 
total of 97 translocations, 19 trisomies and 11 monosomies were detected. The breakpoints 
amounted to 203, with 78 of these clustering around the centromeric regions of 
chromosomes. The chromosomes involving the highest number of abnormalities were 
chromosomes 1, 3, 5, 7, 8, 9, 10, 11, 13, 14, 15, 18, 19, 20 and 22. G-banded metaphases 
also revealed the presence of isochromosomes involving the D group acrocentric 
chromosomes in all the cell lines. In particular isochromosome 13q, i(13)(p10) was common 
to cell lines WHCO3, WHCO5 and WHCO6, isochromosome 14q, i(14)(p10) was common to 
cell lines WHCO1, WHCO5 and WHCO6, and isochromosome 15q, i(15)(p10) was seen in cell 
lines WHCO3 and WHCO5.  
The combined results of cytogenetics, FISH and M-FISH revealed a common translocation 
derivative, der(3)t(1;3)(p11;q11) that combined chromosome 3 and chromosome 1 short 
arms in cell lines WHCO5 and SNO (Figures 2.5, 2.6 and 2.7). The SNP array copy number 
data did not bring further information on these breakpoints, possibly due to a lack of SNP 
probes in this region. Interestingly, the 1p11 breakpoint was also involved in cell lines 
WHCO1 and WHCO6 in differing unbalanced translocations (Figure 2.5). The M-FISH and 
FISH results with probes for the respective partner chromosomes and centromeric Cep1, 
confirmed the interpretation of these derivatives as der(1)t(1;14)(p11;q11) in cell line 
WHCO1 and der(1)t(1;8)(p11;p11) in cell line WHCO6 (results not shown). SNP array copy 
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number data did not provide further information on the specific location of the breakpoints, 
which could have helped pin point possible target genes involved in the rearrangement.  
 
In contrast, a translocation derivative also involving the chromosome 1 pericentromeric 
region in cell line WHCO3 (Figure 2.7) was shown not to involve 1p11 but 1q11, and was 
interpreted as der(15)t(1;15)(q11-12;p11) (result not shown).  
 
Translocation derivatives involving chromosomes 3 and 22 were seen in cell lines WHCO3 
and WHCO5 and were interpreted as der(16)t(3;16;22)(p11;?;q?11) and t(3;22)(p11;q11) 
respectively (Table 2.3). The array data showed corresponding hemizygous deletions at 
3p11.2, in cell line WHCO3. Interestingly deletions at 3p11.2 were also observed in cell lines 
WHCO1, SNO and WHCO6. The minimal region of overlap was 343kb (88184220-
88527215bp) in size and involved c3orf38 and CGG triplet repeat binding protein (CGGBP1) 
genes. Deletions affecting EPHA3 gene were detected by array copy number analysis in 
WHCO1, WHCO3, WHCO6 and SNO (Figure 2.8). The EPHA3 gene encodes a tyrosine kinase, 
which is mutated in lung and breast cancers (Davies et al., 2005;Wood et al. 2006). EPHA3 
locus deletions were confirmed in the cell lines WHCO1, WHCO3 and SNO (Figure 2.9 and 
2.10) by the locus specific FISH probes designed and produced in-house. The signal patterns 
observed can be seen in table 2.3 and 2.4. The WHCO1 cell line showed loss of exons 1-3 
(loss of RP11-598N21). The WHCO3 cell line showed loss of exons 1-3 (loss of RP11-598N21) 
and exons 11-17 (RP11-547K2). The SNO cell line had loss of RP11-535I05, which maps 5’ of 
EPHA3. WHCO5 and WHCO6 didn’t show loss of any of the probes utilized here (Figure 2.9 
and 2.10).  
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Cell lines WHCO1, WHCO3, WHCO5 and WHCO6 all showed a deletion of chromosome 7 
long arm with varying breakpoints, q21 to q31, on G-banded metaphases (Figure 2.6). 
However GISTIC analysis of the SNP array data identified a significant common focal deletion 
(q-value of 0.09) of approximately 5.16Mb at 7q33-q34 (133721542-138880555bp) in only 
three of these cell lines. This region contained 26 genes including the potential target gene 
homeodomain-interacting protein kinase-2 (HIPK2) the product of which activates p53 
expression and is pro apoptotic (Puca et al., 2009).  
 
Although deletions at 20q11.2 were detected in cell lines WHCO5, WHCO6 and at 20q12 in 
cell line SNO on G-banded metaphases (Figure 2.6), copy number analysis (CNAT) revealed 
that there was in fact amplification of 20q sequences in all cell lines implying that complex 
rearrangement occurred for these sequences to be relocated elsewhere in the genome. Two 
minimal regions of amplification were identified, the 20q11.21-q11.22, of approximately 
1.12Mb in size (31799867-32906584bp), which contained 14 genes and a smaller region at 
20q13.12 of 149.48kb which contained 5 genes. Both these regions were amplified in all cell 
lines, yet these amplifications were not found to be significant on GISTIC analysis. 
Cell line SNO showed a large marker chromosome 7 on metaphases analyzed by M-FISH. 
This marker was interpreted as a possible inverted duplication of chromosome 7p 
sequences (Figure 2.5D). FISH with an epidermal growth factor receptor (EGFR) probe, 
revealed a high amplification of the EGFR gene in 14% of the cells (Figure 2.11). A high level 
amplification at 7p13-7p11.2 (genomic location of EGFR) was confirmed by GISTIC (q-value 
0.14) on array analysis in this cell line, while low level amplification was observed in the 
remaining four cell lines in agreement with the presence of 4 to 7 copies on FISH analysis. 
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Table 2.2. Composite karyotypes 
Cell line Composite combined cytogenetics and M-FISH karyotype 
WHCO1 42~73, XY, +X, +X [4], +1 [10], del 1(?) [4], + der(1)t(1;14)(p11;q11) x2 [18], t(1;14;22)(?;?;q?) [4], t(1;22)(?;q?) [6], + 2 
[8], t(2;8)(?;?) [4], +3 [8], +del 3(p21p13) x2 [4], der(3;22)(q10;q10) [4], -4 [8], t(5;21)(?;?) [8], + der(5)t(5;?)(q23;?) [4], 
+ del(6)(q?21) x2 [4], t(6;12)(?q;?p) [16], t(6;13)(?q25;?q14) x2 [18], +7 [4], + del(7)(q21) [4],  + der(7;14)(p10;q10) 
[20], der(7)t(7;18)(p21;q23) [16], der(7)t(7;19)(p22;p13) [4], der(8)t(8;?19)(q?24;q?11) [4], t(8;22)(?;?) [18], +9 [10], + 
der(10)t(9;10)(q13;q?11.2) [4], +11 [8], t(11;17;20)(?;?;?) [4], +12 [10], t(13;22)(?;?) [4], add(14)(q?) [4], i(14)(q10) [6], 
der(15;19)(q10;q10) [20], der(16)t(5;16)(?;?) [8], +18 [4],  der(19)t(5;19)(p?12;q11) [12], der(19) t(5,19)(q33;q13.4) 
[18], + der(19)t(9;19)(q?13;q?13) x2 [4], t(19;21)(?;?) [14], +20, +20 [20], + der (20)t(1;11;20)(?;?;?) [4], +1~7mar [20] 
[cp20]. 
WHCO3 46~50 , X, -Y, +2 [12],  der(5)t(5;8,18)(q?;?;?) [20], + del 7(q22) [4], der(7)t(7;9)(?;?) [6],  t(7;9;16;18)(?;?;?;?) [14], 
t(7;15)(?;?) [4], +12 [6], der(12)t(6;12)(?;?) [16], i(13)(q10) [6], t(13;14)(?;?) [6], t(13;14;20)(?;?;?) [6], +14 [12], + 
der(15)t(1;15)(q11;p11) [6], + der(15)t(1;15;11)(?;?;?) [10], der(15;22)(q10;q10) [20], i(15)(q10) [4], 
der(16)t(3;16;22)(p?11.2;?;q?10) [20], +17 [10], der(?20)t(9;13;20)(?;?;?) [10], der(21)t(13;21)(?;?) [12] [cp20]. 
WHCO5* 99~108, XY, t(X;4;10.22)(?;?;?;q?) [14], t(1;19)(?;?) [8], t(1;18)(?;?) [6], del 2 [2], der(2)t(2;9)(q12;q13) [10], 
t(2;9)(?q31;?q34) [8], +der(3)t(1;3)(p11-12;q11) [12],  t(3;11;13;22)(?;?;?;?) [8], t(3;11;22)(?;?;?) [16], t(3;22)(p11;q11) 
[12], der(5;20)(p10;p10) [4], t(6;13)(?;?) [4], del(7)(q31) [4]; t(8;14;18)(?;?;?) [16], t(8;18)(?;?) [10], der(9)t(9;14)(?;?) 
[16], t(9;15)(q?;q?) [10], t(9;19)(?;?) [6], t(12;19)(?;?) [4], i(13)(q10) [6], i(14)(q10) [8], der(15)t(Y;15)(?;?)[12], 
der(15)t(7;15)(?;?) x2 [14], i(15)(q10) [4], der(19)del(19)(q13.?2)t(5;19)(p?12;p11) [12], del(20)(q11.2) [12]  [cp20]. 
WHCO6 44~54, Y, -X, der(1)t(1;8)(p11;q11) [14], t(3;10)(?;?) [4], t(3;10)(?q13.3;p10) [6], t(4;10)(?;?) [4], t(5;10)(?;?) [10], 
t(5;22)(?;q?) [4], +6 [2], del(6)(q?21) [4]; t(6;11)(p12;q13) [6], der(22)t(6;22)(?;?) [6], +7[7], del(7)(q31) [8]; +8 [8], 
t(9;15)(?;?) [10], t(10;14)(?;?) [6], -11 [6], t(11;22)(p?;q?) [6], +12 [10], i(13)(q10) [6]; i(14)(q10) [6], +16 [8], 
t(17;19)(?;?) [10], +18 [4], del(20)(q?11.2) [6]; -21 [12], t(21;22)(?;?) [6], der(22)t(6;22)(?;?) [6], [cp14]. 
SNO 29~43, XY, +X, del X(?) [14], der(Y;15)(q10;q10) [12], t(1;16)(?;?) [14], der(2)t(X;2)(?;?) [16], der(2)t(1;2)(?;?) [18], 
der(3)t(1;3)(p11-12;q11) [20], t(3;9)(?;?) [4], t(3;10)(?;?) [14], t(3;12)(?;?) [20], t(3;20)(?;?) [8], t(4;9;11)(?;?;?) [20], 
t(4;11)(?;?) [12], der(5)t(1;5)(?;?) [20], -6 [18], del(6)(q?23) [20], der(7)t(3;7)(?q25;p22) [18],  t(7;20;11;8;2)(?;?;?;?;?) 
[18], der(8)t(2;8)(?;?) [14], t(8;18)(?;?) [8], -9 [10], t(9;18)(?;?) [4], t(10;22)(q?;q?) [12], t(11;13)(?;?)[8], t(12;15)(?;?)[8], 
t(12;21)(?;?)[20], t(13;11;20)(?;?;?) [14], der(14;22)(p10;q10) x2 [20], t(14;19)(?;?) [20], -16 [14], 
der(16)t(9;16)(q?22;q?13) [20], der(17)t(6;17)(?;?) [12], -18 [16], -19 [16], der(19)del(19)(q13.?2)t(5;19)(q?12;q10) 
[16], +20 [10], del(20)(q?12) [16]; der(20;21)(q10;p10) [6], -21 [18],  -22 [20] [cp20]. 
* Only structural rearrangements are listed due to the complexity of this cell line. 
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Table 2.3. FISH results for the BAC probes RP11-784B9 (red) and RP11-598N21 (green). 
Cell line Signal pattern No. Cells 
(n=100) 
Conclusion 
WHCO1 
 4 red 3 green 93 93% loss of RP11-598N21 
 2 red 2 green 7  
WHCO3 
 2 red 1 green 100 100% loss of RP11-598N21 
WHCO5 
 4reds 4green 100 100% no loss 
    
WHCO6 
 2reds 2greens 100 100% no loss 
SNO 
 3 reds 3 greens 100 100% no loss 
 
Table 2.4. FISH results for the BAC probes RP11-535I05 (red) and RP11-547K2 (green). 
Cell line Signal pattern No. Cells 
(n=100) 
Conclusion 
WHCO1 
 2yellow2green 93  
 2yellow 7 93% loss of RP11-535I05 
WHCO3 
 1Yellow 74  
 1yellow1red 15  
 1 red 4  
 2yellow 7 74% loss of both RP11-535 
and RP11-547K2 
WHCO5 
 4yellow 73  
 3 yellow 27 100% no loss  
WHCO6 
 2yellow 100 100% no loss 
SNO 
 2 yellow 2 green 45  
 4 green 28  
 3yellow 15  
 5green 12 88% loss of RP11-535I05 
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Figure 2.4.  G-banded and M-FISH representative karyotypes of cell line 
WHCO1. (A) G-banded karyotype and (B) M-FISH karyotype, the arrows 
indicate the marker chromosomes, der(1) t(1;14)(p11;q11) and 
del(7)(q21). 
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Figure 2.5. M-FISH representative karyotypes showing complex rearrangements in four cell 
lines. (A) Cell line WHCO3, the white arrow indicates the der(15)t(1;15)(q11;p11). (B) Cell 
line WHCO5, the white arrow points to the der(3)t(1;3)(p11-12;q11). (C) Cell line WHCO6 
and (D) Cell line SNO, the white arrow points to the der(3)t(1;3)(p11-12;p11) and the yellow 
arrow indicates the marker chromosome 7, mar(7), which involves the EGFR locus (see figure 
2.11).  
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Figure 2.6. Partial G-banded karyotypes of the five cell lines showing shared chromosomal 
aberrations across cell lines. Chromosome derivatives from unbalanced translocations 
involving (A) chromosome 1p11-12 breakpoints in 4 cell lines, 1q11 in cell line WHCO3, (B) 
deletions of chromosome 7q in four cell lines, and (C) deletions of chromosome 20q in 3 cell 
lines. 
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Figure 2.7. DAPI stained metaphasic chromosomes showing the der(3)t(1;3)(p11-12;q11) 
in cell lines SNO and WHCO5.  (A) and (B) Arm-specific paint for chromosomes 1p (green) 
and 3p (red) in cell lines SNO and WHCO5 respectively showing the derivatives 
der(3)t(1;3)(p11-12;q11) arrowed. (C) and (D), arm specific paint for chromosome 1p (green) 
and Cep 3 alpha probe (red) in cell lines SNO and WHCO5 respectively showing that the 
centromere of chromosome 3 is retained on the derivatives der(3)t(1;3)(p11-12;q11). 
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Figure 2.8. CNAT plot of SNP hybridization results showing the map of the region of 
deletion on chromosome 3p11.2-12.1 in cell lines WHCO1, WHCO3, WHCO5, WHCO6 and 
SNO. The red bars indicate the segment of deletion as determined by CNAT 4.0. The dotted 
lines indicate the copy number status for each SNP probe for each cell line. The blue block 
indicates the minimal common region of deletion and the red arrow indicates the two genes 
in this region, c3orf38 and CGGBP1. 
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Figure 2.9. Representative images of DAPI stained interphase nuclei showing FISH results 
for all five cell lines with BAC clones, RP11-589N21 (green) and RP11-784B9 (red). The 
WHCO1 cell line (A) showing an interphase cell with 4 copies of chromosome 3p and loss of  
RP11-598N21 BAC (green) signal, which indicates loss of exon 1-3 sequences in one 
chromosome 3 homologs. The metaphase shows chromosome 3p with loss of RP11-598N21 
as indicated by the white arrow.  The WHCO3 cell line (B) showing two copies of 
chromosome 3p and loss of one RP11-598N21 BAC signal (loss of exon 1-3 sequences, 
indicated by the white arrow). The WHCO5 cell line (C) showing 4 copies of chromosome 3p 
and no loss of RP11-598N21 BAC signal (white arrows).  The SNO cell line (D) showing 3 
copies of both BAC probes (white arrows), indicating that there is no loss of RP11-598N21. 
The WHCO6 cell line (E) with both copies of both probes, indicating that there is no loss of 
either. Cell lines WHCO5 and SNO had 3 to 4 copies of chromosome 3 per cell as determined 
by M-FISH. 
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Figure 2.10. Representative images for DAPI stained interphase cells from each cell line 
showing results for FISH analysis with BAC clones, RP11-535I05 (red) and RP11-547K2 
(green). In the WHCO1 cell line (A), the pattern was 2 fusion and 2 green signals indicating 
loss of the RP11-535I05 BAC, indicating loss of sequences upstream of the EPHA3 gene. In 
the WHCO3 cell line (B) the pattern was 1 fusion showing loss of both RP-11535I05 and RP-
11547K2 BACs on chromosome 3 homolog (white arrow), indicating a loss of exon 11-17 and 
upstream sequences of EPHA3. In the WHCO5 cell line (C) the pattern was 4 fusion signals 
showing no loss (white arrows). In the WHCO6 cell line (D) 2 fusions were seen, showing no 
loss (white arrows).  In the SNO cell line (F), 2 to 3 fusions and two greens (white arrows) 
were observed showing loss of the RP11535I05 clone. 
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Figure 2.11. DAPI stained metaphase from cell line 
SNO showing FISH results with the locus specific EGFR 
probe (red) and Cep7 alpha (green). The arrow 
indicates the chromosome 7 marker with a 
homogeneously stained region (HSR) that contains the 
EGFR locus. 
 
Copy number changes 
In view of the high cell to cell heterogeneity in each cell line, and in order to separate the 
potential driver aberrations out of the background of aberrations that may have occurred by 
chance, we used the software GISTIC specifically designed for this purpose. Target genes, 
defined as genes whose alteration confers a cell growth advantage, are likely to reside in the 
regions amplified or deleted to the highest degree in a majority of cells and within a 
common region of overlap amongst all cell lines. Fourteen common regions of amplification 
and 20 regions of deletion were identified (Figure 2.12 and Tables 2.5 and 2.6). The most 
significant chromosomal regions of amplification were, in descending order of significance: 
11q13.3 and 8q24.21, in 4 and 5 cell lines respectively, 11q22.1-q22.3 and 5p15.2 both 
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detected in 2 cell lines. Chromosomal regions of less significant amplification were 
10p12.33-q21.3, 18p11.32, 20p11.1-p11.22, 22q11.21-q11.22, 22q12.3, 9q31.1, 22q11.21, 
3q11.2-q12.2 and 1p34.2 (Figure 2.12). Similarly, chromosomal regions of deletion were 
seen in the following order of significance: 1p31.1-p31.2, 2q22.1, 3p12.1-p14.2, 4q22.1-
q32.1, 8q11.1-p23.2, 14q21.2, 18q21.1-q21.2 and 21p13-q21.3 detected in all or 4 cell lines. 
Other regions of less significant deletion, and only seen in 1 or 2 cell lines, included: 
10p12.31-p14, 14p13-q32.33, 3p26.3-q29, 9p24.2-p24.3, 6q24.3-q27, 12p13.33-q24.33, 
7q33-q34, 8p23.3-q24.3, 10q11.23-q22.1, 11p11.12-q12.2 and 13q21.33-q34 (Figure 2.12). 
Together the regions of amplification and deletion encompassed a total of 4595 genes. 
 
Significant Gains 
The five regions of amplification that were the most significant on GISTIC analysis (q-value 
<0.25) are selectively described below (Figure 2.12).  
Chromosomes 11q13.3 (68753086-69985447bp) and 8q24.21 (127445828-129661846) were 
the two most amplified and most significant regions with a q-value of 5.76E-05 and 0.0007 
respectively. The 11q13.3 region was 1.23Mb in size and was highly amplified in cell lines 
WHCO3, WHCO5, WHCO6 and SNO while amplified to a lesser degree in cell line WHCO1. 
This region harbours seven candidate genes including the Cyclin D1 (CCND1), the Cortactin 
(CTTN), the protein tyrosine phosphatase, receptor type, polypeptide, interacting protein 
alpha 1 (PPFIA1), the fibroblast growth factor FGF3, FGF4 and FGF19 and the myeloma 
overexpressed (MYEOV) genes, which could all play a role in OSCC oncogenesis. FISH 
validated these findings and confirmed the amplification of CCND1 and FGF4 (Table 2.6, 
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Figure 2.13). The common amplicon of 2.22Mb at 8q24.21 was highly amplified in cell lines 
WHCO1 and WHCO3 and moderately amplified in cell lines WHCO5, WHCO6 and SNO. This 
amplicon involved the oncogene v-myc myelocytomatosis viral oncogene homolog (C-MYC) 
and the family with sequence similarity 84, member B (FAM84B) gene. Locus specific FISH 
confirmed the amplification of C-MYC in cell lines WHCO1, WHCO3, WHCO5, WHCO6 and 
SNO (Table 2.7, Figure 2.13).  
A second focal region of high amplification on chromosome 11 was observed at 11q22.1-
q22.3 (2.23Mb in size) in cell lines WHCO5 and SNO. This region included the regulators of 
apoptosis BIRC2 (cIAP1) and BIRC3 (cIAP2), the matrix metalloproteinases (MMP) and the 
Yes associated protein (YAP-1) genes all potential target genes. The BIRC2 gene was 
previously described as a target of amplification /increased expression in cervical cancers 
(Imoto et al., 2002) and the YAP-1 gene product is a cellular adaptor protein, which can 
induce BIRC2 expression. YAP-1 was reported to be over expressed in hepatic and mammary 
cancers (Da et al., 2009). In turn, the MMP genes, which include MMP1, MMP7, and 
MMP13, have been shown to be co-expressed in early stage OSCC correlating with a poorer 
prognosis (Z. D. Gu et al., 2005).  
A 1.75Mb region on chromosome 5p15.2 (10051329-11800765bp) was highly amplified in 
cell lines WHCO6 and WHCO5 and moderately amplified in cell lines WHCO1 and SNO. This 
region hosts the potential target gene, Delta catenin (CTNND2), over expressed in prostate 
cancer (M. J. Burger et al. 2002).  
Four cell lines, (WHCO6, WHCO3, WHCO5 and SNO) had focal gain on chromosome 3q. The 
minimal common region of amplification mapped at 3q11.2-12.2, and was 6.02Mb in size 
(95917505-101945216bp) (q-value=0.17). This region is commonly amplified in a variety of 
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cancers (Haverty et al., 2009; Or et al., 2005) including oesophageal squamous carcinoma (J 
Chen et al., 2008) and it involved the potential oncogene, MYC induced nuclear antigen 
(MINA). 
The 18p11.32 sub-band was highly amplified in cell lines WHCO3 and WHCO6 and 
moderately amplified in the remaining 3 cell lines. This region of 1.12Mb in size (1-
1118244bp) has previously been described in OSCC (Nakakuki et al., 2002) and involves the 
potential oncogenes TYMS and YES-1. Both genes have been implicated in gastro intestinal 
cancer. The TYMS gene codes for a thymidylate synthase involved in DNA synthesis and 
targeted by the chemotherapy agent Fluorouracil (5FU). TYMS overexpression leads to 5FU 
treatment’s resistance (Nakakuki et al., 2002) and affects colorectal cancer treatment (S. A. 
Jensen et al., 2008). YES-1 is a homologue of the Yamaguchi sarcoma virus v-yes amplified 
and overexpressed in gastric cancers and OSCC (Nakakuki et al., 2002). 
 
Significant Losses 
The most significantly deleted chromosomal regions were 1p31.1-p31.2, 2q22.1, 3p12.1-
p14.2, 4q22.1-q32.1, 8p23.2-q11.1, 14q21.2 and 18q21.1-q21.2 (in descending order of 
significance) in all or four of the cell lines (Figure 2.12).  Less significant regions detected in 
less than 4 cell lines are depicted in table 2.6.  
Three small regions of deletions involved chromosomes 1p, 2q and 18q. 
The 4.5 Mb deletion on chromosome 1 short arm, 1p31.2-p31.1 (66691991-71187083bp) 
was seen in four cell lines (homozygous deletion in cell line SNO and hemizygous in cell lines 
WHCO1, WHCO5, WHCO6) with a high significant q-value of 0.02.  Three genes with a 
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reported tumour suppressor activity were involved in this deletion, the cystathionine γ-lyase 
(CTH), the growth arrest and DNA damage-45 alpha (GADD45alpha) and the DIRAS family, 
GTP-binding RAS-like 3 (DIRAS3) genes. The DIRAS3 gene was shown to be down regulated 
in hepatocellular carcinoma and breast cancers (Jian Huang et al., 2009; Z. Shi et al., 2002) 
and is postulated to have a tumour suppressive activity. Both the CTH and GADD45 genes 
were shown to negatively control cell growth (Rosemary Siafakas & Richardson, 2009; G. 
Yang et al., 2004).  
Chromosome 2, sub-band q22.1 (141590067-141951947bp) was lost in all cell lines 
(homozygous deletion in cell lines WHCO3 and WHCO5 and hemizygous in the other 3 cell 
lines) (q-value= 0.019). The low density lipoprotein 1B (LRP1B) tumour suppressor gene 
maps in this region and is deleted in lung cancer (C. X. Liu et al., 2007; Nagayama et al., 
2007). 
A chromosome 18q sub-band, q21.1-q21.2 (46081464-51919972bp) (5.8Mb) was 
hemizygously deleted in all five cell lines, involving both the SMAD4 and deleted in 
colorectal carcinoma (DCC) genes.  
 
Three large regions of deletion involved chromosomes 3p, 4q and 8p. 
First, the 24.7Mb region of deletion at 3p12.1-p14.2 (60424050-85108679) was significant 
(q-value of 0.02) in all cell lines (homozygous deletion in cell line SNO). This region houses 
the FRA3B associated gene, Fragile Histidine triad (FHIT), whose deletions were previously 
detected by MLPA analysis in these cell lines (Willem et al., 2006). The potential tumour 
suppressor ADAMTS9 gene, a metalloproteinase family member involved in inhibition of 
angiogenesis (P. H. Y. Lo et al., 2010) was also involved in this deletion.  
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Second, the 4q22.1-q32.1 (91972774-162358674bp) (75Mb) region was homozygously 
deleted in cell lines WHCO3 and WHCO5 and hemizygously deleted in the 3 other cell lines 
with a q-value of 0.02. This region encompasses many genes but of interest are the Bone 
morphogenetic protein receptor 1B (BMPR1B), the Caspase 6 (CASP6), the secreted frizzled-
related protein 2 (SFRP2) and the SMAD protein 1 (SMAD1) genes, all potential tumour 
suppressor genes.  
Lastly, a chromosome 8p23.2-q11.1 (4078057-47043375bp) (43Mb) deletion was seen in all 
cell lines (homozygous in cell line WHCO3 and hemizygous in the other 4 cell lines) (q value 
of 0.02). This region is very large and could target numerous genes. Genes that have been 
implicated as tumour suppressors include, secreted frizzled-related protein 1 (SFRP1), the 
BCL2/adenovirus E1B 19kDa interacting protein 3-like (BNIP3L), the leucine zipper tumor 
suppressor 1 (LZTS1) and the three tumor necrosis factor related superfamily genes (TNFRS), 
TNFRSF10A, TNFRSF10B and TNFRSF10C.  
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Table 2.5. Amplification peaks as detected by the GISTIC algorithm.  
Cytoband Location(kb) Approx 
Size (Mb) 
Frequency(n/5
) 
Mean 
log2ratio
a 
q-value Genes
b 
1p34.2 Chr1:39027237-
40780163 
1.75 3 1.1 0.18 MYCL1 
3q11.2-
q12.2 
chr3:95917505-
101945216 
6.02 4 1.4 0.17 MINA 
 
5p15.2 chr5:10051329-
11800765 
1.75 2 1.36 0.09 CTNND2 
7p11.2-p13 Chr7:45294289-
57299457 
12.01 1 1.24 0.13 EGFR 
8q24.21 chr8:127445828
-129661846 
2.22 5 2.1 0.0007 MYC 
9q31.1 chr9:100905143
-102152148 
1.25 1 2.57 0.15  
10q12.33-
q21.3 
chr10:17811791
-65388337 
47.58 1 3.05 0.13  
11q13.3 chr11:68753086
-69985447 
1.23 4 1.81 5.76E
-05 
CCND1, CTTN, FGF3, 
FGF4, FGF19, MYEOV 
 
11q22.1-
q22.3 
Chr11:10081580
1-103042620 
2.23 2 2.35 0.03 BIRC2, BIRC3, YAP1 
18p11.32 chr18:1-
1118244 
1.12 2 1.04 0.13 TYMS, YES1 
20p11.1-
p11.22 
chr20:22140447
-26145930 
4.01 2 1.24 0.13 PYGB 
22q11.21 chr22:16558724
-17937900 
 
1.38 2 1.2 0.21 BID, CLDN5 
22q11.21-
q11.22 
Chr22:18577713
-20667607 
 
2.1 2 1.2 0.13 
 
CRKL, MAPK1 
22q12.3 Chr22:31889314
-32003182 
0.11 2 1.15 0.13 LARGE 
a
The mean log2ratio for the samples with a log2ratio>0.9 (equivalent to 3.7 copies per diploid cell). 
bThe selected genes from the peak region 
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Table 2.6. Deletion peaks as detected by the GISTIC algorithm. 
Cytoband Location(
kb) 
Size 
(Mb) 
Frequency(n/5)  Mean 
log2ratio
* 
q- 
value 
Genes
b 
Hemi Homo 
1p31.1-p31.2  chr1:66691991-
71187083 
4.5 3 1 -3.03 0.02 CTH 
2q22.1  chr2:14159006
7-141951947 
0.36 3 2 -1.66 0.19 LRP1B 
3p26.3-q29  Chr3:1-
199344050 
199.34 2 1 -2.9 0.022  
3p12.1-p14.2    chr7:60424050-
85108679 
24.7 4 1 -2.99 0.02 FHIT, ADAMTS9 
4q22.1-q32.1 Chr4:91972774-
162358674 
70.4           3 2 -2.19 0.02 CASP6, SMAD1 
6q24.3-q27 Chr6:14796744
4-170914576 
22.95           2 1 -2.22 0.07  
7q33-q34 Chr7:13372154
2-138880555 
5.16           2 1 -1.72 0.09 HIPK2 
8p23.2-q11.1 Chr8:4078057-
47043375 
43           4 1 -2.47 0.02 SFRP1, BNIP3L, 
INDO 
8p23.3-q21.13 Chr8:1-
146308819 
146.31           1 1 -2.27 0.09  
9p24.2-p24.3 Chr9:1151516-
2459741 
1.31            2 1 -2.53 0.03  
10p12.31-p14 Chr10:1030902
6-19155158 
408.85           2 1 -2.74 0.02  
10q11.23-
q22.1 
Chr10:5039332
4-70694787 
20.3           1 1 -2.35 0.12  
11p11.12-
q12.2 
Chr11:5025679
8-61426521 
11.2           1 1 -1.9 0.12  
12p13.33-
q24.33 
1-132078379 132.1            1 -2.8 0.08  
13q21.33-q34 68772537-
113042980 
44.3            1 1 -1.7 0.24  
14q21.2 42828345-
44176016 
1.35            3 1 -4.5 0.02  
14p13-q32.33 1-105311216 105.3             1 -5.1 0.02  
18q21.1-q21.2 46081464-
51919972 
5.8            5  -1.03 0.02 
 
DCC, SMAD4 
21p13-q21.3 1-29932926 29.9            3   0.12 BAGE 
aThe mean of the log2ratio of those samples with log2ratios <-1.3 (<0.9 copies per diploid cell). bThe 
selected genes within the deletion peaks.  
 
 78 | P a g e  
 
Table 2.7. FISH for detection of CCND1, FGF4  and C-MYC amplification.  
 
Cell line FISH signals Amplitude# Log2Ratio 
CCND1    
WHCO1 5-15 2 1.56 
WHCO3 >20 2 2.57 
WHCO5 10-20 1 0.78 
WHCO6 4-8 1 0.55 
SNO 15-20 1 0.79 
C-MYC    
WHCO1 4-6 1 0.12 
WHCO3 15->20 2 1.83 
WHCO5 10->20 2 1.83 
WHCO6 10->20 2 2.06 
SNO 4->20 2 1.71 
# Amplitude threshold where log2ratio<0.1 =0, 
log2ratio>0.1<0.9= 1 and log2ratio>0.9=2 as 
determined by SNP array copy number analysis.  
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Figure 2.12. Plots of recurrent genomic amplifications (A) and deletions (B) detected in the 
OSCC cell lines from GISTIC analysis of SNP array data. The x-axis shows the G-score (top) 
and false discovery rate (q value; bottom). The green line indicates the false discovery rate 
cut off of 0.25. The circles indicate the peaks of the most significantly aberrant 
chromosomal regions. 
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Figure 2.13. DAPI stained interphase nuclei hybridised with locus specific probes for C-
MYC Spectrum Orange (red) (A-D) and CCND1 (red)/IGH (green) (E-H). C-MYC 
amplification can be seen in cell lines WHCO1 (A), WHCO3 (B), WHCO5 (C) and SNO (D). 
CCND1 amplification was detected in cell lines WHCO3 (E), WHCO5 (F), WHCO6 (G) and 
SNO (H). 
 
2.4 DISCUSSION 
The karyotype and genomic constitution of five OSCC cell lines established in SA using a 
combination of traditional cytogenetics, M-FISH, FISH and SNP arrays has been 
characterised. The number of OSCC cell lines genetically described worldwide is limited. 
Only eight OSCC cell lines have been investigated previously with traditional cytogenetics to 
our knowledge (Y. C. Hu et al., 2002; Y. P. Wu et al., 2006; S. Xiao et al., 1991; L. C. M. 
Cheung et al., 2007) and 10 with multi color FISH (Y. P. Wu et al., 2006; Yang et al., 2008; C. 
C. Yen et al., 2001), these are the only two techniques that can detect recurrent 
translocation breakpoints. In this study the 5 cell lines had complex karyotypes and were 
hyperploid with WHCO5 being near tetraploid. There was a high level of intra cell-line 
heterogeneity. The chromosomes most frequently involved in translocations were 
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chromosomes 1, 3, 5, 7, 8, 9, 10, 11, 13, 14, 15, 18, 19, 20 and 22. These features were 
comparable to OSCC cell lines previously characterized (Y. P. Wu et al., 2006; S. Xiao et al., 
1991; L. C. M. Cheung et al., 2007) and across all studies that involved karyotyping, including 
the karyotyping of fresh OSCC tumour samples (Yuesheng Jin et al., 2004),  chromosomes 1, 
3 and 8 were the most commonly affected by translocation breakpoints (Y. C. Hu et al., 
2002; Y. P. Wu et al., 2006; S. Xiao et al., 1991; Yang et al., 2008). 
 
Forty percent of translocation breakpoints occurred in near centromeric regions (Table 2.2). 
These were represented by unbalanced whole arm chromosome translocations, frequently 
involving chromosomes 1 and 3, and by isochromosomes for the D group acrocentric 
chromosomes 13, 14 and 15. Indeed, frequent centromeric breakpoints have been 
described in squamous carcinoma including OSCC (Y. C. Hu et al., 2002; S. Xiao et al., 1991) 
with up to 60 % of all breakpoints being in centromeric regions (Yang et al., 2008) 
supporting the idea that centromeric disruption is a frequent event in epithelial cancers. It 
has been suggested that environmental factors may preferentially interact with centromeric 
sequences (Y Jin et al., 2000), and clastogenic compounds, such as mitomycin C, induce 
breaks in centromeric of chromosomes 1, 9 and 16 (B Johansson & F Mertens, 1988). 
Smoking is a major risk factor associated with OSCC and nicotine is known to induce single 
strand DNA breaks (Kleinsasser et al., 2006). Although active smokers exhibit an increased 
number of breaks at fragile sites (C. K. Stein et al., 2002), it is not known if centromeric 
regions are also targeted.  
 
Two chromosomal breakpoints were shared across cell lines. First, chromosome 1p11 was 
involved in a translocation in four cell lines, translocation t(1;3)( p11.2-12; q11) in cell lines  
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SNO and WHCO5 and translocations with differing partners in cell lines WHCO1 and 
WHCO6. Second, chromosome 3p11-12 was involved in translocations in two cell lines and 
deletions in, or near the EPHA3 locus was seen in three cell lines. The EPHA3 gene codes for 
a receptor tyrosine kinase, with a tumour suppressor activity (Clifford et al., 2008). It was 
found to be mutated in lung and breast cancers (Davies et al., 2005; P.; L. D. Wood et al., 
2006) and interestingly, found to be deleted in 18.2% of OSCC patients in a previous study 
(Chen et al., 2008). 
 
Breakpoints, in or near the centromeric regions of chromosomes 1 and 3, have previously 
been reported in several OSCC cell lines (Y. C. Hu et al., 2002; Y.P. Wu et al., 2006; S. Xiao et 
al., 1991), as well as  in fresh  OSCC tumour samples that were karyotyped (Yuesheng Jin et 
al., 2004) and in OSCC cell lines obtained by in vitro transformation with  the human 
papillomavirus (HPV) (H. Zhang et al., 2006). This strongly points to 1p11 and 3p11 
translocation hotspots in OSCC that may affect genes and/or regulatory sequences not 
identified by SNP array. Deletions affecting or near the EPHA3 gene may point to a role for 
this gene which was previously found to be deleted in 18.2% of OSCC patients (Chen et al., 
2008).  
 
It is known from previous studies that these OSCC cell lines, all over express the EGFR gene 
(R Veale, 1989). EGFR DNA amplification observed in cell line SNO is likely to contribute to 
EGFR over expression whilst amplification in other cell lines other factors are likely to be 
involved in the other 4 cell lines where low levels of EGFR amplification were observed. 
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In view of the high clonal heterogeneity observed in each cell line, we used the GISTIC 
software in addition to CNAT to analyze SNP array data and evidence the significant targets 
of amplification and deletions. The most stable genetic rearrangements are thought to 
reflect a proliferative cell growth advantage. In this context, the GISTIC algorithm allowed us 
to prioritize amplicons and regions of deletions in term of their likelihood to host driver 
genes. The five most interesting significant regions of amplification included chromosomal 
regions: 11q13.3, 8q24.21, 11q22.1-q22.3, 5p15.2 and 3q11.2-q12.2 in decreasing order of 
significance.  
 
The 8q24.21, 11q13.3 and 3q11.2-q12.2 regions have all previously been reported in a 
variety of carcinomas (Burkhardt et al., 2010; Freier et al., 2003; Bass et al., 2009) and they 
often co-exist with one another. Genomic amplification at 8q24 occurs in a large variety of 
cancers (Burkhardt et al., 2010; Bass et al., 2009; Camps et al., 2009; X. P. Huang et al., 2006; 
van Duin et al., 2007), and most  amplicons described in the literature involve both the C-
MYC and FAM84B genes, as was observed in this study in four OSCC cell lines. In previous 
reports the target of amplification has been attributed to either both genes (Camps et al., 
2009), or to one or the other (X. P. Huang et al., 2006; van Duin et al., 2007) based on their 
respective increased transcription.  
The 11q13.3 amplicon covered a large region containing a number of potential target genes. 
The CCND1 and MYEOV genes (11q13.3) were co-amplified in four cell lines. Co-
amplification of these genes has been reported in multiple myeloma, breast cancer and 
OSCC (Yuesheng Jin et al., 2004). CCND1 is a downstream effector in the Wnt2/beta-catenin 
pathway and the most frequent target of amplification in several OSCC studies (Yuesheng Jin 
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et al., 2004; Bass et al., 2009; J. W. G. Janssen, Cuny, et al., 2002). While the MYEOV gene 
has been associated with cell proliferation in colon cancer (Moss et al., 2006), its 
amplification in OSCC is not always matched by increased transcription due to its silencing 
by epigenetic mechanisms (J. W. G. Janssen, Imoto, et al., 2002). The cortactin gene, CTTN, 
involved in cell motility (P. Hofman et al., 2008), was previously shown to be over expressed 
in OSCC pre-cancerous lesions, as well as in carcinogen induced murine OSCC supporting a 
role for this gene in OSCC carcinogenesis (N. Y. Hsu et al., 2008). The three fibroblast growth 
factor (FGF) genes, FGF3, FGF4 and FGF19 were part of the 11q13.3 amplicon. FGFs and Wnt 
signalling pathways cross talk in a number of carcinogenesis scenarios (Masuko Katoh & 
Masaru Katoh, 2006). Activated FGF receptors activate the FRS-GR2-GAB1-PI3K-AKT 
signaling cascade, and down regulate GSK-3β protein activity, thus hampering β-catenin 
phosphorylation and degradation (Masuko Katoh & Masaru Katoh, 2006). In particular, 
FGF19 ligand down regulates GSK-3β activity, which results in the release and nuclear 
accumulation of β-catenin. Nuclear β-catenin activates the transcription of downstream 
genes including C-MYC and CCND1 (Novak & Dedhar, 1999).  
In addition to the amplification of Wnt pathway activators, the SFRP1 and SFRP2 tumour 
suppressor genes’ loci were deleted at chromosomes 8p23.2-q11.1 and 4q22.1-q32.1 
respectively (Figure 2.7). The SFRP1 and SFRP2 genes encode frizzled-related proteins and 
are part of the SFRP family of Wnt inhibitors (Rattner et al. 1997; Kawano & Kypta 2003). 
Inactivation of SFRP1 by methylation and lower expression is observed in gastric cancer 
(Kinoshita et al. 2011). Loss of SFRP2 is detected in medulloblastoma and is suggested to 
contribute to carcinogenesis through loss of inhibition of the Wnt pathway (Kongkham et 
al., 2010).  
 85 | P a g e  
 
The copy number data therefore suggests that the Wnt signalling pathway may be at work 
in these OSCC cell lines through one or the combined effects of genes activating the β-
catenin transcriptional activity and/or the FGF signalling pathways as well as deletions of 
genes, at 4q22.1-q32.1 and 8p23.2-q11.1, inhibiting this pathway. Amplicons at both 8q24 
and 11q13.3-13.4 have been described in a variety of squamous cell carcinoma (Camps et 
al., 2009; W. Liu et al., 2008; J. W. Janssen et al., 2000; Fantozzi et al., 2008) suggesting that 
the activation of pathways through the combined effects of genes at 8q24 and 11q13.3-13.4 
contributes to the development and aggressiveness of SCC.  
In addition to the SFRP2 gene, the three tumour suppressor genes BMR1B, SMAD1 and 
CASP6 were also targets of deletion at 4q22.1-q32.1. Both BMR1B and SMAD1 genes have 
previously been reported to have decreased expression in gliomas correlating with poor 
survival (S. Liu et al., 2009), and BMPR1B decreased expression in breast cancer is associated 
with increased cell proliferation and poor prognosis (Bokobza et al., 2009). The CASP6 gene 
encodes the pro apoptotic caspase-6 protein (J. Y. Chan et al., 2008).  
Although large 3q amplicons are commonly observed in squamous carcinoma (Haverty et 
al., 2009; Kanao et al., 2005) in this study the 6Mb, 3q11.2-12.2, amplicon was focal and 
involved the MINA gene. This gene has previously been reported to be over expressed in 
83% of OSCC in one study and its inhibition was shown to suppress OSCC cell proliferation 
(Tsuneoka et al., 2004).  
A 43Mb region of deletion at 8p23.2-q11.1 (4078057-47043375bb) was observed in the five 
cell lines and involved 5 potential target genes in addition to the SFRP1 gene. These included 
the BNIP3L gene deleted or down regulated in prostate cancer and malignant melanomas 
respectively (W. Liu et al., 2008; D. M. Su et al., 2009), the LZTS1 gene, deleted in oral 
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squamous cell carcinomas and down regulated in breast carcinomas (L. Chen et al., 2009; 
Kanae Ono et al., 2003); and the three tumour necrosis factor receptors TNFRSF10A, 
TNFRSF10B and TNFRSF10C whose epigenetic inactivation was reported in gastric cancers 
(K. H. Lee et al., 2009). An 8p loss was previously detected by conventional CGH in a study 
performed on 29 South African black and coloured OSCC patients (Du Plessis et al., 1999). 
Chromosome 8p22 loss has also been reported in prostate, breast, lymphoma, 
hepatocellular and colorectal cancers (Bova et al., 1996; Di Benedetto et al., 2006; J. M. 
Flanagan et al., 2004; Thomassen et al., 2009; Ying et al., 2007). 
 
Active smoking is linked to increased fragile site expression (Sozzi et al., 1997) and is also 
one of the primary risk factors associated with OSCC in South Africa (Pacella-Norman et al., 
2002). We previously hypothesized that deletions affecting anti-oncogenes located at fragile 
sites may contribute to the etiology of OSCC in South Africa and reported FHIT intragenic 
deletions in these cell lines and a small cohort of patients (Willem et al., 2006). FHIT gene 
deletions were confirmed here supporting its role in OSCC carcinogenesis.  
 
Deletion at 18q23 involved the SMAD4 and DCC genes in all cell lines. Both genes have 
previously been reported to be down regulated in OSCC either by deletion, mutation or 
methylation (Metzger et al., 2004).  Decreased expression of the SMAD4 gene, a tumour 
suppressor of the TGF-β family signalling pathway, has been associated with OSCC tumour 
invasion (Fukuchi et al., 2002). The DCC gene was shown to be frequently methylated in 
OSCC tumour specimens (H. L. Park et al., 2008).  
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In summary of this chapter, breakpoints at 1p11 and 3p11 were recurrent in the 5 OSCC cell 
lines and may point to genes such as EPHA3 that may be involved in OSCC carcinogenesis. 
Copy number alterations involved both amplicons previously reported in squamous cell 
carcinoma (8q24, 11q13 and 3q11) as well as novel regions of significant amplification 
(11q22.1-q22.3, 5p15.2 and 18p11.32). The finding that a significant number of genes that 
were amplified (FGF3, FGF4, FGF19, CCND and C-MYC) or deleted (SFRP1 and SFRP2 genes) 
are involved in the Wnt and FGF signaling pathways suggest that these pathways may be 
activated in these OSCC cell lines. These results warranted investigation in patient tumour 
samples and expression studies of these genes in both cell lines and patients’ specimens.  
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CHAPTER 3 
 
 
 
 
 
 
Assessment of expression levels of selected candidate genes in the 
5 OSCC cell lines and fresh tissue samples 
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3.1 Introduction 
Many potential candidate genes were identified from the copy number data obtained from 
the five OSCC cell lines WHCO1, WHCO3, WHCO5, WHCO6 and SNO in chapter 2. The EPHA3 
candidate tumour suppressor gene had deletions by array copy number analysis in four of 
the five cell lines.  It is expected that these deletions may negatively affect the expression of 
the EPHA3 gene in the respective cell lines WHCO1, WHCO3, WHCO6 and SNO. The 11q13.3 
chromosomal region was amplified in the five cell lines and spanned the known oncogenes, 
CCND1, FGF3, FGF4 and FGF19. CCND1 and FGF4 gene amplification was confirmed by FISH 
analysis in chapter 2. Similarly, chromosome 8q24 amplification was detected and 
amplification of the c-MYC oncogene in this region was also confirmed by FISH analysis. The 
EPHA3, FGF3, FGF4, FGF19, CCND1 and c-MYC genes were selected to establish whether 
gene copy number correlated with expression levels.   
Real time relative quantification by reverse transcriptase polymerase chain reaction (RT-
PCR) is the most frequently used methodology to assess relative gene expression levels. 
Relative quantification allows for the assessment of the levels of expression of particular 
mRNAs in one sample relative to another i.e. there is more or less RNA present in the cancer 
sample compared to that of the normal sample. The levels of expression of a target gene are 
measured as a ratio to the reference genes. The purpose of this study was to assess whether 
the expression of selected genes was lower or higher in cancer cell lines compared to 
normal oesophageal tissue and relative quantification was sufficient to answer this 
question.  
This chapter describes the real time RT-PCR experiments performed to assess the expression 
levels of the 6 mentioned genes in the five cell lines, WHCO1, WHCO3, WHCO5, WHCO6 and 
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SNO. The gene expression levels in the 5 cell lines as well as in 4 fresh tumour samples were 
compared to the expression levels in 5 samples from normal oesophageal tissue. 
 
3.2 Materials and Methods 
RNA extraction from cell lines 
The cells from the five cell lines were isolated as described in chapter 2, section 2.2 and 
lysed in 2ml of RLT buffer (Qiagen RNeasy® midi kit). Frozen lysates were thawed at 37⁰C 
and the RNA was extracted using the RNeasy® midi kit as per the manufacturer’s protocol. 
RNA was eluted into 100μl of RNase-free water; the elution was then repeated using 50μl of 
RNase-free water. RNA quantity and quality was then assessed using the Nanodrop-1000 
and with the RNA 6000 Nano kit (Agilent Technologies Inc) on the Bioanalyser 2100 (Agilent 
technologies Inc).  
Fresh OSCC tumour samples 
Eleven biopsy samples were collected from patients presenting with dysphagia at the 
Department of Medical Gastroenterology, Charlotte Maxexe Johannesburg Academic 
Hospital. Upon patient informed consent and during standard medical procedure, biopsies 
from the tumour region as well as the normal appearing epithelium were collected, 
immediately snap frozen in liquid nitrogen and stored at -70⁰C. Four of these patients were 
confirmed to have OSCC by histopathology and one patient had atypia with features of basal 
cell hyperplasia. These four samples were used in the expression study. The remaining six 
samples had a normal epithelium and one of these was used as a control (WITSCA10N).  
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Fifty five samples were collected from patients presenting at the Chris Hani Baragwanath 
Hospital, Soweto upon informed consent. These samples were collected in collaboration 
with the Department of Gastroenterology. Two tumour biopsies were collected and two 
biopsies from normal epithelium were collected from each patient. One tumour and one 
normal specimen were placed into RNAlater® stabilisation reagent and frozen at -20⁰C. The 
other two samples were stored at -20⁰C for DNA extraction.  
RNA extraction from tissue samples 
The RNA stabilised samples were removed from RNAlater® (Qiagen®) and weighed to 
obtain the appropriate weight of no more than 30mg of tissue. A tissue weight of 30mg or 
less was placed into a new tube with 450µl of RLT buffer (from RNA extraction kit) with β-
mercaptoethanol (10µl per 1ml of buffer RLT). Snap frozen samples were thawed on ice and 
450µl of RLT with β-mercaptoethanol was immediately added. One 5mm stainless steel 
bead (Qiagen®) was inserted into each tube. The tissue was homogenised using the 
TissueLyser (Qiagen®) at 25Hertz for 2 minutes, the adaptor set was rotated and then 
homogenisation repeated for another 2 minutes. The tubes were spun down at 14000rpm 
for 3 minutes (Eppendorff centrifuge 5810R, CL021 rotor) and the supernatant was 
transferred to a new tube. The RNA was then extracted according to the RNeasy® mini 
protocol (Qiagen®). RNA quantity and quality was then assessed using the nanodrop-1000 
and the RNA 6000 Nano kit (Agilent Technologies Inc) on the Bioanalyser 2100 (Agilent 
technologies Inc).  
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Target genes and primer design for RQ-PCR 
The primers were designed for candidate and reference genes using the RTPrimerDB public 
database (Pattyn et al., 2003) (Table 3.1), taking into account the presence of SNPs in the 
region of primer binding, secondary structures and specificity to the target by BLAST 
analysis.  
Table 3.1. Reference genes and target genes for RQ-PCR analysis.  
Gene Expected 
expression in 
normal 
oesophagus 
Forward primer (5’-3’) Reverse Primer (5’-3’) Expected 
size 
ACTB High AGCCTCGCCTTTGCCGA GCGCGGCGATATCATCATC 87bp 
YWHAZ Median ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 94bp 
PGK1 Low GAGATTGGCACTTCTCTGTT CAGGCAAGGTAATCTTCACA 95bp 
MYC Low AAGACAGCGGCAGCCCGAAC TGGGCGAGCTGCTGTCGTTG 147bp 
CCND1 Low/Absent CGTGCCCGTGTGCATGTCCT GCTGCAGGGCCGTTGGGTAG 294bp 
EPHA3 Low CATGGTAACTTCTCCAGCAA GAGAGCTGACAATCCATGTT 112bp 
FGF3 Absent TTGGCGAACCGTCCTTTCT  TCCACCCAGGAGCAATGAA  64bp 
FGF4 Absent CCAACAACTACAACGCCTACGA CCCTTCTTGGTCTTCCCATTCT 83bp 
FGF19 Absent ATGCAGGGGCTGCTTCAGTA AGCCATCTGGGCGGATCT 67bp 
 
DNase treatment of RNA 
RNA was first treated with DNase I post RNA extraction in order to eliminate contaminating 
DNA from the samples and to prevent amplification of pseudogenes. One microgram of RNA 
was treated at a time in a final volume of 10µl with 1U of DNase I (Invitrogen), 1x buffer 
(Invitrogen) and AccuGENE® molecular grade water (Lonza). The samples were incubated at 
room temperature for 15 minutes. DNAse I was inactivated by addition of EDTA (Invitrogen) 
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at a final concentration of 5mM and heated at 65⁰C for 10 minutes. cDNA synthesis was 
then immediately performed. 
cDNA synthesis 
cDNA was synthesized from DNAse I treated RNA immediately prior to RQ-PCR experiments. 
Sufficient cDNA was synthesized for each sample to perform all RQ-PCR runs for all the 
genes tested. For 1µg of RNA, 100 units of MMLV reverse transcriptase, 1x RT buffer, 1mM 
dNTPs, 24µM random primers, 10mM DTT and 20 units of RNase out was added in a final 
volume of 25µl. All the reagents are from Invitrogen. One microgram of RNA was set up in a 
10µl reaction volume with RNAse free water (Invitrogen) and incubated for 10 minutes at 
70⁰C, then cooled to 4⁰C. The cDNA master mix was then added to the RNA. The reaction 
was incubated at 25⁰C for 10 minutes, 42⁰C for 45 minutes, 99⁰C for 3 minutes and cooled 
to 4⁰C. The cDNA was kept at 4⁰C until RQ-PCR set up, for long term storage it was placed at 
-20⁰C. 
RQ-PCR experiments 
RQ-PCR was optimised for all the genes using the MCF7 breast cancer cell line as a template 
as this cell line was previously described to express all the targets of interest (Wang et al., 
2003; Fox & Kandpal, 2004; Lukyanova et al., 2009). Melt-curve analysis and gel 
electrophoresis were used to determine that the correct product was being amplified based 
on expected size and presence of one melting peak (Appendix B). Reference gene stability 
was assessed (Appendix B), however all three reference genes were included in each RQ-
PCR run and the most stable reference gene from the run was used in normalisation. The 
RQ-PCR experiments were set up on a 96 well plate, however, some samples had to be 
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carried over to additional plates. To correct for variation between runs, 3 samples (inter-run 
calibrators) were repeated on each plate. Each sample was set up in triplicate. Nine plates 
were run, 2 genes were tested on each plate and non template controls were included for 
each gene (Appendix B). The same cDNA batch for each sample was used for the analysis of 
all genes and 120ng of cDNA was added to the reaction. The five cell lines, 4 fresh OSCC 
samples (delineated OC8BT, OC7BT, WITSCA9 and WITSCA2) and 5 samples from normal 
oesophageal tissue (delineated WITS35N, WITS36N, WITS39N, WITS40N and WITSCA10N) 
were analysed. The final reaction volume (15µl) consisted of 7.5µl of Power SYBR®Green 
PCR master mix (Applied Biosystems) and forward and reverse primers (Operon) at the 
following concentrations, 0.227mM for c-MYC, CCND1 and EPHA3 and 0.454mM for the 
FGF3, FGF4 and FGF19 primers. The reaction was performed on an Applied Biosystems 7500 
real time PCR system in standard run mode, 95⁰C for 10 minutes, 40 cycles of 95⁰C for 15 
seconds and 62⁰C for 1 minute (fluorescence data was collected at this step). A melt curve 
analysis was performed at the end by heating from 60⁰C to 95⁰C at 0.1⁰C increments. The 
passive reference dye was ROX. Data was captured using the Applied Biosystems Sequence 
Detection Software version 1.3.1.  
Data analysis 
Run data was imported from the CSV files taken from the Applied Biosystems sequence 
analysis software into Biogazelle Qbase PLUS.  The cycle threshold values (Cq values) were 
used for subsequent data normalisation and calibration to obtain calibrated normalised 
relative quantities (CNRQ) values. Qbase PLUS has built in algorithms to normalise the data 
based on the replicates, reference genes and the inter-run calibrators (Hellemans et al., 
2007). First, the quality control of the runs was assessed by analysing the raw data to 
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evaluate the non-template controls and the difference in Cq values between replicates 
(experimental/pipetting error). The non-template controls were undetected and the cut-off 
value for the difference in Cq values between replicates was 0.5, a difference of 0.5 of a 
cycle between replicates was considered acceptable. The mean of the Cq values from at 
least 2 replicates were used to calculate relative quantities (RQ values). The RQ values for 
the samples were normalised by Qbase PLUS by dividing the RQ value for each sample by 
the normalisation factor calculated from the reference genes (Hellemans et al., 2007). The 
most stable reference gene (YWHAZ), as determined by GNORM (Appendix B), was used for 
normalisation. Inter-run calibration was then performed, using the Qbase PLUS algorithms, 
to adjust for the variation between runs using the three inter-run calibrators (WHCO1, 
WHCO3 and WHCO5) in order to obtain the calibrated normalised relative quantities (CNRQ) 
(Hellemans et al., 2007). A two tailed t-test was performed to test whether the relative 
expression values (CNRQ values) of the samples were different to the median relative 
expression of the controls using GraphPad InStat® version 3.10. 
 
3.3 Results 
Expression levels of the candidate genes, EPHA3, CCND1, FGF19, FGF3, FGF4 and C-MYC. 
RNA from 4 fresh OSCC samples were of good enough quality and quantity to use in RQ-PCR 
analysis and although it was attempted to obtain additional specimens from normal 
epithelium, several biopsies were contaminated with cancerous cells on touch preparations 
analysed by a pathologist. Thus, the expression levels in the five cell lines and 4 OSCC 
samples were compared to the average expression of 5 normal oesophageal samples (Table 
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3.2). The normal OSCC controls, delineated as WITS35N, WITS36N, WITS39N and WITS40N 
were biopsy samples taken from neighbouring normal epithelium in patients with suspected 
OSCC. The WITSCA10N sample was a normal tissue sample subsequently found to be from a 
patient with normal oesophagus. The normalised, calibrated expression values (CNRQ) were 
log transformed and statistically analysed by a two tailed t-test to establish whether the 
expression levels of each of the candidate genes were statistically different from the median 
expression level observed in the normal samples.  
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Table 3.2. Table of samples used in expression analysis by RQ-PCR.  
Sample ID Sample type Histology RNA 
concentration 
RIN 
WHCO1 OSCC cell line MD SCC 575ng/µl 9.5 
WHCO3 OSCC cell line MD SCC 329.7ng/µl 9.51 
WHCO5 OSCC cell line MD SCC 304.7ng/µl 9.5 
WHCO6 OSCC cell line MD SCC 463.2ng/µl 9.9 
SNO OSCC cell line MD SCC 562ng/µl 9.4 
MCF7 Breast 
Adenocracinoma 
cell line 
Adenocarcinoma 1ug/µl N/A 
OC7BT OSCC tumour tissue MD SCC 419ng/µl 5.2 
OC8BT OSCC tumour tissue Invasive SCC 289ng/µl 5.7 
WITSCA2 OSCC tumour tissue  594.4ng/µl  
WITSCA9 OSCC tumour tissue  197.1ng/µl 8.4 
WITSCA10N Normal 
oesophageal tissue  
 122.6ng/µl 9.4 
WITS35N Normal 
oesophageal tissue 
 280.58ng/µl  
WITS36N Normal 
oesophageal tissue 
 157.09ng/µl  
WITS39N Normal 
oesophageal tissue 
 401.51ng/µl  
WITS40N Normal 
oesophageal tissue 
 223.86ng/µl  
RIN numbers indicate the level of degradation of the RNA and high numbers close to 10 have low 
degradation and are considered good quality RNA. 
MD= moderately differentiated 
SCC= squamous cell carcinoma 
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EPHA3 gene expression 
The EPHA3 gene is usually highly expressed in the developing embryo. The expression levels 
were expected to be low in normal oesophageal tissue and late Cq values were obtained for 
the normal samples averaging at cycle 32 (Appendix B, Table B2). EPHA3 gene expression 
was only detectable in the cell lines WHCO1 and WHCO3 with cell line WHCO1 showing 
higher expression relative to the controls (p=0.0001) and cell line WHCO3 showed 
significantly lower expression than the controls (p=0.0076) (Figure 3.1). The remaining 
samples had Cq values above the threshold limit in Qbase Plus and were considered as not 
expressed (Cq>35). The expression results correlated with deletions detected in the WHCO3, 
WHCO6 and SNO cell lines in chapter 2 and would suggest that these deletions may result in 
the lower or lack of expression observed in these cell lines. The finding that cell line WHCO5 
does not show detectable levels of EPHA3 may suggest that transcription is inactivated by 
other mechanisms, for example, inactivating mutations or silencing through promoter 
hypermethylation. The over expression observed in WHCO1, despite the observed deletion 
of exons 1-3 (chapter2), may be explained by the additional copies of the gene due to the 
precence of additional copies of chromosome 3 as determined by cytogenetics and FISH 
(chapter 2). It is important to note that the limitation of this experiment was that the 
primers were designed to bind in exon 1, which may not represent the expression of 
transcripts that have exon 1 deletions.   
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Figure 3.1 Relative expression levels of the EPHA3 gene as measured by RQ-PCR. 
The corrected normalised relative quantities (CNRQ) are plotted standard error of 
the mean (±SEM). The expression levels are significantly higher than the controls 
for cell line WHCO1 *(p=0.0001) and significantly lower for cell line WHCO3 
(p=0.0076). The other cell lines and OSCC samples had undetectable EPHA3.  
 
CCND1 expression 
The relative expression of CCND1 was significantly increased compared to the controls for 
all the cell lines and three of the fresh samples (WITSCA2, OC7BT and OC8BT) (Figure 3.2). 
The most significantly different expression was detected in the cell lines WHCO6 and SNO 
(p<0.0001).  
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Figure 3.2 Relative expression levels of the CCND1 gene as measured by RQ-PCR. The 
corrected normalised relative quantities (CNRQ) are plotted (±SEM). The expression 
levels are significantly higher *(p<0.05) for cell lines WHCO1, WHCO3, WHCO5 and 
samples WITSCA2 and OC7BT and highly significant ** (p<0.0001) for the cell lines 
WHCO6, SNO and sample OC8BT compared to the controls. 
 
FGF3, FGF4 and FGF19 expression 
The fibroblast growth factors are only expected to be expressed during embryological 
development and were not detected in the normal samples. FGF3 gene expression was only 
detectable for the cell lines WHCO6 and SNO, which were significantly different from the 
controls, p=0.0046 and p= 0.0013 respectively, as well as in fresh samples OC8BT (p= 
0.0028) and WITSCA9 (p= 0.0007) (Figure 3.3 and figure 3.4). The fresh sample WITSCA9 had 
the highest expression with more than 500 fold the expression compared to normal 
oesophagus, which had very high cq values above the detectable limit (averaged at around 
36 cycles). FGF4 gene expression was only significantly increased relative to the normal 
samples in cell line, WHCO1, and samples OC8BT and WITSCA9 (Figure 3.5).  
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The expression of the FGF19 gene was only analysed in the 5 cell lines and two normal 
controls due to lack of sufficient RNA. FGF19 gene expression was almost undetectable in 
the controls and all the cell lines had significantly higher levels of expression compared to 
the two normal samples run (WITSCA10N and WITS35N) (Figure 3.6). The cell lines WHCO5 
and SNO showed the highest expression, almost 50 and 30 fold respectively.   
 
 
Figure 3.3 Relative expression levels of the FGF3 gene as measured by RQ-PCR. 
The corrected normalised relative quantities (CNRQ) are plotted (±SEM). The 
expression levels are highly significant * (p<0.005) for cell lines WHCO6, SNO and 
sample OC8BT compared to the controls. 
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Figure 3.4 Relative expression levels of the FGF3 gene as measured by RQ-PCR 
for the sample WITSCA9. The corrected normalised relative quantities (CNRQ) are 
plotted (±SEM) relative to the controls (indicated by the blue line due to the 
scale). The expression levels are highly significant * (p=0.0007) compared to the 
controls. 
 
Figure 3.5 Relative expression levels of the FGF4 gene as measured by 
RQ-PCR for the. The corrected normalised relative quantities (CNRQ) are 
plotted (±SEM). The expression levels are significant * for cell line WHCO1 
(p=0.0019) and highly significant for samples WITSCA9 and OC8BT 
(p<0.0001) compared to the controls. 
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Figure 3.6 Relative expression levels of the FGF19 gene as measured by RQ-
PCR. The corrected normalised relative quantities (CNRQ) are plotted (±SEM), 
the controls  are indicated by the blue line due to the scale. The expression 
levels are highly significant * (p<0.01) for all five cell lines compared to the 
controls. 
 
C-MYC expression 
The expression of the C-MYC gene was statistically significantly higher than the controls in 
the cell lines WHCO1 (p<0.0001), WHCO3 (p=0.0002), WHCO5 (p<0.0001) and SNO 
(p=0.0004) and sample WITSCA2 (p=0.0004) (Figure 3.7).  
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Figure 3.7 Relative expression levels of the C-MYC gene as measured by RQ-PCR. 
The corrected normalised relative quantities (CNRQ) are plotted (±SEM). The 
expression levels are highly significant **(p<0.0001) for cell lines WHCO1, WHCO3 
and WHCO5 and also highly significant *(p<0.001) for cell line SNO and the samples 
WITSCA2 and OC8BT compared to the controls. 
 
 
3.3 Discussion 
 
Expression of the EPHA3 gene in the 5 cell lines 
EPHA3 gene expression was expressed at low levels in normal oesophageal tissue (late cycle 
thresholds of between 31 and 33 cycles for the 5 normal samples). The EPHA3 gene had 
deletions in cell lines WHCO1, WHCO3, WHCO6 and SNO as determined by array copy 
number array analysis in chapter 2. Apart from the cell line WHCO1, which had higher 
expression levels than the controls (possibly explained by the prescence of additional copies 
of chromosome 3), the cell lines WHCO3, WHCO5, WHCO6 and SNO had low or no 
expression of the EPHA3 gene. The copy number results therefore correlated well with the 
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expression data for cell lines WHCO3, WHCO6 and SNO and would suggest that the 
observed deletions do affect the expression of the EPHA3 gene in these cell lines. Cell line 
WHCO5, where no deletion was observed in the EPHA3 gene, may have alternative 
mechanisms for the lack of EPHA3 gene expression, such as epigenetic changes or inctvating 
mutations. The four fresh tissue samples from OSCC patients also had no detectable levels 
of EPHA3 expression. These results would have to be confirmed in a large number of 
samples before any conclusion can be made about EPHA3 expression in OSSC samples. 
However, these results taken together with the array results highlight the importance of 
testing EPHA3 levels of expression , as well as its known isoform (consists of exons 1-7) and 
the other genes in the EPH/ephrin network in both cell lines and fresh tumour samples. It 
would also be beneficial to do RT-PCR to assess the expression of all possible variants in 
these cell lines.  
Expression of the CCND1, FGF3, FGF4, FGF19 and c-MYC candidate genes 
The 11q13.3 amplicon detected in the cell lines is frequently reported in OSCC . There are a 
number of genes within this amplicon and it is important to establish which of them are 
specifically targeted by amplification. It is hypothesised that genes likely to drive 
oncogenesis are specifically targeted for amplification and would be expected to be over 
expressed.  
The chromosomal region 11q13.3 was highly amplified in cell lines WHCO1, WHCO3, 
WHCO5 and SNO, and included the CCND1, FGF3, FGF4 and FGF19 genes. The increased 
relative expression of the CCND1 gene was found and correlated with amplification of this 
gene (as detected by array and FISH analysis), where 15 to more than 20 copies of the gene 
were detected in cell lines WHCO1, WHCO3, WHCO5 and SNO. However, WHCO1 and 
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WHCO3 cell lines had high CCND1 gene copy numbers (15-20 copies as determined by FISH 
in chapter 2), but did not show the same high level of expression as the other cell lines with 
high copy numbers. Mechanisms for the lack of correlation between gene copy number and 
gene expression have been suggested through study of copy number variants and their 
effects on gene expression (Henrichsen et al. 2009). One mechanism, which may be 
applicable to CCND1 in WHCO1 and WHCO3 where copy number did not show complete 
correlation with expression, could be that extra copies of the gene cause steric hinderence, 
impairing access to the transcriptional machinery (Sexton et al. 2007). Cell line WHCO6 had 
4-8 copies of CCND1, reflecting low to mild amplification; however this cell line still showed 
high expression of the CCND1 gene. In contrast FGF4 gene expression levels were not 
significantly higher for 4 of the cell lines and therefore the expression levels for this gene did 
not correlate with the FGF4 amplification status in the cell lines, which could possibly 
explained by a loss of the regulatory elements of the gene during the amplification event, a 
mechanism reviewed by Henrichsen et al (2009).   
Similarly, the FGF3 gene did not show an increased expression as would be expected from 
the array copy number data, while the FGF19 gene showed over expression relative to the 
normal oesophageal tissue in all 5 cell lines. This would suggest that the CCND1 and FGF19 
genes are important targets of amplification in the 11q13.3 amplicon in the 5 cell lines. 
Fresh oesophageal tumour samples showed higher expression of CCND1 in three of four 
samples and of the FGF3 and FGF4 genes in two of four samples. FGF19 gene expression 
was not assessed in the fresh samples due to lack of RNA. The expression of all these genes 
therefore needs to be assessed in a larger set of fresh samples in order to establish their 
importance in OSCC.  
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The FISH and array data showed the presence of 4 to more than 20 copies of the C-MYC 
oncogene in cell lines WHCO3, WHCO5, WHCO6 and SNO while cell line WHCO1 had 4-6 
copies. All cell lines, except cell line WHCO6, had significantly higher expression of c-MYC 
compared to normal oesophageal tissue showing a correlation with the gene copy numbers. 
Cell line WHCO6, which had 10 to >20 copies, did not show statistically significant increased 
c-MYC expression. Higher expression was detected for cell line WHCO1, which had 4-6 
copies. There was therefore no consistent correlation between C-MYC increased copy 
number and expression. The C-MYC oncogene is therefore likely to be targeted for 
amplification in the cell lines WHCO3, WHCO5 and SNO but amplification may be 
compounded by other mechanisms for C-MYC increased transcription as was observed for 
cell line WHCO1. In addition gene amplification may not always result in over expression, as 
observed for cell line WHCO6. The C-MYC gene was highly expressed in 2 out of 4 OSCC 
samples and more samples will need to be analysed to establish the frequency of C-MYC 
over expression in SA OSCC. 
In summary, deletions in the EPHA3 gene correlated with a low expression in the cell lines. 
In addition, four fresh samples showed no expression of EPHA3. The lowered expression of 
EPHA3 compared to normal oesophageal tissue further supports a role for this gene in OSCC 
and warrants further investigation in a larger cohort of fresh samples. The 11q amplicon and 
8q amplicon correlated with higher expression of the CCND1, FGF19 and C-MYC genes 
respectively, pin pointing these genes as likely targets for amplification in the cell lines. The 
high expression of the FGF19 gene observed in the cell lines warrants assessment of FGF19 
gene expression in fresh samples. Similarly, CCND1 and C-MYC genes were over expressed in 
3/4 and 2/4 of the fresh samples analysed respectively, together with the cell lines 
 108 | P a g e  
 
suggesting their involvement in OSCC. Again, expression levels need verification in a larger 
sample size.  
This was a pilot study to assess the expression levels of the EPHA3 gene and the genes in 
amplified regions in the cell lines. The results do indicate that C-MYC, CCND1 and FGF19 
genes are likely to be over expressed due to gene amplification in both cell lines and tumour 
samples. The CTTN gene, which was part of the 11q13.3 amplicon, is also an important 
candidate gene over expressed in pre-cancerous lesions of OSCC (Man-Li Luo et al. 2006). 
This gene should also be investigated for over expression in these cell lines and fresh 
tumours in a future study.  
The EPHA3 gene deletions resulted in low or no expression. This part of the study was 
however limited by the number of fresh samples available and conclusions regarding the 
involvement of these genes in OSCC in SA cannot be made at present. Additional limitations 
were that only 5 normal samples were available for comparison and only one reference 
gene could be used for data normalisation.  In future studies, a larger selection of reference 
genes will be tested to obtain at least three stably expressed genes for more accurate 
normalisation of RQ-PCR data and a larger collection of fresh OSCC tumour samples and 
normal tissue will be assessed.  
 
 
 
 
 109 | P a g e  
 
CHAPTER 4 
 
 
 
 
 
 
Characterisation of copy number profiles in an OSCC cohort from 
the Eastern Cape 
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4.1 Introduction 
Copy number studies in OSCC 
The development of comparative genomic hybridisation and high resolution DNA copy 
number microarrays has allowed for the assessment of patterns of common copy number 
changes in a wide variety of cancers.  Detection of these patterns of DNA copy number 
aberrations in tumours can highlight key genes and molecular pathways involved in 
carcinogenesis. DNA copy number aberrations have been assessed in OSCC in approximately 
15 studies, which utilised a variety of platforms, from low resolution conventional CGH (8 
studies) to 250K SNP array technology (1 study) (summarised in table 4.1). There is a high 
degree of variation in the results from each group, which makes it difficult to interpret 
regions of importance in OSCC carcinogenesis. However, the most commonly affected 
regions are amplification of 3q, 5p, 7p, 8q, 11q, 20q and deletion of 1p, 3p, 5q, 8p, 9p and 
18q (Z. W. Chang et al., 2009; Y. R. Qin et al., 2008; Y. R. Qin et al., 2005; C. C. Yen et al., 
2001; C. C. Yen et al., 2005; Xu Zhang et al., 2008; Chen, et al., 2008; Du Plessis et al., 1999; 
N. Hu et al., 2006; Carneiro, et al., 2008; Chattopadhyay et al., 2010; Y. C. Chang et al., 2010; 
Sakai et al., 2010). It is possible that variations in copy number results across these studies 
reflect geographical differences in OSCC carcinogenesis. Only one study was performed in 
SA using low resolution conventional CGH to establish DNA copy number patterns from 29 
patients (Du Plessis et al., 1999). This study was performed on a mixed population including 
mixed ancestry, Xhosa speaking black patients and Caucasian patients.  
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Table 4.1 Summary of studies on copy number changes in OSCC 
Author and 
country 
Method No. samples Reported gains Reported losses 
(Du Plessis et al. 
1999), South 
Africa 
Conventional 
CGH 
29, Xhosa, 
mixed ancestry 
and caucasian 
3q, 2q, 5p, 7p, 7q, 8q, X, 
1p in Xhosas 
1q, 1p, 4p, 18q, 22q, 1p36-pter, 8p in 
males, Xp in black males, 5q21-22, 
5q31-qter  
(C. C. Yen et al. 
2001), China 
Conventional 
CGH 
46, Chinese 1q32-42, 2q31-q32, 3q26-qter, 
5p13-p14, 7p14-pter, 8q24-qter, 
11q12.3-q13, 12p12, 14q23-qter, 
17q24-qter, 20q13.1-qter, xq27-
q28 
1p34.1-pter, 3p23-pter, 4p14-p15.3, 
5q32-qter, 8p22-pter, 9p21, 9q21, 
11q23-qter, 13q12-q14, 16p13.1-
pter, 18q22, 19p, 19q 
(Y.-R. Qin et al. 
2005), China 
Conventional 
CGH 
52,  Chinese 3q, 8q, 5p, 1q, 6q, 18p, 20q 3p, 1p, 9q, 19p, 4p, 8p 
(Y.-R. Qin et al. 
2008), China 
Conventional 
CGH 
37, Chinese 1p31, 1p11-q22, 3q22-qter, 4p13, 
5p, 6p12-14, 8q, 9p, 11q13-q23, 
16p11, 18p, 20p 
3p, 8p, 9q, 11q, 13q, 5q, 1p, 4p, 18q, 
16q, 17p, 19p 
(Y.-R. Qin et al. 
2008) 
Conventional 
CGH 
37 ,Chinese 8q, 3q, 5p 3p, 8p, 9q 
(Z.-W. Chang et al. 
2009), China 
Conventional 
CGH 
13, Chinese 3p, 5p, 7p, 8q, 10q, 15q 3p, 9q, 19q  
(Y. C. Chang et al. 
2010), Taiwan 
Conventional 
CGH 
40,  Taiwanese 2q, 3q, 8q, 13q 1q, 4q, 3p, 5q, 18q 
(Sakai et al. 2010), 
Japan 
Conventional 
CGH 
51, Japanese 17q12, 17q21, 3q29, 3q28, 8q24.2, 
22q12, 3q27, 8q24.3, 1q22, 5p15.3, 
22q13, 3q26.3, 8q23, 8q24.1, 9q34, 
11q13, 17p12, 17q25, 20q12, 
20q13.1, 1q32, 1q42, 20q13.2 
3p26, 13q21, 4q32, 13q22 
(C.-C. Yen et al. 
2005), China 
Copy number 
changes of target 
genes, Q-PCR, 
IHC 
60, Chinese 3q25.3-qter, TP63 gain and over 
expressed, ECT2, PIK3CA 
 
(Carneiro, Isinger, 
Karlsson, J. 
Johansson, 
Jönsson, et al. 
2008), Sweden 
32K BAC array 30, Swedish 5p15.33, 7p22.3, 7p11.2, 8q24, 
10q, 11q13.3-q13.4, 12p13.33, 
14q32, 16p13.3, 17p, 19p, 19q, 
20q13.33 
3p26.3-p24.2, 3p14.2-p14.1, 3p14.1-
p13, 5q12.13, 8p23.2, 9p24.3-p24.2, 
9p21, 11q25 
(Jing Chen, L. Guo, 
Peiffer, L. Zhou, O. 
T. M. Chan, 
Bibikova, 
Wickham-Garcia, 
S.-H. Lu, Q. Zhan, 
Wang-Rodriguez, 
Wei Jiang & J.-B. 
Fan 2008b), China 
Illumina SNP 
bead array, 766 
genes 
33 FFPE 
,Chinese 
DVL3, ABCC5, TNK2, SKIL, TERT, 
CCND1, FGF12 
FANCD2, EPHA3, CTNNB1, FGF2, 
APC, CDKN2A, CDKN2B, DCC 
(Y. R. Qin et al. 
2008) 
SNP, LOH 
analysis of 386 
markers on 3p 
100, Chinese  3p26.3, 3p22, 3p21.3, 3p14.2 
(N. Hu et al. 2006), 
China 
10K SNP array  26 Chinese 1p36, 2p14, 2q11.2, 3q, 5p15.2, 
6p25.3, 7p14, 7p12, 7q11.21, 
8q24.2, 9q31, 14q21, 17p13, 
18p11, 20p11.1-q11.1, 22q12.1 
1p13.3, 3p24, 4q28, 5q33, 9p21.3, 
10p12.1, 11p15.5, 11q21, 13q12.2, 
18q 
(Chattopadhyay et 
al. 2010), India 
10K SNP arrays 20, Indian 1p36.13, 1p21, 1q21,1, 2p25.3, 
2q14.1, 3q28, 3q29, 4p15.2, 
4q21.23, 5p15.2, 6p25.3, 7p21, 
10q21.2, 11p13, 11q12.2, 12p13, 
17q21.2, 18q11.2, 20p13-p11.12 
1p36.32, 3p26-p14.3, 5q32, 6p21, 
6q13, 6q23, 8p23, 8p21.1-p12, 
10p15.3-p11.21, 12q15, 13q12.11, 
17q21.31, 18q21.1, 22q11.21 
(Xu Zhang et al. 
2008), China 
250K Nsp SNP 
array 
5, China 1p, 1q, 2p, 2q, 3q, 4q, 5p, 6p, 6q, 
7q, 8q, 11p, 11q, 12p, 12q, 14q, 
20q, 18p, 22q 
1p, 2q, 3p, 3q, 4p, 4q, 8p, 9p, 9q, 
10q, 11p, 13q, 16p, 18q, 19p, 19q, 
22q 
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The variation in chromosomal regions affected in studies across the world and the lack of 
high resolution data, warrant new studies, especially in South Africa where the incidence of 
OSCC is one of the highest in the world . The last objective of this project was therefore to 
identify common copy number changes in 50 tumour samples obtained from patients with 
OSCC using high resolution Affymetrix® 500K SNP array technology. Patients’ samples were 
all collected from the Eastern Cape where the highest OSCC incidence is reported. 
Challenges of OSCC pathology sampling 
OSCC is a malignancy of the epithelium of the oesophagus with squamous cell 
differentiation (Domanowski G, www.eMedicine.medscape.com, Accessed 21.04.2009). 
Below are the basic stages and histological characteristics of these tumours. They may have 
extracellular or intracellular keratinisation. Keratin is deposited at the site of the trauma on 
the surface of the epithelium; these traumas may be physical, thermal or chemical. 
Dysplasia describes a lesion where the cells show atypia i.e. enlargement and darkening of 
the nuclei and distortion of the nucleus shape. In dysplasia the architecture is abnormal; 
there are an increased number of cell layers described as hyperplasia. The thickness of the 
atypical cell layers determines the severity of dysplasia and if the bottom of the lesion is not 
distinguishable, looking at the epithelium alone, this is usually considered as severe 
dysplasia (Domanowski G, www.eMedicine.medscape.com, Accessed 21.04.2009). 
Carcinoma in situ is represented by full thickness, atypical squamous epithelium without 
invasion of cancerous cells beyond the basement membrane. Invasive carcinoma is 
characterised by atypical squamous cells having penetrated the basement membrane.  One 
of the problems with invasive SCC is that not all of these tumours have gone through a 
progression from dysplasia, to carcinoma in situ, to invasive carcinoma, often resulting in a 
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normal appearing surface epithelium hiding a de novo invasive SCC (Domanowski G, 
eMedicine.medscape.com, Accessed 21.04.2009). The degree of differentiation is a 
subjective feature of the tumour which can be difficult to determine yet it helps in 
evaluating the potential of a tumour to metastasize which affects treatment outcome. 
Generally, if it is difficult to determine that the cells are squamous in origin the tumour is 
considered poorly differentiated, if there is obvious squamous differentiation then the 
lesion is classified as well differentiated and anything in between is moderately 
differentiated (Domanowski G, eMedicine.medscape.com, Accessed 21.04.2009). There is 
often a lot of variability in one tumour, with varying degrees of differentiation occurring in 
different areas. Some of these particularities make it difficult for researchers to obtain fresh 
samples from tumours with a particular stage of disease or differentiation type as well as 
obtaining normal epithelium from the same patient. Initially, the objective was to collect 
fresh tumour samples and neighbouring normal epithelium. However, the size and quality of 
the samples we obtained was unsuitable for copy number analysis due to the presence of 
admixture of normal cells in tumour samples and the presence of tumour cells in what was 
apparently normal epithelium. 
In view of the above, formalin fixed paraffin embedded (FFPE) tissue specimens were 
considered for this study. The tumour area can be ringed on these specimens and a clear 
histological examination is made to appropriately select the tumour material for analysis. In 
addition, a set of normal FFPE samples from a matched population has to be used as a 
reference set for copy number estimation. Using a matched population should account for 
population specific copy number variations that naturally exist and therefore highlight only 
somatic cell derived copy number aberrations. 
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Common copy number aberrations in an OSCC cohort of 51 (FFPE) tumour samples collected 
in the Eastern Cape region, the similarities/differences of these copy number changes to 
those of the cell lines and the comparison to published data are described in this chapter. 
 
4.2 Materials and Methods 
Oesophageal cancer cohort 
One hundred and seventy seven FFPE tissue specimens were collected from the Nelson 
Mandela Academic Hospital in Umtata, Eastern Cape. These samples were biopsies taken 
from patients presenting at the hospital with dysphagia and were confirmed as OSCC by the 
histo-pathologists from the Department of Anatomical Pathology, Nelson Mandela 
Academic Hospital. The samples were selected from archive, based on histo-pathology 
reports. Each sample had a Haematoxylin and Eosin stained slide from routine diagnosis. 
These slides were used by the collaborating pathologist to ring the tumour area containing 
more than 80% tumour cells. The ringed slide was used to match the tumour region in the 
block. The tumour region was then macro-dissected out using a scalpel. 
Control samples 
A collection of normal samples from a matched population was retrieved from archived 
material and used as a reference set for copy number analysis. Fifty seven FFPE tissue 
specimens from a range of tissue sites including fallopian tube, ovary, prostate, appendix, 
epididymis, oesophagus, liver, oral mucosa, uterus, small bowel and skin were selected. All 
these blocks were confirmed to be normal by histopathology examination at the Nelson 
Mandela Academic Hospital, Department of Anatomical Pathology.  The normal tissue was 
macro-dissected for DNA extraction in the same manner as for the tumour sample sin order 
to keep the methodology consistent for all FFPE samples. 
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DNA isolation 
The macro-dissected tissue was placed in a 1,5ml centrifuge tube. An area of similar size to 
the patient specimens in the FFPE block was chosen for each control specimen and macro-
dissected in the same way.  De-paraffinisation was performed by adding 1ml of xylene 
(Merck laboratory supplies) and incubating at room temperature for 5 minutes. The samples 
were centrifuged for 3 minutes at 13000rpm (Eppendorff centrifuge 5810R, CL021 rotor) 
and the ethanol removed. This step with xylene was repeated twice more. To wash the 
pellets, 1ml of 100% ethanol was added and the samples vortexed. They were then 
centrifuged for 3 minutes at 13000rpm (Eppendorff centrifuge 5810R, CL021 rotor). The 
ethanol was poured off and the pellets allowed to air dry. One millilitre of 1M sodium 
thiocyanate (SMM) was added and the samples were incubated in an Eppendorf 
Thermomixer® Compact (shaking at 1000rpm) overnight at 39⁰C.  The samples were then 
centrifuged for 3 minutes at 13000rpm (Eppendorff centrifuge 5810R, CL021 rotor), the 
sodium thiocyanate was removed completely and allowed to air dry. Five hundred 
microlitres of lysis buffer (Appendix A) was added as well as 40µl of proteinase K (Roche) 
(10mg/ml). The samples were incubated overnight at 56⁰C in the shaking heating block. The 
samples were checked for homogenisation, if longer digestion was required additional 
proteinase K was added and the samples monitored until complete homogenisation was 
achieved. Phenol-chloroform extraction was then performed. Addition of equal volumes of 
phenol and chloroform (dependant on the total volume of the lysate) was followed by 
vortexing and then centrifugation was performed at 13000rpm for 3 minutes (Eppendorff 
centrifuge 5810R, CL021 rotor). The aqueous phase was transferred to a new tube and half 
volumes of phenol and chloroform was added. The samples were vortexed and then 
centrifuged at 13000rpm for 3 minutes (Eppendorff centrifuge 5810R, CL021 rotor). The 
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aqueous phase was transferred to a new tube and 500µl of chloroform was added. The 
samples were vortexed and centrifuged at 13000rpm for 3 minutes (Eppendorff centrifuge 
5810R, CL021 rotor). The aqueous phase was transferred to a new tube and the DNA was 
precipitated by adding 1/10 volume of 3M Sodium Acetate (Merck) and 2.5 volumes of ice-
cold, 100% ethanol. The samples were mixed by inversion and then placed at -70⁰C 
overnight. The samples were then centrifuged at 13000rpm for 30 minutes at 4⁰C 
(Eppendorff centrifuge 5810R, CL021 rotor). The supernatant was removed and the DNA 
pellets were washed in 200µl of ice-cold 70% ethanol. Centrifugation was performed at 
13000rpm for 10 minutes to pellet the DNA (Eppendorff centrifuge 5810R, CL021 rotor). The 
ethanol was removed and the DNA was allowed to air dry before re-suspending the DNA in 
an appropriate volume of 1XTE at pH7 (Promega), depending on the pellet size, 30-100µl. 
Assessment of DNA integrity 
FFPE samples were assessed for the proportion of high molecular weight DNA as they were 
generally degraded to some extent. They were assessed by gel electrophoresis and run on a 
2% agarose (Bioline) gel at 100mV for 45 minutes in 1X TAE buffer (Appendix A). 
DNA Quantification 
The samples were quantified by spectrophotometry using the ND-1000 spectrophotometer 
(Nanodrop® Technologies). The A260/280 and A260/230 ratios were recorded. 
Sample preparation 
The DNA samples were diluted in a separate aliquot to 50ng/µl using AccuGENE® molecular 
grade water (Lonza). They were assessed on the Nanodrop-1000 to check the concentration. 
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Multiplex PCR to assess PCR performance of DNA from FFPE samples 
An additional step to assess the performance of PCR amplification of large fragments in DNA 
from FFPE was done. The performance in PCR is linked to degradation and cross-linking in 
FFPE tissue. A multiplex PCR designed to amplify different regions of the GAPDH gene on 
chromosome 12 was used to assess this (van Beers et al., 2006). Seven fragments, at 
increments of 100bp were amplified from 100 to 700bp in size. Each primer was added at a 
specific concentration (Table 4.2) as advised by the published method (van Beers et al., 
2006). The reaction was performed in a total reaction volume of 30µl, and was made of 1x 
PCR buffer (Bioline), 1mM dNTPs (Promega), 1.4mM MgCl2 (Bioline), 1 unit of Biotaq taq 
DNA polymerase (Bioline), primers (Operon) and 50ng of DNA. 
Table 4.2 Multiplex primers and final concentrations of primers used for PCR 
Primers Forward Reverse Final 
Concentration 
100bp 5’-GTTCCAATATGATTCCACCC-3’ 5’-CTCCTGGAAGATGGTGATGG-3’ 266nM 
200bp 5’-AGGTGGAGCGAGGCTAGC-3’ 5’-TTTTGCGGTGGAAATGTCCT-3’ 133nM 
300bp 5’-AGGTGAGACATTCTTGCTGG-3’ 5’-TCCACTAACCAGTCAGCGTC-3’ 133nM 
400bp 5’-ACAGTCCATGCCATCACTGC-3’ 5’-GCTTGACAAAGTGGTCGTTG-3’ 67.5nM 
500bp 5’-AGCCCCTAAGGTCTTCAAGC-3’ 5’-CATGCCTGTAGCTGGGACTA-3’ 266nM 
600bp 5’-GGCTCCCTTGGGTATATGGT-3’ 5’-GGAGCCAGTCTTGGATGAGA-3’ 266nM 
700bp 5’-CCCCACACACATGCACTTAC-3’ 5’-AATGAAGGGGTCATTGATGG-3’ 266nM 
 
The reaction was performed with the following cycles, initial denaturing for 14 minutes at 
95⁰C, 35 cycles of 94⁰C for 1 minute, 57⁰C for 1 minute and 72⁰C for 3 minutes. Final 
elongation was done at 72⁰C for 10 minutes and held at 15⁰C. PCR products were resolved 
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on a 2% agarose gel, run at 100mV for 1 hour. An example of the results for this PCR is 
shown in Figure 4.1.  
 
Figure 4.1 Example of the results for a multiplex PCR on 8 FFPE 
OSCC samples that amplified all 7 fragments of the GAPDH gene. 
The red arrow indicates the 500bp mark. Fifty five of the extracted 
samples amplified up to 700bp (white arrow).  
 
Affymetrix 500K Genotyping assay for copy number analysis of the OSCC cohort 
The 500K assay, consisting of the Affymetrix® 250K Nsp I and 250K Sty I GeneChips, was 
used for interrogation of copy number changes in the cohort of OSCC samples. The FFPE 
control samples were used as the reference data set for copy number estimation. The 
Affymetrix Genechip® mapping 500K protocol (P/N 701930 Rev. 3) was followed strictly 
apart from a modification in the number of PCR reactions per sample. Five hundred 
nanograms of DNA was used in total. The protocol involved restriction digestion with either 
Nsp I or Sty I , adaptor ligation, PCR amplification, fragmentation, labelling , hybridisation to 
the GeneChips® and washing the following day (Appendix C). Quality control gels were run 
after both the PCR reaction and after fragmentation. The protocol stipulates three PCR 
reactions per sample to yield an optimal 90µg of PCR product. FFPE samples do not amplify 
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as efficiently as other DNA sources and it was found that 6 separate PCR reactions per 
sample were optimal to yield 90µg of PCR product. Six PCR reactions were set as the limit 
due to cost and samples which failed to yield a sufficient quantity of PCR product were 
excluded from further experiments. Hybridisation was performed in the Affymetrix® 
hybridisation chamber for 18 hours. Post hybridisation washing was performed using the 
Affymetrix® Fluidics 450 station. Scanning was done by the Affymetrix® GeneChip® 
Scanner 7G. The scanned chips’ images were converted to CEL files (signal intensity files); 
these files were used to assess the assay performance based on the SNP call rates which 
were generated in Genotyping Console™ (Affymetrix®). 
500K data analysis 
The Affymetrix®, Genotyping Console™ 2.0 (Affymetrix®) was used to generate call rates 
for quality control. Subsequently the data was analyzed with third party software, Partek® 
Genomics Suite (PGS). The performance of the assay on FFPE samples determines the 
quality of the array data. Call rates of 60% or more for FFPE were accepted. The Nsp call 
rates were above 70% for 51% of the samples and the Sty call rate was above 70% for 76.5% 
of the samples (Tables C1 and C2 in appendix C). Affymetrix array based PCR amplification 
should yield products ranging from 100bp to 1100bp, however, due to degradation and 
cross-linking of DNA extracted from FFPE specimens, the largest fragment size amplified was 
always less than 1100bp and varied from sample to sample. All samples amplified up to at 
least 800bp. In order to be stringent, SNP probes that reside on fragment sizes larger than 
700bp were excluded from the analysis in PGS. This lowered the array resolution by 30% 
(since approximately 30% of the SNP data were lost), there was however sufficient data for 
analysis as per reported validation (Jacobs et al., 2007). The CEL files generated by the 
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Affymetrix command console were imported into PGS. During importation, quantile 
normalisation was performed to adjust for background. At this stage exclusion of large PCR 
fragments was performed. There may be variation in signal intensity from one batch of 
arrays to another since batches are run at different times. This variation was corrected in 
PGS by analysis of variance (ANNOVA), using the scan date for Sty and Nsp arrays. The raw 
copy number was then estimated from the model file generated from the intensities of the 
normal controls. Copy number data were then smoothed using the segmentation algorithm 
(Picard et al., 2011), a segment was defined as a minimum of 10 markers with the same 
copy number and the p-value cut off for a neighbouring segment having a different mean 
copy number was set to the default (p= 0.001). Segments with a minimum of 10 data points 
were reported when a small p-value (<0.001) was obtained in comparing signal intensity of 
the adjacent regions (breakpoints/ boundaries) (i.e. significant difference in copy number 
from the next set of data points, segments could then cover multiple data points (>10)). 
Regions of significant gain or loss on individual samples were reported using a default range 
of <1.7 or >2.3 with a p-value threshold of 0.01 (i.e. the copy number was significantly 
different from an expected value of 2 copies). Common regions of gain or loss across 
multiple samples were reported when a minimum of 10 samples showed the same 
aberration and the genes included within these common regions were reported using the 
Refseq database, genome build hg18. For the multiple sample analysis, PGS reports the 
average copy number for a region across all samples and specified the number of samples 
with that aberration. In a homogeneous sample with no contaminating normal cells, the 
presence of 1 copy would be equivalent to a heterozygous loss; however in cancer samples 
heterogeneity for any particular abnormality can be expected, which may affect the average 
copy number. For this reason, in manual analysis the cut off value for homozygous deletion 
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was chosen as <0.7 and >0.7<1.3 for hemizygous deletion. Copy numbers considered highly 
amplified range in the literature from above 3.7 copies to above 7 copies (Beroukhim et al., 
2007; Xiaojun Zhao et al., 2005). In the manual analysis, the cut off values for amplification 
were chosen as >10 copies for highly amplified and >5 but <10 copies for moderately 
amplified. 
The publically available software, EASE version 2 was used to determine the biological 
pathways in which genes identified in regions of copy number change, may be involved. 
EASE is free software from the National Institute of Health in the USA (Hosack et al., 2003). 
The EASE software looks for biological themes (as specified by the user, for example 
apoptosis), in the specific list of genes entered by the user. The genes significantly linked to 
a particular biological pathway are then listed (significance was assessed using Bonferoni 
multiple comparison test). The software also generates an output list with all the gene 
annotations (describing gene features) for the genes entered by the user. The database 
accessed by the EASE software for gene ontology is DAVID (database for annotation, 
visualisation and integrated discovery) (Dennis et al., 2003). To identify and visualise 
functional associations of candidate genes, the STRING software, a functional protein 
association networks database and web tool, was used with a confidence score set at 0.4 
(confidence limit at which the associations were reported was 0.4, a confidence score of 0 
would indicate 100% confidence) (http://string-db.org) (L. J. Jensen et al., 2009). The STRING 
software identifies interactions between two proteins that jointly contribute to the same 
process using databases of biological pathways. These include the molecular interaction 
database (MINT), the database of interacting proteins (DIP), Human protein reference 
database (HPRD), biomolecular interaction network database (BIND), BioGRID and KEGG. 
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The STRING software only assesses one protein per gene, the longest isoform for a 
particular gene. The functional relationships are determined by a set of prediction 
algorithms and text mining (L. J. Jensen et al., 2009).  
FISH for confirmation of the array results on OSCC samples  
Ten patient’s blocks were selected per candidate gene on the basis of their array data 
analysis. The CCND1, MYC and EPHA3 genes copy number were evaluated with FISH. Three 
micron slides were cut from the blocks and placed on positively charged slides. The slides 
were baked in the oven at 60⁰C overnight. The slides were de-waxed by immersing them in 
Xylene (Merck) for 15 minutes at room temperature and this was repeated twice more. 
Slides were then dehydrated twice in 100% ethanol for 5 minutes at room temperature and 
air dried for 2-5 minutes at 42⁰C. Thereafter, the slides were treated in 0.2N HCl (Appendix 
A) for 20 minutes, rinsed in distilled water for 3 minutes and then 2X SSC (Appendix A) for 3 
minutes at room temperature. The slides were then immersed in 1M sodium thiocyanate at 
80⁰C for 30 minutes, rinsed in distilled water at room temperature for 1 minute and then 
twice in 2xSSC for 5 minutes at room temperature. The slides were air dried before treating 
them in Pepsin (Roche) (0.5mg/ml) dissolved in 0.1N HCl (Appendix A) for 20 minutes to 
1h30 minutes depending on the tissue. This buffer was pre-warmed to 37⁰C. The slides were 
then rinsed twice in 2xSSC for 5 minutes each at room temperature. Slides were dried at 
42⁰C for 2-5 minutes and then fixed in 1% formaldehyde (Appendix A) at room temperature. 
Slides were rinsed once more, twice in 2XSSC for 5 minutes and briefly dipped in distilled 
water. The slides were placed on a heating block at 42°C and then denatured as described in 
chapter 2, section 2.1. The Vysis® LSI C-MYC SpectrumOrange probe (Abbott Molecular Inc) 
and the Vysis® LSI t(11;14) dual colour probe (Abbott Molecular Inc) were denatured at 
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76°C for 5 minutes and 10µl was applied to the denatured slides.After a minimum of 16hrs 
hybridisation, the slides were washed in 0.3% Tween20 in 2XSSC for 4 minutes at 74⁰C, 
counterstained in DAPI solution (Appendix A) for 15 minutes and rinsed in 2xSSC with 0.3% 
Tween20® for 2 minutes at room temperature. The slides were mounted in Vectashield 
(Vecta Laboratories) and analysed on the fluorescent microscope.  Images were captured 
using the Cytovision 4.0 software (Applied Imaging). 
The EPHA3 gene deletion status was assessed using the “in-house” probe combination 
(prepared according to the methods in chapter 2, section 2.1 on BAC probe development for 
analysis of EPHA3 gene deletions) of RP11-598N21 (spectrum orange) and RP11-547K2 
(spectrum green).This probe combination covered exons 1-3 and 11-17 of the gene. The 
slides were treated, hybridised and washed as above.  
 
4.3 Results 
Demographics of the OSCC Patient cohort from the Eastern Cape 
The 177 samples were all from black individuals from the Eastern Cape region, collected in 
the years 2004-2006. The mean age was 59.74 years with a male to female ratio of 1:0.97. 
All samples collected were from invasive, keratinising squamous cell carcinoma.  
DNA assessment and copy number analysis of the OSCC FFPE cohort from the Eastern 
Cape. 
DNA was extracted from all samples and 84 samples had sufficient DNA concentration, 
purity and integrity to continue with the array assay. These samples were further assessed 
for PCR performance using the multiplex PCR assay for amplification of seven fragments 
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(100bp to 700bp) of the GAPDH gene. There was inter-sample variability in amplifying the 
various fragment sizes thought to be due to varying length of fixation in formalin, differing 
methods of fixation and embedding, which could affect the level of DNA degradation.  A 
minimum of six separate PCR reactions were required for each sample in order to obtain the 
90µg necessary for hybridisation. Fifty five samples had sufficient DNA amplification and 
were hybridised to microarrays.  Four of these samples had a call rate below 60% and were 
removed from further analysis (Appendix C). The male to female gender ratio for the 51 
samples analysed was 1:1.16. The controls had a male to female gender ratio of 1:0.94.  
Copy number gains 
The genetic heterogeneity of OSCC was made evident by the number and complexity of 
copy number changes present in this cohort (Figure 4.2). To simplify data interpretation and 
to pull out important aberrations more likely to contribute to OSCC carcinogenesis as 
opposed to being random carrier aberrations, data were analysed as follows. As mentioned 
in materials and methods, copy number gains were characterised as high and moderate and 
were reported on the basis that a minimum of 10 samples (±20%) had the same region 
affected. Most studies do not stipulate a minimum number of samples affected by a 
particular aberration, in this study 20% was selected based on the average of a few studies 
(Y. C. Chang et al., 2010; Z. W. Chang et al., 2009; Carneiro et al., 2008; Xiaojun Zhao et al., 
2005).  
Fifteen regions with high amplification (>10 copies) and 21 regions with moderate 
amplification (>5<10 copies) were detected (Table 4.3, 4.4 and figures 4.3 and 4.4). The 
aberrations most likely to target key genes involved in OSCC carcinogenesis are those with 
high copy number changes that occur most frequently across samples. The most important 
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regions of high amplification, in descending order of frequency were 11q13.3 (66.7%) 
(70061246-70310057bp), 11q13.3-q13.4 (57%) (70310057-71374778bp), 2p21 (47%), 
11q13.3 (37.2%) (68884395-70061246bp), 19p13.11-p13.12 (33.3%) (15972003-
16438337bp), 19q13.43 (33.3%), 10q24.1 (33.3%), 1q32.2 (31.4%), 8p23.1 (31.4%), 1p32.3 
(29.4%), 16p13.3 (25.5%), 15q22.31 (25.5%), 4q35.1 (21.6%), 10q22.1 (19.6%) and 11q13.3 
(19.6%) (68405316-68471560bp) (Figure 4.3).  
The moderate amplifications sorted in order of frequency were (Figure 4.4), 8q24.3 (70.6%) 
(140629509-144457635bp), 3p25.1-p25.2 (13232589-13450155bp) (68.6%), 3p25.2 
(12775362-13086971bp) (68.6%), 2q37.3 (56.9%), 5p15.33 (43.1%), 7p22.2-p22.3 (41.2%), 
1p34.2 (39.2%), 17q25.1-q25.2 (29.4%), 12q24.31 (29.4%), 3q21.3 (29.4%) (127551516-
129106253bp), 12q24.31 (29.4%), 4p16.1 (27.5%), 20q13.3 (25.5%), 3q29 (25.5%), 19p13.2 
(25.5%), 11q13.4 (25.5%) (71428559-72219067bp), 12p13.32 (21.6%), 2q14.2 (21.6%), 
5q31.1 (21.6%), 10q22.3 (19.6%), 3q27.3 (19.6%) and 11q13.1 (19.6%). The amplicons with 
potential oncogenic genes in regions occurring at the highest frequency and with the 
highest amplitudes are described in more detail below.  
Chromosome 11q gains 
Four sub bands on chromosome 11q were amplified (an example of 11q amplification on 
copy number data can be seen in figure 3.5). 
The region with the highest amplitude involved in the highest number of samples was a 
248.81kb region at 11q13.3 (70061246-70310057bp). This region includes the known 
oncogene, CTTN gene, amplified in 66.7% of cases. Other amplicons affecting 11q included 
the 11q13.3 region from 68884395-70061246bp in 19 samples (37.2%), which included the 
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known oncogenes, Fibroblast growth factor 3 (FGF3) and fibroblast growth factor 4 (FGF4), 
fibroblast growth factor 19 (FGF19), and the cyclin D1 (CCND1) genes. Amplification of 
CCND1 and FGF4 genes was verified in 10 samples with a FISH probe covering the region 
that included both the CCND1 and FGF4 loci. On FISH, the average copy number for CCND1 
and FGF4 was 15.65 copies per cell in 100 cells analysed per sample. The array results 
correlated closely (average of 13.3 copies) with the FISH results (Table 4.5 and Figure 4.6). 
Chromosome 11q13.3-q13.4 (70310057-71374778bp) included the SH3 and multiple 
ankyrin repeat domains 2 gene (SHANK2), which was amplified in 56.9% of cases. This gene 
encodes a protein involved in the regulation of trans-epithelial absorption in normal 
epithelial cells (W. Han et al., 2006). 
The fourth 11q region, 11q13.1 (63678703-64497435bp), was moderately amplified in 
19.6% of cases with an average copy number of 8.3. The region has 2 genes potentially 
targeted (BAD, and SP1). The potential target gene, the bcl-xl/bcl2-antagonist causing cell 
death (BAD) gene, is a regulator of the pro-apoptotic molecule Bcl-2. In a phosphorylated 
state, the Bad protein no longer promotes apoptosis. Phosphorylated Bad protein 
expression is elevated in colon cancers, which may deregulate apoptosis in colorectal 
tumours (M. R. Kim et al., 2007). An increase in phosphorylated BAD expression was also 
detected in prostate cancer (A. J. Smith et al., 2009). The splicing factor 1 gene (SP1) is the 
last of the potential oncogenes in this region. 
Chromosome 8 gains 
Three regions on chromosome 8 were affected by amplifications. 
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The 8q24.3 region (140629509-144457635bp) affected the most number of samples (70.6% 
of cases) and was moderately amplified with an average copy number of 5.7. A potential 
oncogene reported in cancer in this region is the prostate-specific membrane antigen gene 
(PSCA).  
The 8p23.1 (6482787-6495845kb) focal region of amplification (13.06kb in size) was 
amplified in 31.4% of cases. This region harbours the microcephalin 1 gene (MCPH1) which 
is involved in chromatin remodelling in response to DNA damage (G. Peng et al., 2009). 
MCPH1 has been shown to mediate BRCA2-Rad51 dependent homologous recombination in 
the repair of DNA damage and it is suggested to function as a tumour suppressor gene and 
not as an oncogene which makes the relevance of this particular gene in OSCC 
carcinogenesis questionable (Xianglin Wu et al., 2009). 
The region harbouring the c-MYC oncogene was increased in copy number in the cohort 
below the cut off value of 5 copies for moderate amplification at an average of only 3.9 
copies. This region on 8q24.13-q21.33 (123539799-137116755bp) was 13.58Mb in size and 
was detected in 21.57% of cases (11 cases). Ten of these cases were selected for FISH 
analysis using a locus specific probe for the c-MYC oncogene. It was found that across these 
samples an average copy number of 8.5 copies in 100 cells analysed was present (Table 4.6 
and Figure 4.7). The samples had heterogeneity for c-MYC copy numbers within the tumour 
regions. For example, UROC16, had a copy number ranging from 5 copies to more than 20 
copies in 100 cells analysed (Figure 4.5). This heterogeneity could explain the discrepancy 
with the array results, the number of cells affected by high copy number could have been 
diluted out by cells with low to normal copy number. There may have been pockets of cells 
with high amplification within the tumour population. 
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Chromosome 3 gains 
Two regions on chromosome 3p and three regions on chromosome 3q were affected by 
amplification. 
The 3p25.1-p25.2 (13232589-13450155bp) and 3p25.2 (12775362-13086971bp) regions 
were amplified in 68.6% of cases with an average amplitude of 8.4 and 8.5 copies 
respectively. No genes described in cancer map in these regions currently.  Chromosome 
3q29 (195427099-195612723bp) was amplified in 25.5% of the cases, the average copy 
number was 6.1 and the tyrosine kinase non-receptor 2 gene (TNK2) is located in this 
region.   
Chromosome 3q21.3 (127551516-129106253bp) region had the highest average copy 
number of the moderately amplified regions with 9.3 copies in 29.4% of cases. The region 
was 1554.74kb in size, harbouring 22 genes, none of which have previously been described 
in cancer.  
The chromosome 3q27.3 (187252322-187509741bp) sub-band had an average of 8.2 copies 
in 19.6% of cases. One potential key gene is in this region is the B-cell CLL/lymphoma 6 gene 
(BCL6). 
Chromosome 2 gains 
Chromosome 2p21 (45016287-45119536bp) had an average copy number of 14.2 copies in 
47.1% of cases.  Chromosome 2q37.3 (238430400-239560898bp) was amplified in 56.9% of 
cases with an average amplitude of 5.4 copies. Currently, there are no known oncogenes 
reported in either of these regions. 
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Chromosome 7p gain 
Chromosome 7p22.2-p22.3 (141311-2851256bp) was a large region that showed moderate 
amplification (average of 5.2 copies) in 41.2% of cases. Two potential oncogenes locate in 
this region, the ADAP1 and CYP2W1 genes. The ArfGAP with dual PH domains 1 gene 
(ADAP1) encodes a phosphotidylinositol 3,4,5- triphosphate binding protein and its 
expression results in Erk (elk-related tyrosine kinase) activation (Hideko Hayashi et al., 
2006). The CYP2W1 gene encodes a cytochrome p450 enzyme expressed in colon and 
adrenal cancers and is a potential drug target (Karlgren et al., 2006).  
Chromosome 5p gain 
An average copy number of 5.6 for the chromosomal region 5p15.33 (1036116-1678508bp) 
was detected in 41.2% of cases. This region harbours the oncogene TERT (telomerase 
reverse transcriptase) and the cleft lip and palate transmembrane protein 1-like protein 
gene (CLPTM1L) which has been described as pro-apoptotic in lung cells (McKay et al., 
2008). 
Chromosome 19p gains 
Chromosome 19 was affected by the highest level of amplification. Two regions on 
chromosome 19 were amplified. 
Chromosome 19p13.11-p13.12 (15972003-16438337bp) affected 33.3% of samples and had 
the highest level of amplification (an average of 110 copies). The Kruppel-like factor 2 gene 
(KLF2) overlaps with this 273.93kb region along with 16 other genes and several micro 
RNAs. The third region on chromosome 19 amplified in 33.3% of cases was 270.81kb in size, 
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at position 58858174-59128983bp on 19q13.43, and covered one potential target described 
in cancer, the alpha-IB-glycoprotein precursor gene (A1BG).  
Chromosome 1 gains 
Chromosome 1 was affected by two amplicons, one on 1p and one on 1q.  
Chromosome 1q32.2 (207893164-207891765bp) was amplified in 31.37% of the cases with 
a mean copy number of 13.61. This region was only 1.4Kb in size with one target gene, the 
complement component (3b/4b) receptor 1-like gene (CR1L). This gene’s function is poorly 
understood and has no current involvement in cancer.   
Amplification of 1p32.3 (54534339-54745164bp) was detected in 29.41% of cases with an 
average copy number of 18.2 copies. The tetratricopeptide repeat motif containing protein 
4 gene (TTC4) interacts with heat shock proteins and the Cyclin dependant kinase 6. The 
gene is over expressed in cancer cell lines, whereas it is undetectable in normal non-
proliferating tissues (Crevel et al., 2008). 
Chromosome 20q gain 
Chromosome 20q13.3 (45146901-46502912bp) was moderately amplified in 25.5% of cases 
with an average copy number of 5.7. The region contains the developmental gene eyes 
absent homologue 2 (EYA2) and over expression is reported in epithelial ovarian cancer (L. 
Zhang et al., 2005).  
Chromosome 16p gain 
In 25.5% of samples, amplification of a 71.5kb region on chromosome 16p13.3 (11574742-
11646325bp) was detected, with an average copy number of 13.63 copies. This region has 
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one gene, the lipopolysaccharide-induced TNF factor gene (LITAF). This gene is induced by 
p53 and is involved in apoptosis (Moriwaki et al., 2001). Deletion of the LITAF gene was 
detected in B-cell lymphomas and it has tumour suppressor activity in diffuse large B-cell 
lymphomas and Burkitt’s lymphomas (Mestre-Escorihuela et al., 2007). The role of the 
above three genes as oncogenes has not been reported.  
Chromosome 15q gain 
A focal region of 69.08kb on chromosome 15q22.31 (64782565-66994674bp) was also 
amplified in this cohort, with one gene reported in cancer, the Smad family protein 6 gene 
(SMAD6). The region was highly amplified in 23.53% of cases with an average of 24.7 copies. 
The Smad proteins are involved in the transforming growth factor-β pathway. Over 
expression of SMAD6 was previously described in pancreatic cancers and acts in an 
oncogenic way by blocking the cell growth inhibiting activity of the TGF-β gene (Kleeff et al., 
1999).   
Chromosome 4q gain 
Chromosome 4q35.1 (186169423-186303602bp) was amplified in 21.6% of cases with an 
average amplitude of 15.2 copies. There are no potential oncogenes previously described in 
this region.  
Chromosome 10q gains 
Three regions on chromosome 10q were amplified.  
Chromosome 10q24.1 (98872389-98967971bp) was gained in 33.3% of cases with average 
amplitudes of 34.1 copies. No apparent potential oncogenes are described here. 
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Chromosome 10q22.1 (70839876-70921831bp) was gained in 19.6% of cases with average 
amplitude of 19.7 copies. Chromosome 10q22.3 (78583974-78724496bp) was moderately 
amplified in 19.61% of cases with average amplitudes of 19.7 copies. The potassium large 
conductance calcium-activated channel, subfamily M, alpha member 1 gene (KCNMA1) is 
located in this region. The KCNMA1 gene is overexpressed in breast cancer and is involved in 
metastasis (Khaitan et al., 2009).  
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Figure 4.2 Chromosomal mapping of regions of copy number alteration across all 51 samples (generated 
in PGS). Increased copy numbers are indicated in red and blue refers to decreased copy number. The 
higher the peak for the red/blue bar the more samples affected in that region. 
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Table 4.3 Regions affected by high amplification in a minimum of 10 samples and with an 
average copy number larger than 10 copies. The regions are arranged in order of 
chromosome. 
 
 
 
 
 
 
Cytoband Location 
(bp) 
Approximate 
size (Kb) 
Frequency 
(n=51) 
Mean 
copy no. 
No of 
genes 
Genes 
1p32.3 54,534,339-
54,745,164 
210.82 15 18.2 7 SSBP3 
1q32.2 207,891,765-
207,893,164 
1.4 16 13.61 1 CR1L 
2p21 45,016,287-
45,119,536 
103.25 24 14.2 0  
4q35.1 186,169,423-
186,303,602 
134.18 11 15.2 2  
8p23.1 6,482,787-
6,495,845 
13.06 16 25.35 1 MCPH1 
10q22.1 70,839,876-
70,921,831 
81.95 10 19.68 2  
10q24.1 98,872,389-
98,967,971 
95.58 17 34.12 3  
11q13.3 68,405,316-
68,471,560 
66.25 10 13.53 1  
11q13.3 68,884,395-
70,061,246 
1176.85 19 14.66 13 CCND1,MYEOV, 
FGF19,FGF4,FGF3 
11q13.3 70,061,246-
70,310,057 
248.81 34 57.24 3 CTTN 
11q13.3-
q13.4 
70,310,057-
71,374,778 
1064.72 29 14.62 13 SHANK2 
15q22.31 64,782,565-
66,994,674 
69.1 13 26.9 2 SMAD6 
16p13.13 11,389,965-
11,646,325 
256.36 13 14.18 3 LITAF 
19p13.11-
p13.12 
15,972,003-
16,438,337 
466.33 17 110.8 16 KLF2 
19q13.43 58,858,174-
59,128,983 
270.81 17 12 21 A1BG 
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Table 4.4 Regions of moderate amplification detected in a minimum of 10 samples (>5<10 
average copies). The regions are ordered by chromosome. 
Cytoband Location 
(bp) 
Approximate 
size (Kb) 
Frequency 
(n=51) 
Mean 
copy no. 
No of 
genes 
Genes 
1p34.2 41680889-
42044382 
363.5 20 5.67 4  
2q14.2 121307843-
121587908 
280.06 11 8.7 1 GLI2 
2q37.3 238430400-
239560898 
1130.5 29 5.4 52 HES6, PER2 
       
3p25.1-p25.2 13232589-
13450155 
217.57 29 8.4 1  
3p25.2 12775362-
13086971 
311.61 35 8.5 4  
3q21.3 127551516-
129106253 
1554.74 15 8.65 22  
3q27.3 187252322-
187509741 
257.42 10 5.7 3 BCL6 
3q29 195427099-
195612723 
185.63 13 6.1 6 TNK2 
4p16.1 7528891-
7648574 
119.68 14 5.5 1  
5p15.33 1321181-
1678508 
642.4 22 5.6 14 TERT, 
CLPTM1L, 
5q31.1 134,552,169-
135,480,185 
928.02 11 6 17 H2AFY, 
TGFBI, 
SMAD5 
7p22.2-p22.3 141322-
2851256 
 
2709.94 21 5.2 36 ADAP1, 
CYP2W1, 
GPER, 
8q24.3 140,629,509-
144457635 
3828.13 36 7.1 28 PSCA 
10q22.3 78583974-
78724496 
140.52 10 7 1 KCNMA1 
11q13.1 63678703-
64497435 
818.73 10 8.3 36 BAD, ESRRA, 
MACROD1, 
MIR192, SF1 
11q13.4 71428559-
72219067 
790.51 13 8.8 5  
12p13.32 3115831-
3332452 
216.62 11 7.5 2  
12q23.31 123310702-
123885293 
574.6 15 6.55 15  
17q25.1-q25.2 73571719-
75133860 
1562.14 15 5.3 54  
19p13.2 7745413-
8317060 
571.65 13 7.1 17 ELAVL1, 
MAP2K7 
20q13.13 45146901-
46502912 
1356.01 13 5.7 9 EYA2 
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Figure 4.3 Graph representing the regions of high amplification (> 10 copies) with the 
number of samples affected and the average copy number per sample. The regions were 
sorted from the smallest to largest copy number. 
 
 
Figure 4.4 Graph representing the regions of moderate amplification (>5<10 copies) with 
the number of samples affected and average copy numbers per sample for that region. 
The regions were sorted from smallest to largest number of samples affected. 
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Table 4.5 FISH results for detection of CCND1/FGF4 gene amplification 
in 10 FFPE samples.  
 
 
 
 
 
 
 
 
 
 
 
*moderate amplification was defined as 5 to 10 copies and high amplification was 
defined as more than 10 copies in keeping with the array interpretation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Average copy no. (100 
cells analysed) 
Overall result for FISH 
analysis* 
UROC26 17.5 High Amplification 
UROC34 15 High Amplification 
UROC37 20 High Amplification 
UROC46 6.5 Moderately amplified 
UROC62 10 Moderately Amplified 
UROC71 17.5 High Amplification 
UROC87 12.5 High Amplification 
UROC124 20 High Amplification 
UROC156 20 High amplification 
UROC171 17.5 High amplification 
Average copy number for 10 samples= 15.65 
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Table 4.6 FISH results for detection of c-MYC gene amplification in 10 
FFPE samples. 
Sample Average copy no. (100 
cells analysed) 
Overall result for FISH 
analyis* 
UROC16 12.5 High Amplification 
UROC26 15 High Amplification 
UROC30 6.5 Moderate Amplification 
UROC33 4.5 Polyploidy 
UROC47 8 Moderate Amplification 
UROC55 8.5 Moderate Amplification 
UROC84 7.5 Moderate Amplification 
UROC98 6.5 Moderate Amplification 
UROC125 10.5 High amplification 
UROC130 6 Moderate amplification 
Average copy number for 10 samples= 8.55 
*moderate amplification was defined as 5 to 10 copies and high amplification was 
defined as more than 10 copies  
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Figure 4.5 Chromosome 11 mapping of copy number changes detected in one 
representative FFPE sample by 500K SNP arrays (generated in PGS). The red arrow 
indicates the significant region of high amplification detected at 11q13.3 (67226192-
71208231bp). The blue dots represent the smoothed data points while the grey dots reflect 
the unsmoothed data points.  
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Figure 4.6  Selected images of DAPI stained nuclei for each of the 10 tumours chosen for FISH analysis with the Vysis LSI t(11;14) dual colour 
probe showing CCND1 and FGF4 (red) gene amplification. The green signal is the locus specific probe for the IGH gene on chromosome 14 acting 
as an internal control. Each tumour shows varying copy number with an average copy number of 15.65 across the 10 samples.  
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UROC16 UROC26 UROC30 
UROC55 
UROC33 UROC47 
UROC125 UROC98 UROC84 UROC130 
Figure 4.7 Selected images of DAPI stained nuclei for each of the 10 tumours chosen for FISH analysis using the Vysis LSI MYC 
probe. Moderate to low copy numbers of the c-MYC gene (Red) were seen. The average copy number across the 10 samples was 8.5.  
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Copy number losses 
Two homozygous deletions (copy number <0.7) were detected. The first was a 
1.41Mb region on chromosome 15q11.2 (18427103-19837012bp) in 12 samples (23.53%), 
which involved 8 genes. One of these genes, the B-cell CLL/lymphoma 8 gene (BCL8), has 
previously been reported in cancer but not in OSCC. The second homozygous deletion on 
chromosome 19p13.2 (11628007-11922344) was detected in 10 samples (19.6%), and 
included 9 genes, five of which encoding zinc finger proteins and the other four genes being 
the ACP5, ELOF1, ECSIT and CNN1 genes. Apart from CNN1, these genes do not have well 
understood functions and no reported involvement in cancer.  The Calponin 1 (CNN1) gene 
encodes an actin binding protein, which is down-regulated in pre-cancerous lesions of the 
rat esophagus under conditions of zinc deficiency (C.G. Liu et al. 2005). No hemizygous 
deletions were observed for either of these regions. 
Thirty one regions of hemizygous deletion (copy number >0.7<1.3) were detected (Table 4.7 
and Figure 4.8 and 4.9).  
Deletions frequently involved large portions of chromosomes. It is thought that more focal 
regions affecting the smallest minimal region of overlap across many samples would be 
regions more likely to target genes involved in carcinogenesis (Beroukhim et al., 2007; Weir 
et al., 2007). For this reason the deletions in focal regions (less than a whole chromosome 
arm) that harbour potential tumour suppressor genes and larger regions that encompass 
well described tumour suppressor genes are reported. 
Chromosome 3p deletion 
Chromosome 3p deletion is commonly reported in cancer and four major regions of deletion 
on chromosome 3p were detected. 
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The sub band 3p11.1-p12.1 (85803132-90338670bp) was deleted in 74.5% of cases. This 
region affects the same gene reported in the OSCC cell lines (see chapter 2), EPHA3, as well 
as 6 other genes. The CADM2 gene is the only other gene reported to have a tumour 
suppressor activity in prostate cancer (G. Chang et al. 2010). EPHA3 gene deletions were 
confirmed in a selected 8 cases by FISH analysis using BAC clones, RP11-598N21 and RP11-
547K2 (Figure 4.10 and Table 4.8). The hemizygous deletions were detected in 50-100% of 
70-100 cells analysed per case and the average copy number across the 8 samples was 1.25. 
There were hemizygous deletions in the EPHA3 gene in the 8 samples analysed but there 
were areas of the tumour that still had both copies of the gene. This supports the selection 
for a copy number cut off of <1.3 used in this study, where the cells with normal copy 
numbers may dilute out those cells where there is a deletion. 
Another region on 3p25.2-p26.3 (966545-12654748bp) was deleted in 68.6% of cases, and 
affects the E3 ubiquitin-protein ligase RAD18 (RAD18) and TIMP metallopeptidase inhibitor 
4 (TIMP4) genes. The TIMP4 gene was shown to inhibit metalloproteinase activity and 
inhibit growth of breast cancer cells (M. Wang et al., 1997). 
The larger region of deletion affecting 3p12.2-p21.2 (50688518-81859001bp) was detected 
in 21.6% of the cases. This region included the known tumour suppressor gene, fragile 
histidine triad (FHIT).  
Chromosome 6q deletion 
The smallest region of deletion detected was on chromosome 6q26 (163464809-
163471799bp), which was 6.99kb in size. This region was deleted in 66.67% of the samples 
and affects the Park2 co-regulated gene (PACRG). This region was reported to be deleted in 
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renal cell carcinomas and correlated with a lowered expression of PACRG (Toma et al., 
2008). The common fragile site FRA6E is located in 6q26 and encompasses the PACRG locus.  
Chromosome 4q deletion 
Chromosome 4 had a deletion which included the whole q arm, 4p14-q35.2. The region was 
deleted in the largest proportion of samples (84.3%). This large region contains 5 potential 
gene targets, the CASP3, FBXW7, SFRP2, HMGB2 and DCK genes. The Caspase 3 gene 
(CASP3) is involved in apoptosis and lower expression is detected in colorectal carcinoma (J. 
ting Guan et al., 2009). The F-box and WD repeat domain containing 7 gene (FBXW7) is a 
tumour suppressor, which targets proliferative factors for degradation through 
ubiquitination (N. Liu et al., 2010). The secreted frizzled-related protein gene (SFRP2) was 
also deleted in the OSCC cell lines, (chapter 2), and is involved in Wnt signalling control. The 
high-mobility group box 2 gene (HMGB2) product is shown to stabilise p53 by preventing 
HPV E6 protein mediated ubiquitination and degradation of p53 (D. Lee et al., 2010). The 
HMGB2 gene was only activated in HPV infected cells (D. Lee et al., 2010). The deoxycytidine 
kinasegene (DCK) is in this region, this enzyme is involved in rate-limiting catabolism of 
chemotherapies like gemcitabine, which is used in treatment of pancreatic adenocarcinoma. 
DCK gene expression has been associated with prolonged survival post resection in patients 
with pancreatic adenocarcinoma and patients with adenocarcinoma of the oesophagus 
(Maréchal et al., 2010; C. J. Peters et al., 2010).  
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Chromosome 18q deletion 
Chromosome 18q21.1-q21.2 (46295514-53583643bp) was deleted in 70.6% of cases 
affecting the well known tumour suppressors deleted in colorectal cancer (DCC) and Smad 
protein family 4 (SMAD4).  
Chromosome 5q deletion 
Three regions of deletion on chromosome 5q were detected. 
Chromosome 5q14.2 (82203607-82649577bp) was deleted in 54.9% of the samples. The X-
ray repair complementing defective repair in Chinese hamster cells 4 gene (XRCC4) is 
located in this region. This is an important gene involved in DNA repair by non-homologous 
end joining. 
The second region on chromosome 5, 5q14.3-q21.2 (83674394-103025813bp) was deleted 
in 65% of cases. This region encompasses the RAS p21 protein activator [GTPase activating 
protein] 1 (RASA1) gene, which is a suppressor of the oncogenic RAS. Loss of heterozygosity 
of this gene has been reported in HER2 positive breast cancers (Xiaolan Hu et al., 2009). 
 The third region on chromosome 5 was 5q21.2-q23.3, deleted in 47% of samples. The 26Mb 
base region is large but includes the important tumour suppressor genes, APC and MCC. 
Chromosome 1q deletion 
A deletion of chromosome 1q23.1 (156789994-156870545bp) of 80.55kb in size was 
detected in 52.9% of samples. This deletion may target the spectrin, alpha, erythrocytic 1 
gene (SPTA1) encoding a molecular scaffolding protein. Chromosome 1q23.1 deletions have 
been reported previously in breast cancer (L. C. Chen et al., 1989) and a translocation 
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mapping to the SPTA1 locus, t(1;x), was detected in renal carcinoma (Weterman et al., 
1996). 
Chromosome 11q deletion 
The ataxia telangiectasia mutated gene (ATM) (11q22.3) was examined in this data set as it 
is an important tumour suppressor reported to be deleted in OSCC. Forty nine percent of 
the samples had a copy number of 1.34 for the 11q22.3 (107663328-107745036bp) region, 
which is 2.96Mb in size and harbours the ATM gene. This region was just above the cut off 
value of 1.3 for hemizygous deletion. Confirmation of this deletion by an alternative method 
would be needed. 
Chromosome 10p deletion 
 A small (161.6kb) region on 10p11.11 (38013117-38174719bp) was deleted in 31.4% of 
cases. The zinc finger protein 248 gene (ZNF248) is located in this region. This gene has not 
been described previously in cancer. 
Chromosome 8p deletion 
Two discrete regions on chromosome 8p were deleted.  
Chromosome 8p22 deletions have been reported in the literature in a variety of cancer 
types and specifically in oesophageal cancers (Du Plessis et al., 1999; Di Benedetto et al., 
2006; Bova et al., 1996). Chromosome 8p22 (16014369-16057542bp) was deleted in 21.6% 
of samples. The region is 43.17kb in size and involves the macrophage scavenger receptor 1 
gene (MSR1). Perhaps more relevant is another region on chromosome 8, 8p12-p21.3 
(22587295-32018598bp), deleted in 21.57% of the samples. This region harbours the 
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Werner syndrome helicase/exonuclease protein (WRN) gene. Loss of this gene is associated 
with Werner syndrome, a premature ageing and cancer predisposing syndrome (Franchitto 
et al., 2008). Chromosome 8p12-p21.3 also harbours the platelet-derived growth factor 
receptor-like gene (PDGFRL), which is down-regulated in colorectal cancers and was shown 
to inhibit proliferation of colon cancer cells (F. J. Guo et al., 2010). This 8p12-p21.3 region 
harbours two other potential tumour suppressors, the leucine zipper, putative tumour 
suppressor 1 (LZTS1) and the N-acetyltransferase 2 [arylamine N-acetyltransferase] (NAT2) 
genes. The NAT2 gene is involved in the metabolism of carcinogens (X. Zhong et al., 2010). 
Chromosome 7p deletion 
A deletion of chromosome 7p15.1 (28142894-28372542bp), of 229.65kb in size, was 
detected in 19.6% of the cases. This region harbours one gene, the cAMP responsive 
element binding protein 5 (CREB5). Currently it has no reported involvement in cancer.   
Chromosome 9p deletion 
Chromosome 9p21.1-p21.3 (21792634-27938527bp), a 6.15Mb region, was deleted in 
15.7% (8 samples) of the samples, which was below the cut off of 10 samples. This region 
includes the well known tumour suppressors cyclin dependent kinase 2A and B (CDKN2A 
and CDKN2B) genes commonly deleted in OSCC.  
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Figure 4.8 Graph showing the focal regions of deletion and the copy number for that 
region. Hemizygous deletions were defined as those regions with a copy number < 1.3 
(red line). Homozygous deletions were defined as regions with a copy number <0.7 
(black line).  
H UROC62 
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Figure 4.9 Graph showing the regions of hemizygous deletion and the number of samples with that deletion. The minimum number of 
samples affected was 10. The data was sorted from smallest number of samples to largest number of samples affected.  
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Table 4.7 Regions of hemizygous (<1.3 copies) deletion detected in a minimum of 10 samples. Regions are arranged by chromosome. 
Cytoban
d 
Location 
(bp) 
Approx 
siz e 
(Mb) 
Frequenc
y (n=51) 
Mean 
copy 
no. 
No of 
genes 
Genes Cytoband Location 
(bp) 
Appro
x size 
(Mb) 
Frequen
cy (n=51) 
Mean 
copy no. 
No of genes Genes 
1p21.2-
p21.3 
95128120-
10209494
5 
6.97 16 1.3 35 DPYD 
 
10q21.1 53471227-
53487091 
0.02 15 1.22 1  
1p22.2-
p31.1 
70258477-
89926222 
19.7 10 1.26 84 IFI44,M
SH4 
10q21.3-
q22.1 
69697598-
70167452 
0.47 27 1.26 7  
1q23.1 15678999
4-
15687054
5 
0.81 27 0.78 3 NTRK1 11p12 37029613-
42832684 
5.8 18 1.3 3  
3p11.1-
p12.1 
85803132-
90338670 
4.53 38 1.32 7 EPHA3, 
CADM2 
11p14.3 22795608-
23901634 
1.1 13 1.3 3 SVIP 
3p12.2-
p21.2 
50688518-
81859001 
31.2 22 1.22 166 FHIT 11q24.1-
q24.2 
123583522
-
123975617 
0.39 25 1.3 12  
3p25.2-
p26.3 
966545-
12654748 
11.7 35 1.18 61 RAD18, 
HRH1,TIM
P4 
11q22.3 106893561
-
106962829 
0.07 26 1.3 0  
4p14-
q35.2 
37962765-
19115264
5 
153.2 43 1.23 483 RFC1, KIT, 
DCK, 
SMAD1, 
CASP3, 
FBXW7, 
SFRP2 
12q12 40815395-
41047532 
0.23 10 1.21 3  
5q14.2 82203607-
82649577 
0.44 28 1.3 3 XRCC4 12q23.1 98,292,180
-98450546 
0.16 25 1.3 0  
5q14.3-
q21.2 
83674394-
10302581
3 
19.35 33 1.3 54 RASA1, 
PCSK1 
18q21.1-
q21.2 
46295514-
53583643 
7.3 36 1.27 3 DCC, SMAD4 
5q21.2-
q23.3 
10406349
2-
13006733
26 24 1.3 49 APC, MCC 18q22.1-
q22.3 
64854005-
68986680 
4.13 40 1.28 10  
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7 
6q26 16346480
9-
16347179
9 
0.007 34 1.22 1 PACRG 18q23 75902093-
76115139 
0.21 38 1.3 0  
7p15.1 28142894-
28372542 
0.23 10 1.23 3 CREB5 19p12-
p13.11 
19,898,571
-22510844 
2.6 11 0.9 21  
8p12-
p21.3 
22587295-
32018598 
9.43 11 1.3 51 WRN 21q21.2-
q22.11 
25435155-
33624585 
8.2 38 1.24 81  
8p22 16014369-
16057542 
0.043 11 1.17 1 MSR1 21q22.11-
q22.12 
35177445-
38271413 
3.1 22 1.28 20  
9q34.2 13657226
6-
13688484
7 
0.312  12 1.25 2  21q22.3 42986775-
44046571 
1.06 13 1.24 21  
10p11.1
1 
38013117-
38174719 
0.16 16 1.26 2 ZNF248        
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Table 4.8 FISH results for analysis of EPHA3 gene deletions using the BAC clones RP11-
598N21 (red) and RP11-547K2 (green). 
Sample Signal pattern # Cells  Average copy no. Overall result 
UROC156 2 yellow 
1 yellow 
50 
50 
1.5 50% hemizygous deletion 
UROC128 2 yellow 
1 yellow 
10 
90 
1.1 90% hemizygous deletion 
UROC125 2 yellow 
1 yellow 
0 yellow 
12 
85 
7 
1.05 82% hemizygous deletion 
UROC16 1 yellow 
2 yellow 
30 
40 
1.57 75%  hemizygous deletion 
(n=70) 
UROC171 1 Yellow 
2 yellow 
2 red 
30 
20 
20 
1.0 42.8% hemizygous 
deletion and 28.6% loss of 
exons 11-17  (n=70) 
UROC130 1 yellow 
2 yellow 
40 
60 
1.6 40% hemizygous deletion 
(n=100) 
UROC124 1 red 
2 red 
0 signal 
60 
20 
 20   
1.0 100% Complete loss of 
exons 11-17 and 
hemizygous loss of exons 
1-3. (n=100) 
UROC158 1 yellow 
2 yellow 
0 yellow 
2 green 
1 yellow, 1 red 
1 green 
59 
21 
5 
4 
8 
1 
1.14 60.2% Hemizygous 
deletion (n=98) 
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Figure 4.10 Representative images from 6 of the 10 cases selected for FISH analysis of EPHA3 gene deletions. 
DAPI stained interphase nuclei for UROC125, UROC 128, UROC130, UROC156, UROC16 AND UROC158, showing 
hemizygous deletion within EPHA3. The white arrows show cells with one yellow signal representing the presence 
of exon 1-3 and exon 11-17 sequences for one allele. The red arrows indicate nuclei where both alleles are intact.   
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Functional associations of candidate genes in amplified and deleted regions 
The list of genes, from segmented copy number data that was generated by Partek 
Genomics Suite, was screened for potential tumour suppressors and oncogenes by 
reviewing the published literature. This refined list of genes was then analysed in the data 
mining software programs, EASE and STRING, to identify biological pathways in which these 
genes are involved as well as identify functional associations between them.  
Using the EASE software to elucidate the common biological pathways amongst the selected 
candidate genes from amplified regions, twenty of the 36 candidate genes could be linked 
to common pathways. The EASE software establishes links to pathways selected by the user 
through text mining and by accessing the DAVID database for gene annotations. The most 
common pathways highlighted by EASE were DNA metabolism, RNA transcription, cell 
proliferation, cell growth and cell maintenance (Table 4.9 and figure 4.11). Other pathways 
involved included cell signalling, chromatin modelling, RNA processing, cell motility and cell 
development.  In terms of the regions of deletion, 21 of 27 candidate tumour suppressor 
genes identified could be linked to pathways involved in cell growth and maintenance, 
nucleic acid metabolism and cell communication, RNA transcription, DNA damage responses 
and apoptosis (Table 4.10 and Figure 4.12).  
The STRING 8.0 software was then used to identify functional relationships between 
candidate genes and graphically represent these associations. The associations between 
genes are reported by strength of experimental evidence or by literature based evidence. 
First, analysis was done between the 36 amplified genes and the 27 deleted genes, results 
can be seen in figure 4.13. The CCND1, NCOR2, FGF19, FGF3, FGF4, CTTN, TERT and SHANK2 
genes were the most strongly linked among amplified genes with CLPTM1L, PSCA, H2AFY, 
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BAD and TGFBI linking with a weaker confidence (Figure 4.14). Of interest, the majority of 
strongly associated genes, FGF19, FGF3, FGF4, CTTN, CCND1 and SHANK2 were all closely 
located on chromosome 11q13.3. Functional relationships between CTTN and SHANK2 are 
reported in the literature, where CTTN is reported to bind SHANK2 and together are 
involved in cytoskeletal reorganisation in neurons (Y. Du et al., 1998). The CTTN protein may 
also indirectly interact with Cyclin D1 as CTTN is found to regulate transcription of the cyclin-
dependant kinase inhibitors p21, p27 and p57 (which bind CyclinD1), allowing for cell cycle 
progression in a head and neck carcinoma cell line (Croucher et al., 2010). The FGF growth 
pathway can interact with and activate the Wnt pathway, which results in transcription of 
the CCND1 gene (Masaru Katoh, 2007), which would explain the functional relationship 
observed between the FGF genes and CCND1.  
The deleted genes were weakly associated. Stronger associations were shown for KIT and 
RFC1 as well as DCC and CASP3 genes. The FHIT, PDGFRL, NDEA, PACRG, LZTS1, SMAD4, 
RFC1, RAD18, WRN, XRCC4, RASA1 and EPHA3 genes linked in weakly into this network of 
proteins (Figure 4.15). The analysis of functional relationships between both amplified and 
deleted genes showed strong associations between the deleted genes FHIT, SMAD4, SMAD6 
and amplified TGFBI and CCND1 (Figure 4.14). These genes are all involved in cell cycle 
control and particularly SMAD4, SMAD6 and TGFBI genes are involved in the TGF-β pathway 
(Attisano et al., 2001). The FHIT protein is involved in Wnt inhibition, which regulates 
expression of the CCND1 explaining the interaction observed between these genes (Weiske 
et al., 2007). 
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Table 4.9 Biological pathways associated with genes amplified in this study. 
DNA 
metabolism 
Transcription Proliferation, 
Growth and 
Maintenance 
Cell 
death 
Cell 
signalling 
Chromatin 
structure/nuclear 
organisation 
RNA 
processing 
Cell 
motility 
and 
attachment 
Development 
MCM2 TGFBI EYA2 BAD FGF3 MCM2 SF1 KCNMA1 ELAVL1 
KCNMA1 LITAF FGF4  FGF4 TERT ELAVL1 TGFBI EYA2 
TERT BAD CCND1  KCNMFGFA1    FGF19 
BAD ESRRA PSCA  MAP2K7    FGF3 
ELAVL1 HES6 FGF3  PER2    KCNMA1 
ESRRA KLF2 MAP2K7  PSCA     
EYA2 LITAF MCM2       
HES6 MCM2 TERT       
NCOR2 NCOR2 TGFBI       
PER2 PER2        
SF1 SF1        
TERT         
12 11 9 1 6 2 2 2 5 
 
 
Figure 4.11 Pie chart showing the proportion of the 20 candidate genes 
involved in each biological process listed. This data was established using 
the EASE 2.0 software.  
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Table 4.10 Biological pathways associated with deleted genes in this study. 
Cell growth/maintenance Nucleic acid 
metabolism 
Cell communication transcription DNA damage 
response/DNA 
repair 
Apoptosis 
ADAMTS1 FHIT ADAMTS1 HMBG2 RAD18 FHIT 
DCC HMGB2 ASB5 LZTS1 RFC1 CASP3 
FHIT LZTS1 EPHA3 RFC1 XRCC4 DCC 
KIT RAD18 HUNK ZNF248   
MSR1 RFC1 KIT    
RASA1 WRN PCSK1    
RFC1 XRCC4 PDGFRL    
SPTA1 ZNF248 RASA1    
8 8 8 4 3 3 
 
 
Figure 4.12 Pie chart showing the proportion of deleted genes associated with the 
listed biological pathways.  
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Figure 4.13 Predicted functional interactions for all potential oncogenes and tumour 
suppressor genes amplified or deleted in this study using the STRING 8.3 software 
(http://string.embl.de, accessed July 2010). The colour of the respective lines listed in the 
key relates to the type of relationship linking the proteins. 
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Figure 4.14 Predicted functional interactions for the genes in amplified regions as 
determined by the STRING 8.3 software. This network is the confidence view; with the line 
linking proteins being thicker depending on the combined confidence score for those two 
proteins. The thickness of the line represents the confidence score based on literature and 
experimental evidence. Confidence was set to medium confidence of 0.400. 
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Figure 4.15 Predicted functional interactions for the genes in deleted 
regions as determined by STRING 8.3 software. This network is the 
confidence view. The confidence limit was set to medium confidence of 
0.400.   
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4.4 Discussion 
4.4.1 OSCC demographics in SA 
In cancer registries, including the most recent PROMEC and MRC cancer registry report from 
the Eastern Cape of SA, the incidence of OSCC is said to be higher in males than in females 
with a prevalence of 31.3 and 18 per 100 000 individuals respectively with the age range 
between 65-69 years (Somdyala et al., 2010) i.e. a male to female gender ratio of 1.74:1. In 
contrast, the data from the cohort collected from the Nelson Mandela Academic Hospital in 
Umtata showed a gender ratio of 1:0.97 and a lower age of incidence at about 58.86 years 
compared to the report of Somdyala et al (2010).  Although no definitive conclusion can be 
drawn from this observation, this warrants proper epidemiology studies to be conducted in 
Umtata where nearly as many females as males seem to be affected.  
4.4.2 SNP arrays as a method for copy number analysis for FFPE samples 
FFPE samples provide an important source of genomic material for research, and the 
availability of histological information allows for microdissection of samples with a high 
content of tumour cells. The challenges in using formalin fixed paraffin embedded tissues 
result from the variation in fixation methodologies. The major factors that affect sample 
quality are the time a sample is fixed in formalin and years of storage, which both have 
damaging effects on the DNA. The major effects of prolonged fixation are the cross-links 
formed between DNA strands, which inhibit downstream PCR techniques. These factors are 
not under the control of the researcher and good quality array results can be difficult to 
obtain. Analysis of SNP array technology results obtained from FFPE samples has been 
evaluated previously; it is found that larger fragments usually fail to amplify in the PCR step 
of the assay, which reduces the call rates (Jacobs et al., 2007). A multiplex PCR is 
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recommended to pre-determine the performance of samples in PCR and exclude poor 
samples. The average call rates detected in a published study were 79.84% and 75.17% for 
Nsp and Sty respectively (Jacobs et al., 2007). The average call rates for the samples in the 
present study were 70.05% and 73.38% for Nsp and Sty arrays respectively, with highest call 
rates obtained of 79.86% and 83.53% for Nsp and Sty respectively. Call rates for fresh tissue 
or blood are usually greater than 93% and the study by Jacobs et al (2007) determined that 
excluding SNPs residing on fragments of sizes larger than 700bp improved the call rates of 
FFPE samples such that they were concordant with those of fresh samples. Adding this step 
reduced the signal to noise ratio and although the number of SNPs available for copy 
number analysis was reduced to 308,788, there was sufficient data for copy number 
analysis. In addition, the FFPE samples generally do not yield as much PCR product as fresh 
samples and it was determined here that an additional three separate reactions were 
needed to make up the 90µg required for hybridisation to an array. Another study found 
good concordance between results from fresh samples and matching FFPE samples using 
the Affymetrix® 10K arrays (E. R. Thompson et al., 2005). Since Partek® Genomics Suite has 
a function to remove SNPs on large fragments from the data, it was used to analyse the 
copy number changes in the FFPE samples.  
Only 51 out of 117 samples, for which DNA was extracted, could be analysed by SNP array 
technology, showing that the quality of FFPE samples remains an issue. More than double 
the required number of samples for analysis needs to be collected due to the poor sample 
quality of DNA obtained from FFPE samples. In instances where there is not enough DNA 
material, newer or alternative methods may be more suitable, for example, oligonucleotide 
arrays designed specifically for copy number detection. For example, the Agilent 4x44K 
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array platform was suggested to outperform SNP based analysis (Nasri et al., 2010). Next 
generation sequencing has also been suggested for analysis of FFPE samples and generated 
reproducible results comparable to those obtained from array-CGH (H. M. Wood et al., 
2010). More recently, molecular inversion probes have been applied to copy number 
analysis in FFPE samples. This technique involves probes with two specific homology 
sequences that leave a 1bp gap when hybridised to the genome, they have sequence tags, 
which are read on a tag array. Molecular ligation is performed and then exonucleases 
eliminate the linear probes and two PCR primers (common to all probes) are used to amplify 
circularised sequences and introduce a fluorescent label (Yuker Wang et al., 2005). The 
sample is then hybridised to the tag array. The technology only requires sequences that are 
~ 40bp in size, which is advantageous for samples with degraded DNA (Yuker Wang et al., 
2005). Some of these methods are likely to improve analysis of copy number analysis 
changes in FFPE samples in the future. 
Depsite the challenges in obtaining results on arrays with FFPE samples, 51 samples gave 
good quality results for analysis of copy number changes. The analysis of copy number 
changes in this OSCC cohort identified 20 regions of high amplification, 25 regions of 
moderate amplification, one homozygous deletion and 55 regions of hemizygous deletion. 
These regions encompassed 36 potential oncogenes and 27 potential tumour suppressor 
genes respectively.  
4.4.3 Similarities between the five cell lines and the Eastern Cape patient cohort. 
The similarity between the cell lines and the cohort is important for future studies as cell 
lines could be used as a model for functional analysis. The most striking similarity was a 
common deletion affecting the EPHA3 gene on 3p11.1-p12.1. The 3p11 deletion observed in 
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the cohort coincided with the translocation breakpoints and deletions detected in the four 
cell lines WHCO1, WHCO3, WHCO6 and SNO. Amplification of the 11q13.3 region, which 
affected the CCND1, CTTN, FGF3, FGF4 and FGF19 genes and the 8q24.21 region, involving 
the c-MYC gene, were also common to both data sets.   
Additional regions shared by the cell lines and the FFPE patient’s cohort included deletion of 
chromosome 1p31.1 and involved the anti-proliferative gene, IFI44. This gene product binds 
and depletes GTP, resulting in cell cycle arrest (Hallen et al., 2007). Also commonly deleted 
was a 3p26.3 chromosomal region with a minimum region of overlap 966545-2566394bp. 
No genes previously described in cancer are in this region. Both data sets had a deletion 
affecting the 3p14.2 region harbouring the important tumour suppressor gene, FHIT. 
Chromosome 4p14-q35.2 deletion and 4q31.3 overlapped both data sets and involved the 
SMAD1 gene and SFRP2 genes respectively. Chromosome 6q26 deletion, affecting the 
PACRG gene, was also common to both data sets. Chromosome 8p22 was deleted in the 
cohort and the nearest deletion detected in the cell lines was 8p23.3-q21. Chromosome 
18q21.1-q21.2, which was deleted in the cell lines, overlapped with the 18q21.1-q21.2 
region in the cohort and involved the DCC and SMAD4 genes.   
Genes that were commonly affected by copy number changes in both cohorts need to be 
assessed by expression studies and could then be studied in the cell lines to evaluate their 
role in OSCC cell biology. The relevance of these genes in cancer is discussed further. 
4.4.4 Comparison of this study’s results to published literature on copy number changes 
Previous international studies have highlighted amplification of chromosomes 1p36.13-
p36.21, 2q31-q32, 3q28, 5p15.2, 6p25.3, 7p14, 8q24, 11q12.3, 20p11.1 and 20q12.1 as the 
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most common aberrations detected in OSCC (C. C. Yen et al., 2001; C. C. Yen et al., 2005; Xu 
Zhang et al., 2008; Chen, et al., 2008; Y. R. Qin et al., 2008; N. Hu et al., 2006; Carneiro, et 
al., 2008; Chattopadhyay et al., 2010).  
The 11q and 8q amplicons are the most frequently reported amplicons which were also 
detected in this study (Chattopadhyay et al., 2010; Carneiro et al., 2008; Y. R. Qin et al., 
2008; N. Hu et al., 2006; C. C. Yen et al., 2001; Du Plessis et al., 1999; Chen et al., 2008). Due 
to the recurrent involvement of these aberrations in different studies and including this one, 
they are likely to represent key abnormalities in OSCC carcinogenesis. In addition, 
amplification of 3q, 5p and 20q are also common, but the variability in the reported sub-
bands is high. Chromosome 3q amplification is reported to affect the SOX2 gene (3q26) in 
15% of OSCC cases in the USA (Bass et al., 2009). This gene was not detected in the current 
study, again highlighting population or geographic differences in OSCC carcinogenesis. 
Chromosome 5p15.33 amplification may target the TERT oncogene, which is known to be 
involved in the maintenance of telomeres and has been implicated in multiple malignancies 
(C. G. Hsu et al., 2007; X. Kang et al., 2009; Metzger et al., 2004). Interestingly, TERT gene 
over expression results in the immortalization of oesophageal epithelial cells (H. Zhang et 
al., 2006). The 5p15.33 gain is shown to be the most frequent event in early stages of lung 
cancer (J. U. Kang et al., 2008) and it would be interesting to test for this abnormality in 
early lesions of OSCC in SA. 
Chromosome 20q13.3 amplified in the present study was similar to the most frequently  
amplified region, 20q13.1, reported in other studies (Y. Fujita et al., 2003; C. C. Yen et al., 
2001; Hirasaki et al., 2007). Gain of a whole chromosome 20, iso 20q or duplication of 20q 
was also the most persistent event in HPV16E6/E7 immortalized oesophageal cells (H. Zhang 
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et al., 2006). These findings suggest that 20q gain could be a non-random, early event 
contributing to cell immortalization. Chromosome 20q amplification has been associated 
with a poor prognosis in OSCC (Y. Fujita et al., 2003; C. C. Yen et al., 2003) as well as in 
various tumour types (Carneiro et al., 2008; Chen et al., 2008b; C. C. Yen et al., 2001; 
Hirasaki et al., 2007; Derek J Nancarrow et al., 2008). The 20q13.3 region amplified in this 
study harbours the EYA2 gene, which is a transcriptional co-activator, up-regulated in 
ovarian carcinoma and promotes tumour growth (L. Zhang et al., 2005). Ovarian carcinoma 
patients with elevated expression of EYA2 are shown to have a poor survival rate (L. Zhang 
et al., 2005). The EYA2 gene is a likely target gene for amplification on chromosome 20q and 
may contribute to OSCC carcinogenesis.  
The epidermal growth factor (EGFR) gene is commonly over expressed in OSCC, sometimes 
due to amplification of the gene on chromosome 7p14, which is a frequently reported 
amplicon in the literature (Hanawa et al., 2006; Gongyuan Zhang et al., 2010). Amplification 
of the EGFR gene was not detected in this cohort indicating that gene amplification of EGFR 
is not important in OSCC in SA. However, expression of this gene needs to be assessed in 
fresh samples from South Africa to establish if EGFR over expression occurs. The non-
receptor tyrosine kinase gene, TNK2, located in the amplified 3q29 region, is known to bind 
EGFR and maintain EGFR on the cell surface. Knockdown of TNK2 by siRNA results in fewer 
EGFR molecules being expressed on the cell surface (Howlin et al., 2008). In the 5 OSCC cell 
lines EGFR is known to be over expressed (R Veale, 1989). It is possible that TNK2 gene 
amplification may be one of the mechanisms contributing to EGFR protein expression on the 
cell surface in OSCC cell lines. It would be of value to assess EGFR expression in patient’s 
samples.  
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Five novel or rarely described regions of amplification were seen in this study. Chromosome 
1p amplification has also been reported in the literature with the most common region at 
1p36. In this study a novel region, chromosome 1p32.3, was amplified. Chromosome 19p 
and 19q amplification have only been reported once before in OSCC by Carneiro et al (2008) 
(Carneiro et al., 2008). Here, 19q13.43 amplification was detected in 33 % of cases and was 
the region with the highest copy number change affecting one potential gene (the A1BG 
gene) not reported before in OSCC. Other novel regions of amplification included the 2p21 
and 4q35.1 regions, which had no genes previously reported in cancer. 
The deletions previously reported in OSCC in the literature most frequently affected 
chromosome 1p, 4p14-p15.3, 3p14.2, 3p26.3, 3p24.2, 5q33, 8p23.2, 9p21.3 and 18q21.2-
q22 (C. C. Yen et al., 2001; C. C. Yen et al., 2005; Xu Zhang et al., 2008; Jing Chen, 2008; Y. R. 
Qin et al., 2008; N. Hu et al., 2006; Carneiro et al. 2008; Chattopadhyay et al., 2010).  
Two homozygous deletions were detected and included the BCL8 gene on chromosome 
15q11.2 and the CNN1 gene on chromosome 19p13.2. The BCL8 gene has been implicated 
in translocations detected in diffuse-large B-cell lymphomas (DLBCL). Translocations 
involving the gene results in ectopic expression of BCL8 and supports a role in DLBCL 
(Dyomin et al. 1997). There has been no evidence of BCL8 disruption in OSCC and the exact 
function of the gene is unknown.  Functional studies would be important to establish how, if 
at all, deletion of this gene could contribute to cacinogenesis in OSCC. The CNN1 gene is a 
putative tumour suppressor gene in OSCC. CNN1 is an actin binding protein and over 
expression of CNN1 was shown to decrease cell proliferation in a uterine leiomyosarcoma 
cell line (Horiuchi et al. 1999). The gene is also down-regulated in rats with pre-cancerous 
lesions of the esophagus induced by zinc deficiency (Horiuchi et al. 1999). Dietary 
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deficiencies are associated with OSCC carcinogenesis and the CNN1 gene deletions could be 
important in the carcinogenic process of OSCC. Both these regions were not affected by 
hemizygous deletion; this does not exclude the possibility of inactivating mutations in 
samples that did not have homozygous deletion in these two genes.  
Similar regions of deletion, previously reported in the OSCC studies mentioned above, 
affecting chromosomes 4p (4p14-q35.2) and 3p26 (3p25.2-p26.3) were detected here. The 
commonly reported 3p14.3 (FHIT), 5q22.2 (APC), 9p21.3 (CDKN2A and B) and 18q21.2-q22 
(DCC and SMAD4) deletions in the above studies were also deleted in this study, highlighting 
them as important tumour supressors.  
Chromosome 6q26 (PACRG) deletion has not been reported before in OSCC copy number 
studies. The high frequency (66.7%) of 6q26 deletion and the small size of the region 
suggests that this is a key target tumour suppressor gene in this study.  
Chromosome 8p deletions are frequently reported in a variety of cancers (Di Benedetto et 
al., 2006; J. M. Flanagan et al., 2004; Kanae Ono et al., 2003) and an 8p loss was previously 
reported in a small cohort of OSCC from SA by Du Plessis et al (1999). These authors used 
conventional CGH and found that 8p deletion was found exclusively in black male patients 
from a cohort that included 29 males and females patients of black, colored and Caucasian 
ethnic groups (Du Plessis et al., 1999). The 8p deletions detected in this study were not 
exclusive to male patients but were present in both male and female patients. The 8p22 
chromosome band has also been reported to be deleted in prostate, breast, lymphomas, 
hepatocellular and colorectal cancer (Bova et al., 1996; Di Benedetto et al., 2006; J. M. 
Flanagan et al., 2004; Thomassen et al., 2009; Ying et al., 2007). Chromosome 8p deletion is 
therefore an important region, requiring further investigation in OSCC. 
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4.4.5 EPHA3 as a candidate gene in OSCC 
Three of the cell lines had deletions affecting chromosome 3p11.2, harbouring the EPHA3 
gene, which consists of 17 exons. Two cell lines had deletions of sequences spanning exons 
1-3, one cell line had deletions of both exons 1-3 and exons 11-17 and one cell line had a 
deletion in the region 5’ to the EPHA3 gene. In addition, the expression of the gene was 
found to be lower in the four OSCC cell lines that had an EPHA3 deletion compared to 
normal oesophageal tissue (chapter 3, section 3.3). Hemizygous deletion of 3p11.1-12.1, 
which overlaps EPHA3, was detected in 74.5% of the patients by array copy number 
analysis. This was confirmed in 8 of these cases by FISH analysis. This gene is therefore of 
great interest and is suspected to be a candidate gene in OSCC. To interpret the possible 
role that deletion of EPHA3 may have in OSCC, its function in normal and other cancerous 
tissues needs to be understood.  
Structure and function of EPHA receptors 
The EPHA3 protein is an ephrin receptor tyrosine kinase. Eph receptors form the largest 
subfamily of receptor tyrosine kinases (Pasquale, 2010). Ephrins are the activating ligands 
for these receptors; they are tethered to the membrane by a glycosol phosphotidyl inositol 
moiety and are also capable of activating signalling within a cell (Binns et al., 2000). There 
are two classes of Eph receptors, A and B. The ephrin ligands are also classed as A or B as 
they usually bind specifically to either A or B class Eph receptors (Pasquale 2010). When 
ephrin receptors interact with an ephrin on an opposing cell, activation of signalling by the 
ephrin protein in that opposing cell can occur (reverse signal) and at the same time 
activation of the Eph receptor by the ephrin ligand induces signalling within the cell (foward 
signal) (Figure 4.16) (Pasquale 2010). The Eph receptors and ephrins that interact with 
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opposing cells, termed a trans interaction, results in the above mentioned bi-directional 
signalling. Eph receptors and ephrins can interact on the same cell, termed a cis interaction, 
which inhibits this bi-directional signalling (Figure 4.16) (Arvanitis & Davy, 2008). The bi-
directional signalling of Eph receptors and ephrins regulates cytoskeletal structure and cell 
adhesion (Binns et al., 2000). 
The EphaA receptors consist of an extracellular N-terminal domain, which binds with a 
ligand, a juxtamembrane domain, tyrosine kinase domain and a sterile alpha motif (SAM) 
(Binns et al., 2000). Binding of ephrin ligands to the extracellular domain, results in 
oligomerisation, which causes autophosphorylation of tyrosine residues, causing direct 
stimulation of catalytic activity of the tyrosine kinase. The oligomerisation also activates 
autophosphorylation within the juxtamembrane domain, which creates docking sites for 
SH2 domain containing proteins, activating these signalling molecules (Binns et al., 2000). In 
this way, the Eph/ephrin signalling interacts with other signalling pathways in mammalian 
cells, for example, MAPK, Akt, PI3K, FAK, JNK and ZO-1 (Arvanitis & Davy, 2008). These 
signalling interactions result in modulation of cell adhesion, cell sorting and patterning, cell 
migration, fusion, craniofacial development and platelet aggregation (Arvanitis & Davy, 
2008). The deregulation of the Eph/ephrin signalling can therefore also contribute to 
carcinogenesis (Surawska et al., 2004). 
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Figure 4.16 Schematic diagram of EphA/ephrin signalling 
adapted from Arvanitis et al (2008). Interaction between EphA 
receptors and ephrins on neighbouring cells results in signalling 
in both directions, reverse signalling activated by ephrin 
stimulation and forward signalling is activated by EphA receptor 
stimulation. Activation across cells is termed trans interaction. 
Cis interaction is when co-expressed EphA receptors and ephrins 
on the same cell interact and this inhibits signalling (Arvanitis & 
Davy 2008).   
 
Role of Epha/ephrin signalling in cancer 
The most important role for EphA proteins seems to be in cellular adhesion and de-
adhesion. Cell adhesion is mediated through contact points or focal adhesions. These focal 
adhesions often bring activated receptor tyrosine kinases and their substrates into contact 
(Surawska et al. 2004). For example, EphA2 protein association with Fak protein (focal 
adhesion kinase) is constitutional and results in cell adhesion. Stimulation of EphA2 protein 
by ephrinA1 results in dissociation of the EphA2/Fak complex, which leads to cell 
detachment (Surawska et al., 2004). Contrastingly it was also shown that ephrin stimulation 
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triggers FAK phosphorylation, cell spreading and formation of adhesive structures (Surawska 
et al., 2004). The explanation for the contrasting functionality is proposed to be that Eph 
and ephrin density and composition on cells determines the signalling and cellular response. 
This in turn determines whether there is detachment or attachment of cells (Fox & Kandpal, 
2004).  This was illustrated by the study by Fox et al (2004).  
The Eph receptors and ligands are involved in the correct positioning of epithelial cells in 
breast tissue (Fox & Kandpal, 2004). Fox et al (2004) studied the expression profiles of 13 
Eph receptors and their 8 ligands in breast carcinoma cell lines. The study showed that up 
regulation of some of the Ephrins and EphA receptors contribute to tumourigenesis and 
down regulation of others plays a role in invasiveness (Fox & Kandpal, 2004). The up 
regulation of EPHA2, 7 and 10 specifically were related to tumourigenesis and invasiveness 
while down regulation of EPHA3 was one of the factors specifically contributing to 
invasiveness (Fox & Kandpal, 2004). The Eph/ephrin network is therefore complex and the 
mechanisms of the signalling network are not fully understood and contradicting roles for 
EPHA3 in cancer are reported in the literature. 
Further evidence of EPHA3 acting as a tumour suppressor is that soluble forms of EphA3 
appear to inhibit tumour angiogenesis and tumour progression. Soluble EphA receptors 
delivered by transgene or osmotic mini pumps into pancreatic islet cell carcinoma results in 
inhibition of angiogenesis and reduced tumour size (N. Cheng et al., 2003). The soluble 
forms of EphA receptors were used in treatment of 4TI mouse mammary adenocarcinoma 
cell lines transplanted into Balb/c mice. This resulted in decreased vascular density and 
tumour growth (D. M. Brantley et al., 2002). This supports the idea that Eph receptors and 
their ligands function in tumour progression (D. M. Brantley et al., 2002).  
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One example of the EPHA3 gene acting in an oncogenic way is that over expression of 
EphA3 protein results in resistance of prostate cancer cells to p53 mediated damage 
induced apoptosis. Down regulation of EphA3 by sh-RNA results in sensitization of prostate 
cancer cells to DNA damage induced apoptosis (T. Jiang et al., 2004). EphA3 appears to 
retain p53 in the cytosol, possibly by masking p53s nuclear localization signal thus inhibiting 
p53 (T. Jiang et al., 2004). EphA3 therefore has inhibitory effects on both the transcriptional 
activity and mitochondrial functions of p53 (T. Jiang et al., 2004).  
The evidence for EPHA3 acting as a tumour suppressor in the literature indicates that 
deletion of EPHA3 may contribute to OSCC, perhaps in a similar mechanism to breast cancer 
as described by Fox et al (2004). Further investigation is required of the full Eph/ephrin 
complement in order to assess the exact contributions these proteins have in 
carcinogenesis. It is hypothesized that lowered expression of EPHA3 may contribute to cell 
detachment, migration and metastasis.  
4.4.6 Common copy number aberrations and potential pathways affected 
The results of the analysis of biological pathway and functional interaction with the EASE 
and STRING software programs showed that the genes potentially affected by amplification 
were mostly involved in DNA metabolism (24%), transcription (22%), proliferation (18%) and 
cell signalling (12%). The deleted regions affected genes involved in cell communication 
(24%), nucleic acid metabolism (23%) and RNA transcription (12%). All of these pathways 
may be up-regulated or down-regulated resulting in uncontrolled cell growth in OSCC or any 
cancer. Potential mechanisms of these contributions are discussed. 
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Chromosome 11q amplification 
There were three sub-amplicons on chromosome 11q. The CTTN gene is part of the most 
frequent (66.7%) and most amplified (57 copies) region on chromosome 11q13.3 
(70061246-70310057bp). The two sub amplicons flanking the CTTN locus, 11q13.3 
(68884395-70061246bp) and 11q13.3-q13.4 (70310057-71374778bp), were less amplified 
at 14 copies and in a lower number of samples (37.2% and 56.8% respectively). These two 
regions include the oncogenes, CCND1, FGF3, FGF4, FGF19 and SHANK2. In light of the high 
level of amplification of the CTTN locus, the CTTN gene is likely the main target of 
amplification on chromosome 11q13 and an important oncogene. It has been shown that 
gene copy number in 11q13 amplicons is variable and that distinct cores (groups of genes) 
had differing levels of amplification (Sugahara et al. 2011). The combination of these cores, 
one of which included the CTTN gene, was specifically associated with lymph node 
metastasis in oral squamous carcinoma (Sugahara et al. 2011).  The sub-amplicon detected 
on 11q in this study may also hold distinct groups of genes that are important in OSCC 
carcinogenesis. The CTTN gene is over expressed in OSCC pre-cancerous lesions, as well as in 
carcinogen induced murine OSCC supporting a role for CTTN in OSCC carcinogenesis (N. Y. 
Hsu et al. 2008). CTTN is an actin-binding protein and is involved in cell motility (P. Hofman 
et al. 2008), and has a role in actin reorganization (Du et al. 1998). CTTN facilitates cell 
motility by preventing anoikis through the PI3-Akt pathway (Du et al. 2009).  
The SHANK2 gene on the subamplicon 11q (70310057-71374778bp) encodes a protein 
involved in the regulation of trans-epithelial absorption (Han et al. 2006). The SHANK2 gene 
is amplified in other cancers including oesophageal cancer (Carneiro, Isinger, Karlsson, J. 
Johansson, Jönsson, et al. 2008). The SHANK2 protein is also a ligand for the CTTN protein 
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through the SH3 binding domain of cortactin (Du et al. 1998). As co-amplified genes, 
SHANK2 and CTTN over expression together may have a compound effect on carcinogenesis. 
In addition to these genes on chromosome 11q13, the FGF genes are also implicated in 
cancer and although CTTN is probably a more important target due the high level of 
amplification, the other genes in 11q13 may still contribute to OSCC. 
In the literature, the FGF proteins (FGF3, FGF4, and FGF19) are reported to induce the Wnt 
pathway, which in turn is responsible for CCND1 induced expression (Masuko Katoh & 
Masaru Katoh, 2006). CTTN was previously shown to down regulate the expression of 
cyclin–dependant kinase inhibitors; knockdown of CTTN by sh-RNA results in increased 
binding of the p21, p27 and p57 proteins to cyclin D1, inhibiting cells from progressing into 
the S-phase (Croucher et al., 2010). These reported interactions between the FGF3, FGF4, 
FGF19, CCND1, CTTN and SHANK2 genes may be at play in OSCC in SA and all contribute to 
providing cell growth advantage. However, one or more of these genes may have a stronger 
impact on carcinogenesis, while others may be passenger genes within an amplicon. As 
could be seen in the relative quantification by RT-PCR in the cell lines (chapter 3), where the 
FGF4 gene was not over expressed and is likely a passaneger in the 11q amplicon.  
Chromosome 19p amplification 
The most highly amplified region was on chromosome 19p13.11-p13.12, where an average 
of 111 copies was detected in 33.3% of samples. The region has 16 genes, none with clear 
involvement in cancer except the KLF2 gene. This gene encodes a transcription factor. The 
KLF2 gene has not been implicated in OSCC before and it is unclear whether it is oncogenic. 
Although it is over expressed in prostate cancer samples and neuroblastoma cell lines, it is 
also reported to have tumour suppressor function (Duhagon et al. 2010;Cotterman & 
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Knoepfler 2009). The KLF2 protein causes quiescence in T-cells by down-regulating C-MYC 
expression (Buckley et al. 2001). In addition to the other genes located in this region, many 
microRNAs have been mapped here and perhaps amplification of these may have a role in 
OSCC carcinogenesis.   
The 270.81kb region from 58858174-59128983bp at 19q13.43 encompasses a target gene, 
the A1BG (alpha-IB-glycoprotein precursor) gene. This gene is over expressed in pancreatic 
cancer and was identified as a potential biomarker in pancreatic cancer as well as 
hepatocellular and bladder cancer (M. Tian et al., 2008; S. Y. Yoon et al., 2006; Kreunin et al., 
2007). Higher levels of the A1BG protein are detected in the serum of patients with 
gastrointestinal tumours such as colorectal and gastric tumours, highlighting this gene as a 
biomarker for non-invasive screening procedures (Szilvás et al., 1998).  
The high level of amplification on chromosome 19, suggests that novel candidates located in 
these sub-bands may be of interest in OSCC carcinogenesis. Amplification of the above 
mentioned candidate genes should be verified in more samples by an alternative method 
and investigation into their role in OSCC is warranted. 
Amplifications and deletions affecting the TGF-β and Wnt signalling pathways 
Transforming growth factor-beta signaling (TGF-β) disruption is also implied by the 
aberrations detected in this study. TGF-β signalling can have a tumour suppressive role or 
promote tumour growth depending on the balance of molecules within the pathway 
(Ikushima & Miyazono 2010). The SMAD6 oncogene was amplified on chromosome 
15q22.31 (average copy of 26.9 copies) in 25.5% of samples. The SMAD6 gene encodes a 
protein involved in the TGF-β pathway and usually inhibits the apoptotic function of the 
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TGF-β pathway (Attisano, Silvestri, Izzi, & Labbé, 2001). Increased expression of SMAD6 
increased cell growth in pancreatic cancer (Kleeff et al., 1999). In contrast, SMAD6 over 
expression was found in early OSCC tumours and was inversely correlated with depth of 
invasion (Osawa, Nakajima, Kato, Fukuchi, & Kuwano, 2004). In addition, in oral squamous 
cell carcinoma, SMAD6 over expression was associated with a better outcome in 
conjunction with a loss of SMAD2 expression (Mangone et al. 2010). It is suggested that 
expression of SMAD6 inhibits the pro-oncogenic role of the TGF-β pathway in later 
carcinogenesis (Mangone et al. 2010). It is clear from the contrasting results on SMAD6 
expression that further investigation of the role of the SMAD6 protein in OSCC is required. 
The Smad 4 protein (encoded by SMAD4) is activated by TGF-β and together with other 
proteins activates transcription of genes involved in cell cycle regulation (Attisano, Silvestri, 
Izzi, & Labbé, 2001). The SMAD4 gene was part of the deleted region on chromosome 
18q21.1-q21.2 in 70.6% of cases. Loss of SMAD4 expression was previously reported in 
51.2% of OSCC patients and correlated with depth of invasion (Fukuchi et al. 2002). Hence, 
loss of expression of SMAD4 may cumulatively add to decreased cell cycle regulation within 
the TGF-β signaling pathway.   
In addition to the SMADs, the FBXW7 gene also involved in the TGF-β pathway, was targeted 
by deletion of chromosome 4p14-q35.2. The FBXW7 protein targets proteins for 
degradation and specifically the TGIF1 (TGF-β induced factor 1) protein. When TGIF1 is not 
degraded, accumulation of phosphorylated TGIF results in suppression of TGF-β dependant 
transcription and de-regulated cell growth and migration (Bengoechea-Alonso & Ericsson 
2010).  The MYC gene on 8q24 was moderately amplified (8.5 copies) in 21.57% of the 
samples, which may result in over expression of MYC. The MYC protein is also targeted for 
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degradation by the FBWX7 protein (Y. Fujii et al. 2006). Consequently, deletions of the 
FBXW7 gene could contribute to the the loss of apoptosis normally induced by TGF-β and 
also contribute to the accumulation of the MYC oncoprotein. A graphic representation of 
the potential interactions of the above mentioned genes in TGF-β signalling can be seen in 
figure 4.17.  
 
 
Figure 4.17. Schematic representations of TGF-β signalling. 
The red coloured blocks are genes amplified in the OSCC 
cohort and blue blocks are genes deleted in this cohort. The 
potential interaction of these amplified and deleted genes 
may contribute to inactivation of the TGF-β pathway and 
induction of apoptosis. Smad 6 inhibits the activity of smad2/3 
and smad4, which would normally activate apoptosis through 
activation of transcription. If TGIF1 is not targeted for 
degradation by the Fbxw7 protein, it will inhibit the smad2/3 
and 4 proteins again inhibiting apoptosis.  
 
The FHIT gene was part of a deleted region on 3p detected in 21.6% of samples. This gene is 
an important known tumour suppressor. The mode of FHIT tumour suppressor function has 
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been debated but it has been shown that it likely regulates the Wnt pathway (Weiske et al. 
2007). The FHIT protein binds to the LEF-1/TCF/β-catenin complex and binding of Fhit to β-
catenin is essential in the repressive function of Fhit on transcription through the LEF-
1/TCF/β-catenin complex (Weiske et al., 2007).  Previous studies of FHIT knock out, resulted 
in increased TCF/β-catenin mediated transcription of genes such as CCND1 (Weiske et al., 
2007). FHIT may also regulate CCND1 expression by down-regulating cyclophilin A, a 
promoter of Cyclin D1 synthesis (Shuho Semba & Kay Huebner, 2006). Loss of FHIT may 
therefore contribute to the deregulation of the Wnt pathway and transcription of genes 
downstream of this pathway.  
The gene, APC, is a key regulator of β-catenin degregadation and therefore downregulation 
of the Wnt pathway. The gene was included in the deleted region on chromosome 5, 
5q21.2-q23.3. The SFRP2 gene deletion, on chromosome 4q31.3-q35.1, was detected in 
74.5% of samples. This gene is also a regulator of the Wnt pathway as described in chapter 
2. The SFRP2 gene encodes a frizzled-related Wnt inhibitor (Kongkham et al., 2010). The 
fibroblast growth factor pathway, involving the FGF3, FGF4 and FGF19 genes may also feed 
back into Wnt signalling, by inhibiting GSK-3β targeting of β-catenin for degradation 
(Masuko Katoh & Masaru Katoh, 2006). In a scenario where the FGF genes are 
overexpressed and stimulate the Wnt pathway, over expression of the c-MYC and CCND1 
genes  may occur as they are transcriptional targets of the TCF/β-catenin complex, which 
would not be inhibited if β-catenin is not degraded. Graphic representation of the Wnt 
pathway and the gene interactions can be seen in figure 4.18. A recent publication found 
that treatment of oesophageal carcinoma cell lines with methylselenic acid could reduce the 
β-catenin levels and inhibit the TCF/β-catenin pathway, which would suggest that this is one 
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manner in which selenium reduces oesophageal cancer risk (W. Zhang et al., 2010). This 
effect was reversed by over expressing β-catenin (W. Zhang et al., 2010). This would suggest 
that a selenium nutrient deficiency, commonly associated with OSCC, may act on the 
Wnt/β-catenin pathway. 
 
 
Figure 4.18. Schematic representations of the Wnt, FGF and Hedgehog pathway 
interactions. A In the non activated state, β-catenin is targeted for degradation. B 
Stimulation of the Wnt pathway results in activation of β-catenin/TCF/LEF transcription of 
genes. Blue blocks indicate genes deleted in this cohort and red blocks indicate genes 
amplified in this cohort.  
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Genes with aberrant copy number involved in genomic stability  
Genes, in regions of deletions in this study, are implicated in DNA repair pathways and 
genomic instability. These genes included WRN, ATM, XRCC4 and RAD18.  
The WRN gene (deleted on 8p21.3-p22 in 21.57% of cases) expresses a protein involved in 
processing stalled replication forks and recovery from replication stress (Franchitto et al., 
2008). The WRN protein is phosphorylated under conditions of replication arrest or DNA 
damage, causing stalling of the replication fork (Pichierri et al., 2003). In addition WRN is 
important for maintaining stability of fragile sites. WRN accumulates at the sites of 
aphidicolin induced replication delay and cells lacking WRN showed increased incidence of 
gaps and breaks in the common fragile sites including FRA3B (Pirzio et al., 2008). Cells 
showing loss of this protein generally show premature senescence, genomic instability and 
telomere loss (F. J. Liu et al., 2010). Wrn depleted cells are more sensitive to DNA damage 
(Mao et al., 2010). 
The ATM gene, deleted on 11q22.3 in 49% of cases, is a critical gene involved in the repair of 
double-stranded breaks and DNA damage checkpoints (K. Suzuki et al., 2010). The ATM 
protein is also involved in regulating WRN; the ATM protein is required to maintain WRN 
protein in a phosphorylated status (Pichierri et al., 2003) and together they assist in the 
prevention of double stranded breaks (Ammazzalorso et al., 2010). The RAD18 gene was in 
the deleted region on 3p25.3-p26.3 in 66.7% of cases; this gene is involved in DNA damage 
responses during replication stress and suppresses the formation of gross chromosomal 
rearrangements (Putnam et al., 2010). RAD18 protein accumulates at sites of DNA damage 
and promotes homologous recombination (Jun Huang et al., 2009). The XRCC4 gene on 
chromosome 5q14.1-q14.2, which was deleted in 54.9% of cases and encodes a ligase that is 
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essential for canonical non-homologous end-joining repair of double stranded breaks, 
specifically related to radiation induced DNA damage (Ferguson & Alt, 2001). This enzyme 
was shown to suppress the occurrence of translocations in mammalian cells exposed to 
radiation (Simsek & Jasin, 2010). Deletion of this gene may also contribute to genetic 
instability in OSCC.  
The combination of deletions affecting these genes involved in repair and maintaining 
genomic stability may contribute to the high number of rearrangements and genomic 
instability seen in OSCC. Specifically, they may contribute to the deletion or amplification of 
tumour suppressor genes/oncogenes residing in areas of chromosome instability like the 
FHIT, BCL6, C-MYC and PACRG genes residing in the FRA3B, FRA3C, FRA8C and FRA6E fragile 
sites respectively.  
Potential markers for prognosis, diagnosis and treatment 
Comments on prognostic markers cannot be made in this study due to the lack of clinical 
data but genes with reported involvement in disease progression and metastasis in cancer 
are worth mentioning. C-MYC gene expression is associated with a poor prognosis, 
correlating with depth of invasion and short survival and could therefore be used as a 
marker for prognosis (Wei Wang et al., 2010). Although this gene was not highly amplified in 
the cohort, high expression was detected in the cell lines and the expression of C-MYC 
should be investigated further in OSCC samples.  
Five genes potentially affected here could contribute to invasiveness and metastasis. The 
MACROD1 gene (amplified on 11q13.1 in 19.6% of cases) is also known as the leukaemia 
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related protein 16 (LRP16). Over expression of this gene is detected in gastric cancers and is 
associated with lymphoid invasion and metastasis (Y. Z. Li et al., 2009). 
Higher expression of KCNMA1 (amplified on 10q21.3 in 19.6% of cases) is reported in 
metastatic breast cancer and siRNA knockdown of KCNMA1 resulted in reduced invasion 
(Khaitan et al., 2009).  
The PSCA gene (amplified on 8q24.3 in 70.6% of cases) is over expressed in prostate cancer 
and is associated with metastasis (Ananias et al., 2009; Raff et al., 2009). The PSCA gene is 
also over expressed in pancreatic cancer and can be detected in blood of these patients; it 
could therefore be used as a marker for detection (Grubbs et al., 2006).  
Genes involved in drug metabolism or resistance were CYP2W1 (amplified on 7p in 41.2% of 
cases), LZTS1 (deleted on 8p12-p21.2 in 19.6% of cases) and KLF2 on 19p13.43 (amplified in 
66.7% of cases). The CYP2W1gene encodes a cytochrome p450 enzyme that is expressed in 
colon and adrenal cancers and could be a potential drug target (Karlgren et al., 2006).The 
LZTS1 gene loss is shown to predict treatment response to taxane-based therapy in ovarian 
carcinoma (D. Califano et al., 2010), it is also highlighted as a candidate tumour suppressor 
in oesophageal squamous carcinoma (Chattopadhyay et al., 2010). 
Some of these genes have not been described in OSCC before and may be worth 
investigating in a study of OSCC samples from different stages of disease where accurate 
clinical data is available. 
4.4.7 Summary 
In summary, this chapter has established the genomic copy number map in OSCC from 
patients in the Eastern Cape and has highlighted genes potentially contributing to the 
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uncontrolled cell growth and genomic instability which is characteristic of OSCC. The 
detection of EPHA3 deletions possibly implicates a new signalling network (Eph/Ephrin) that 
may contribute to OSCC development. DNA repair pathways were highlighted by the 
potential disruption of the homologous recombination (loss of RAD18) and non homologous 
end joining repair (loss of XRCC4) pathways, which would fit with the high level of genomic 
instability observed in OSCC. There were key pathways highlighted by the abnormalities 
detected in this study. These included the Wnt signalling (FHIT, SFRP2, CCND1, C-MYC), the 
FGF signalling (FGF3, FGF4, FGF19) and TGF-β signalling (SMAD4, SMAD6, FBXW7) pathways, 
which may contribute to uncontrolled cell growth. There is cross talk between these 
pathways, which may additively contribute to OSCC carcinogenesis. Future studies will be 
aimed at investigating the most commonly rearranged genes/ pathways in depth. These 
results opened new avenues for the investigation of OSCC in SA, and are likely to be 
valuable in developing an understanding of OSCC carcinogenesis in the future. 
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CHAPTER 5 
 
 
 
 
 
 
 
 
 
Final conclusions and future directions 
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5.1 Conclusions 
This study is the first in South Africa to look at whole genome copy number aberrations in 
OSCC using microarray technology and the first comprehensive molecular cytogenetic 
analysis of South African OSCC cell lines. Twenty nine key candidate genes have been 
highlighted by this study. The KLF2, A1BG, SHANK2, CCND1, FGF3, FGF4, FGF19, CTTN, C-
MYC, MACROD1, KCNMA1, PSCA, CYP2W1, BCL6, TNK2 and SMAD6 genes were in regions of 
amplification. The SMAD4, FBXW7, FHIT, EPHA3, SFRP2, LZTS1, WRN, ATM, APC, RAD18, 
XRCC4 and PACRG genes are potential tumour suppressor genes that were affected by 
deletions in this study.  
The EPHA3 gene is a novel gene described in OSCC. This gene locus was deleted, in a large 
proportion of samples and cell lines and EPHA3 gene expression appears to be lost in cell 
lines with deletions. A hypothesis is proposed that the Eph/ephrin protein network, ephrin 
receptors and their ligands, are at play in the aggressive and invasive nature of OSCC. 
Deletion of the EPHA3 gene may contribute to cell detachment and invasiveness. This 
hypothesis needs to be tested by analysing the expression of Ephrin receptors and their 
ligands in fresh OSCC samples. Ideally, a cell line model in normal oesophageal epithelium 
and oesophageal carcinoma cell lines would facilitate functional studies of the interplay of 
these molecules in oesophageal epithelium and whether they function in OCC 
carcinogenesis. In addition, EPHA3 mutations have been detected in various tumours (Wood 
et al. 2006) and in view of this, investigation of the prescence of EPHA3 mutations should be 
done on these patients and the five OSCC cell lines. 
The genes identified in copy number aberrations in the tumour samples appear to be 
involved in four main signalling pathways, the Wnt, TGF-β, Hedgehog and Fibroblast growth 
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factor pathways. These pathways are all interconnected and the combined deregulation of 
molecules in these pathways is likely to contribute to the aggressive nature of OSCC. The 
CCND1, CTTN, FGF3, FGF4, FGF19, C-MYC, FHIT, SPRP2, EPHA3, SMAD4 and DCC genes were 
affected in the 5 cell lines, which would suggest that these aberrations have been carried 
through numerous passages and would indicate that they are essential gene aberrations 
required for maintaining  permanent cell survival. The fact that aberrations affecting these 
genes were detected in the cohort supports their potential importance. Expression studies 
in the cell lines confirmed that gene amplification of the CCND1, c-MYC and FGF19 genes 
correlated with over expression of these genes making them likely targets of amplification. 
In addition, the CCND1 and C-MYC genes were over expressed in cell lines showing 
polyploidy. Other mechanisms in addition to amplification may also contribute to over 
expression of these genes. For example, the loss of the FBXW7 gene, which targets the C-
MYC protein for degradation, could contribute to the accumulation of C-MYC protein. Loss 
of FHIT protein contributes to the deregulation of the Wnt pathway, which results in 
transcription of CCND1 and C-MYC. Fhit also regulates the cyclophilin A protein which 
promotes Cyclin D1 synthesis. In light of this, cases where amplification of CCND1 and C-
MYC were not observed may still have over expression of these genes. 
The genomic instability of this cancer was recognised in the complexity of genetic 
aberrations as seen in this study. This could be explained by deletions of genes that are 
important for normal functioning of DNA repair and control of genomic stability such as the 
WRN, ATM, RAD18 and XRCC4 genes. The genes FHIT, BCL6, C-MYC and PACRG all reside at 
fragile sites. Fragile sites are prone to deletion and rearrangement, especially in DNA repair 
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deficient cells, and are sensitive to environmental carcinogen exposure, the main risk factor 
associated with OSCC.  
 
5.2 Future directions 
The genes that are of specific importance going forward are the EPHA3, CCND1, CTTN, FGF3, 
FGF4, FGF19, C-MYC, FHIT, SFRP2, SMAD4, APC, DCC, WRN, ATM, PACRG, RAD18 and XRCC4 
genes. It is envisaged that an expression study of these genes in a cohort of at least 50 fresh 
OSCC samples will be done to confirm the association between amplification/deletion and 
deregulated expression. A second objective would be to isolate the functional roles of 
deregulated candidates in normal and cancerous oesophageal cell line models, either by 
knock down of over expressed genes or re-introduction of deleted genes. A full scale study 
of this kind for the Ephrin receptor/ligand network is of particular interest as it has not been 
studied in OSCC. Studies of this nature could contribute to establishing how these genes 
contribute to OSCC carcinogenesis and assist in identifying targets for therapy.  
Markers for early detection of OSCC have not yet been isolated and implemented. The 
difficulty in obtaining early disease specimens for research is owing to the late presentation 
of patients to clinics and hospitals. If early and late stage disease specimens could be 
obtained, some of the aberrations detected in this study could be analysed for their stage of 
involvement. In particular, it would be hypothesized that genes involved in DNA repair 
would be deregulated first, so loss of WRN, ATM, XRCC4 and RAD18 would be expected to 
be lost early in disease pathogenesis. Loss of DNA repair and genome stability functions 
would facilitate deletion of genes in genetically instable regions early on and then 
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amplification of chromosomal regions targeting genes that facilitate cell proliferation such 
as the CCND1, FGF3, FGF4, FGF19, CTTN and C-MYC genes may occur. A suggested method 
to study early events would be to analyse tissue blocks by immunohistochemistry to 
determine the expression patterns of the above mentioned candidate genes in samples with 
various stages of disease that can be identified by a pathologist. This may help identify those 
genes that are deregulated early in the development of the disease and which of them could 
be used as markers for early screening. Overall, this study has contributed to the literature 
on DNA copy number aberrations in OSCC and has generated some hypotheses and 
strategies for investigation of OSCC pathogenesis going forward.   
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Cell culture and banding buffers 
 
0,075M KCl 
2,8g KCl (Merck) 
500ml distilled water 
Incubate at 37°C 
 
Fixative 
 
3 parts methanol (Merck) 
1 part glacial acetic acid (Merck) 
Keep ice-cold  
 
Stock Trypsin 
2.5g Trypsin (Difco) 
200ml distilled water 
 
Working Trypsin solution 
2ml of Stock trypsin in 48ml 0.9% Saline 
 
Wright’s stain 
0.2% Wright’s (Sigma®) stain in 100% methanol 
Filtered through Whatman no 1 filter paper.  
 
Stock Gurr buffer 
Dissolve one Gurr buffer ampoule of pH 6.8 (Gibco) in 100ml Deionised water 
 
Working solution- Gurr 
Make up a 5% solution 
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DNA extraction buffers 
10X PBS 
80g NaCl 
2g KCl 
14,4g Na2PO4 
2,4g KH2PO4 
800ml distilled water 
pH to 7,4 with HCl 
Adjust to 1litre 
 
1X PBS 
20ml 10X PBS 
180ml distilled water 
 
0.4X SSC/0.3% tween 
1ml 20X SSC pH 7 
47,5ml distilled water 
150μl Tween® 20 (Merck Laboratory Supplies) 
 
Lysis buffer 
 
50mM Tris HCl 
1mM EDTA 
0.5% tween® 20 
 
2% Agarose gel 
 
2g multi-purpose agarose (Bioline) 
100ml 1x TAE buffer 
10μl Gel Red™ (Biotium, CA) 
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Heat until clear 
Pours 3 gels 
 
1x TAE buffer 
 
40mM Tris-acetate (pH 7.6) (Merck) 
1mM Na₂EDTA (Merck) 
 
BAC culture 
LB top agar – per litre 
 
10g Bacto® tryptone (DIFCO) 
5g Bacto® yeast extract (DIFCO) 
5g AAR® NaCl (SMM Instruments) 
Autoclave 
 
Frozen Stock cultures 
 
Glycerol solution 
 
65% Glycerol (vol/vol) (Merck® Laboratory Supplies) 
0.1M MgSO₄ (Merck® Laboratory Supplies) 
0.025M Tris.Cl, pH 8 (Merck® Laboratory Supplies) 
 
Glycerol Stock 
850ul of BAC culture 
150ul Glycerol solution 
Immediately freeze at -70°C 
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Probe labelling 
10X Nick translation buffer  
0,5M Tris-HCl pH8.0 (Merck® Laboratory Supplies) 
50mM MgCl₂ (Merck® Laboratory Supplies) 
0,5mg/ml Bovine Serum Albumin (Boerhinger Mannheim) 
 
0,1M β-mercaptoethanol 
0.1ml β-mercaptoethanol (BDH) 
14,4ml double-distilled water 
 
10x nucleotide stock - SpectrumOrange 
0.5mM dATP (Promega) 
0.5mM dGTP (Promega) 
0.5mM dCTP (Promega) 
0.25mM dTTP (Promega) 
0.25mM SpectrumOrange d-UTP (Abbott Laboratories) 
 
10x nucleotide stock – SpectrumGreen 
0.5mM dATP (Promega) 
0.5mM dGTP (Promega)  
0.5mM dCTP (Promega) 
0.25mM dTTP (Promega) 
0.25mM SpectrumGreen d-UTP (Abbott Laboratories) 
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DNase I solution 
3mg DNase I (Roche) 
0.5ml of 0.3M NaCl 
0.5ml glycerol 
Store at -20˚C 
 
Hybridisation buffer 
50% deionised formamide (Appendix C) (Saarchem) 
2x SSC 
10% dextran sulphate (Sigma®) 
50mM sodium dihydrogen orthophosphate (Saarchem) 
pH to 7,0 with disodium hydrogen orthophosphate (Saarchem) 
Store at -20˚C 
 
FISH solutions 
 
Denaturing buffer 
35ml deionised formamide (Saarchem) 
5ml phosphate buffer 
5ml 20x SSC 
5ml distilled water 
pH to 7 with concentrated HCl 
 
Deionised formamide 
1 spatula full Analytical grade mixed bed resin AG 50-X8 (BioRad®) for every 100ml 
formamide (Biorad) 
Place on stirrer for 2 hrs 
Filter with Whatman® No1 filter paper 
Store at 4ºC 
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Phosphate buffer 
Solution A: KH₂PO₄ (Saarchem) – 4,5g per 500ml, pH to 4,51 
Solution B: Na₂HPO₄, 2H₂O (Saarchem) – 5,94g per 500ml, pH to 8,97 
For 100ml add 41,3ml solution A and 58,7ml solution B 
PH to 7.0 
Autoclave 
  
 
50% formamide 
20ml 20x SSC 
80ml distilled water 
100 ml formamide 
pH to 7 with HCl 
 
20x SSC 
3M NaCl (SMM Chemicals) 
0.3M sodium citrate (SMM Chemicals) 
Adjust to pH 7.0 with concentrated HCl 
Autoclave and store at room temperature 
 
2X SSC with tween 
 
2X SSC 
0.05% Tween® 20 (Merck) 
 
DAPI (4’, 6-diamino-2-phenylindole) stock solution 
 
0,2mg/ml DAPI (Merck) 
2x SSC 
 227 | P a g e  
 
 
DAPI working solution 
 
100 ml 2x SSC 
100μl DAPI (0.2μg/ml) 
 
DAPI wash solution 
 
2x SSC: 5ml 20x SSC in 50ml 
25μl Tween® 20 (Merck Laboratory Supplies) in 50ml 
 
1N HCl 
31ml of 37% HCl (Merck Laboratory Supplies) 
Distilled water up to 1000ml 
 
1% Formaldehyde 
13.5ml of 37% formaldehyde (Merck Laboratory Supplies) 
450ml distilled water 
Ph to 7.0 with NaOH 
Make up to 500ml, autocalve 
Store at 4°C 
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RQ-PCR optimisation and experiment set up 
Selection and assessment of stability of reference genes for RQ-PCR analysis. 
Internal control genes or reference genes are required for accurate normalisation of 
expression data. The mRNA for these genes should not be variable in levels of expression 
between cancerous and normal tissues nor under experimental conditions, i.e. stably 
expressed or constantly expressed (Vandesompele et al., 2002). The number of reference 
genes used for normalisation depends on the number of target genes being assessed, the 
more target genes, the more reference genes are required. A minimum of three genes is 
recommended where possible (Vandesompele et al., 2002). The stability of reference genes 
also needs to be assessed experimentally and so reference genes for this study were 
selected based on the article by Rubie et al, 2005. This paper describes work done to 
establish a list of reference genes that are stably expressed in various cancerous and 
corresponding normal tissues, particularly OSCC. Based on their experimental results, three 
genes were chosen, a highly expressed gene (ACTB), a median expressed gene (YWHAZ) and 
a low expressed gene (PGK1). These genes appeared to be stably expressed between normal 
oesophagus and cancerous tissue (Rubie et al., 2005).   
The stability of the reference genes was also examined in-house by performing an RQ-PCR 
experiment using 5 normal oesophageal tissue samples and 2 normal blood samples with 3 
replicates each. The run data was imported into Qbase PLUS (Hellemans et al., 2007) and 
the GNorm methodology was used to establish the reference gene stability (Vandesompele 
et al., 2002). The reference gene stability was established by comparing the expression 
ratios of two genes at a time (pairwise variation), the increasing variation in this ratio means 
that there is decreased stability of expression for one of the genes, this stability value is 
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delineated M. The lower the M value the more stable the expression of that gene 
(Vandesompele et al., 2002). The recommendation is that the M values and CV values 
(coefficient of variation) calculated in Qbase PLUS (Hellemans et al., 2007) are below 0.5 and 
25% respectively and the closer the M value is to 0.1 the better the stability (Vandesompele 
et al., 2002). 
Results of the reference gene stability test 
The reference genes should be stably expressed across all samples being analysed in an 
experiment so that accurate normalisation factors can be calculated for correction of the 
relative quantities of each gene being investigated in each sample. It has been established 
that a minimum of 3 reference genes is required for accurate normalisation and no specific 
gene is stable in all tissues (Vandesompele et al., 2002). The three genes chosen for this 
study were selected based on the study by Rubie et al (2005), which looked at reference 
gene stability in normal and cancerous oesophageal tissue. The three most stable genes 
were ACTB, PGK1 and YWHAZ. Seven different samples, 5 from presumed normal 
oesophagus and 2 peripheral blood samples from healthy volunteers were used to establish 
the stability of expression of the 3 chosen reference genes, ACTB, PGK1 and YWHAZ. The 
three genes were also run in all the experiments to verify their stability in the cell lines and 
samples. To establish the stability of reference genes, the co efficient of variability (CV) and 
stability values (M) were calculated in Qbase PLUS. The results can be seen in table B1. The 
M values should be as close as possible to 0.1 with an acceptable value less than 0.5 
(Vandesompele et al., 2002). The reference genes had relatively low expression stability; the 
gene that had the most stable expression was the YWHAZ gene (figure B1). The 
normalisation factors for each sample decreased when all 3 reference genes were used for 
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calculation of the normalisation factors. When YWHAZ was used alone, a higher 
normalisation factor was calculated per sample. Although one gene is not ideal, the 
recommendation in GNorm was to use the gene with the lowest M value due to the 
instability of the remaining two genes. Therefore the YWHAZ gene was used to normalise 
the RQ-PCR data for the experiments.  
Table B1. Reference gene stability 
evaluation based on M and CV values 
Reference 
gene 
M value CV 
ACTB 0.584 0.252 
PGK1 0.64 0.327 
YWHAZ 0.488 0.153 
Average 0.571 0.224 
   
 
 
Figure B1. Graphic represenstation of the M-values calculated for each 
reference gene in Qbase PLUS. YWHAZ had the lowest M value  (0.488) 
and was therfore the most stably expressed gene in this experiment. 
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Melt curve and gel analysis of PCR products 
Melt curves were established and compared to the resolved bands by gel electrophoresis to 
insure the correct products with only one melt peak were amplified (figures B2 B3 and B4). 
 
Figure B2. Dissociation curves and 2% gel electrophoresis showing the correct size 
products detected for the reference genes, ACTB, PGK1 and YWHAZ in replicates of a 
blood control sample. The dissociation curve for ACTB (A) showed a melting temperature of 
approximately 84°C, corresponding to the expected product size of approximately 87bp (red 
arrow) (D). The dissociation curve for PGK1 showed an approximate melting temperature of 
76°C (B) corresponding to an expected product size of 95bp (green arrow) (D). The melt 
curve analysis for YWHAZ showed a melting temperature of approximately 76°C (C), 
corresponding to a product size of 94bp (blue arrow) (D). 
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Figure B3. Dissociation curves and 2% gel electrophoresis showing the correct size 
products detected for the target genes, CCND1, c-MYC and EPHA3 in replicates of the 
positive control cell line, MCF7. The CCND1 amplicon showed an approximate melting peak 
at 84°C (A) corresponding to a 124bp product (red arrow) (D). C-MYC melts at approximately 
85°C, which corresponded to a product size of 147bp (green arrow) (D). EPHA3 shows very 
low amplification (D) with a product size of 112bp (blue arrow) and the melting temperature 
was approximately 80°C (C).  
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Figure B4. Dissociation curves and 2% gel electrophoresis showing the correct size 
products detected for the target genes FGF3, FGF4 and FGF19 in replicates of the MCF7 
cell line positive control. The FGF3 amplicon shows an approximate melting peak at 75.5°C 
(A) corresponding to 64bp product (red arrow) (D). FGF4 melts at approximately 80°C, which 
corresponded to a product size of 83bp (green arrow) (D). FGF19 showed a product size of 
67bp (blue arrow) and the melting temperature was approximately 80°C (C).  
 
RQ-PCR experiment set up 
The following tables represent the plate set up for the RQ-PCR experiments in plates 1-9. 
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Plate 1 1 2 3 4 5 6 7 8 9 10 11 12 
A:ACTB WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
B:ACTB WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
C:ACTB WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
D:PKG1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
E:PGK1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
F:PGK1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
G:             
H:             
Plate 2 1 2 3 4 5 6 7 8 9 10 11 12 
A:ACTB WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
B:ACTB WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
C:ACTB WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
D:PKG1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
E:PGK1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
F:PGK1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
G:             
H:             
Plate 3 1 2 3 4 5 6 7 8 9 10 11 12 
A:YWHAZ WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
B:YWHAZ WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
C:YWHAZ WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
D:EPHA3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
E:EPHA3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
F:EPHA3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
G:             
H:             
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Plate 5 1 2 3 4 5 6 7 8 9 10 11 12 
A: CCND1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
B:CCND1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
C:CCND1 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
D:MYC WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
D:MYC WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA3 WITSCA10 WITSCA10N  
D:MYC WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA4 WITSCA11 WITSCA10N  
 
Plate 6 1 2 3 4 5 6 7 8 9 10 11 12 
A: CCND1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
B:CCND1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
C:CCND1 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
D:MYC WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
D:MYC WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
D:MYC WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
G:             
H:             
 
 
 
Plate 4 1 2 3 4 5 6 7 8 9 10 11 12 
A:YWHAZ WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
B:YWHAZ WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
C:YWHAZ WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
D:EPHA3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
E:EPHA3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
F:EPHA3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
G:             
H:             
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Plate 7 1 2 3 4 5 6 7 8 9 10 11 12 
A:FGF3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
B:FGF3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
C:FGF3 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N NTC 
D:FGF4 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA2 WITSCA9 WITSCA10N  
E:FGF4 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA3 WITSCA10 WITSCA10N  
F:FGF4 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 OC7BT OC8BT WITSCA4 WITSCA11 WITSCA10N  
G:             
H:             
 
Plate 8 1 2 3 4 5 6 7 8 9 10 11 12 
A:FGF3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
B:FGF3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
C:FGF3 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N    NTC 
D:FGF4 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
E:FGF4 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
F:FGF4 WHCO1_A WHCO3_A WHCO5_A WITS35N WITS36N WITS37N WITS39N WITS40N     
G:             
H:             
 
Plate 9 1 2 3 4 5 6 7 8 9 10 11 12 
A:FGF19 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 WITSCA10N WITS35N    NTC 
B:FGF19 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 WITSCA10N WITS35N     
C:FGF19 WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 WITSCA10N WITS35N     
D:             
E:             
F:             
G:             
H:            
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Well Sample 
Name 
Detector Ct StdDev 
Ct 
Tm  Well Sample 
Name 
Detector Tm 
A6 MCF7 ACTB 15.19 0.028 84.4  A1 WHCO1_A ACTB 83.6 
B6 MCF7 ACTB 15.18 0.028 84.4  B1 WHCO1_A ACTB 83.6 
C6 MCF7 ACTB 15.23 0.028 84.7  C1 WHCO1_A ACTB 84.3 
A7 OC7BT ACTB 16.02 0.032 84.4  A2 WHCO3_A ACTB 83.9 
B7 OC7BT ACTB 15.96 0.032 84.7  B2 WHCO3_A ACTB 83.9 
C7 OC7BT ACTB 15.97 0.032 84.7  C2 WHCO3_A ACTB 84.3 
A8 OC8BT ACTB 16.7 0.068 84.4  A3 WHCO5_A ACTB 83.9 
B8 OC8BT ACTB 16.57 0.068 84.4  B3 WHCO5_A ACTB 84.3 
C8 OC8BT ACTB 16.67 0.068 84.7  C3 WHCO5_A ACTB 84.3 
A5 SNO ACTB 15.19 0.057 84.4  A4 WITS35N ACTB 84.3 
B5 SNO ACTB 15.1 0.057 84.4  B4 WITS35N ACTB 84.3 
C5 SNO ACTB 15.09 0.057 84.7  C4 WITS35N ACTB 84.7 
A1 WHCO1 ACTB 15.57 0.096 83.6  A5 WITS36N ACTB 83.9 
B1 WHCO1 ACTB 15.4 0.096 84  B5 WITS36N ACTB 84.3 
C1 WHCO1 ACTB 15.41 0.096 84.4  C5 WITS36N ACTB 84.7 
A2 WHCO3 ACTB 15.53 0.047 84  A6 WITS37N ACTB 84.3 
B2 WHCO3 ACTB 15.56 0.047 84  B6 WITS37N ACTB 84.3 
C2 WHCO3 ACTB 15.47 0.047 84.4  C6 WITS37N ACTB 84.7 
A3 WHCO5 ACTB 15.03 0.055 84  A7 WITS39N ACTB 84.3 
B3 WHCO5 ACTB 14.96 0.055 84  B7 WITS39N ACTB 84.7 
C3 WHCO5 ACTB 14.92 0.055 84.4  C7 WITS39N ACTB 84.7 
A4 WHCO6 ACTB 15.4 0.043 84  A8 WITS40N ACTB 84.3 
B4 WHCO6 ACTB 15.32 0.043 84.4  B8 WITS40N ACTB 84.3 
C4 WHCO6 ACTB 15.4 0.043 84.4  C8 WITS40N ACTB 84.7 
A11 WITSCA10N ACTB 15.14 0.067 84  A11  ACTB  
B11 WITSCA10N ACTB 15.23 0.067 84  D1 WHCO1_A PGK1 76.7 
C11 WITSCA10N ACTB 15.27 0.067 84  E1 WHCO1_A PGK1 76.7 
Table B2 Raw data from RQ-PCR 
experiments. 
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A9 WITSCA2 ACTB 15.38 0.025 84  F1 WHCO1_A PGK1 76.3 
B9 WITSCA2 ACTB 15.35 0.025 84.4  D2 WHCO3_A PGK1 76.7 
C9 WITSCA2 ACTB 15.39 0.025 84.7  E2 WHCO3_A PGK1 76.7 
A10 WITSCA9 ACTB 15.49 0.037 84  F2 WHCO3_A PGK1 76.7 
B10 WITSCA9 ACTB 15.42 0.037 84.4  D3 WHCO5_A PGK1 76.7 
C10 WITSCA9 ACTB 15.46 0.037 84.4  E3 WHCO5_A PGK1 76.7 
A12  ACTB 21.59  82.2  F3 WHCO5_A PGK1 76.7 
D6 MCF7 PGK1 20.74 0.211 76.7  D4 WITS35N PGK1 76.7 
E6 MCF7 PGK1 20.97 0.211 76.7  E4 WITS35N PGK1 77 
F6 MCF7 PGK1 20.55 0.211 76.7  F4 WITS35N PGK1 76.7 
D7 OC7BT PGK1 21.65 0.669 77.1  D5 WITS36N PGK1 77 
E7 OC7BT PGK1 20.43 0.669 77.4  E5 WITS36N PGK1 77 
F7 OC7BT PGK1 21.51 0.669 76.7  F5 WITS36N PGK1 76.7 
D8 OC8BT PGK1 22.3 0.135 76.7  D6 WITS37N PGK1 77 
E8 OC8BT PGK1 22.04 0.135 76.7  E6 WITS37N PGK1 77 
F8 OC8BT PGK1 22.13 0.135 76.7  F6 WITS37N PGK1 77 
D5 SNO PGK1 19.89 0.307 77.1  D7 WITS39N PGK1 77 
E5 SNO PGK1 20.03 0.307 76.7  E7 WITS39N PGK1 77 
F5 SNO PGK1 19.44 0.307 76.7  F7 WITS39N PGK1 77 
D1 WHCO1 PGK1 20.08 0.115 76.7  D8 WITS40N PGK1 77 
E1 WHCO1 PGK1 20.28 0.115 76.7  E8 WITS40N PGK1 76.7 
F1 WHCO1 PGK1 20.28 0.115 76.4  F8 WITS40N PGK1 76.7 
D2 WHCO3 PGK1 20.65 0.18 76.7  C11  PGK1  
E2 WHCO3 PGK1 20.33 0.18 76.7      
F2 WHCO3 PGK1 20.63 0.18 76.7      
D3 WHCO5 PGK1 18.82 0.255 76.7      
E3 WHCO5 PGK1 19.02 0.255 76.7      
F3 WHCO5 PGK1 18.52 0.255 76.7      
D4 WHCO6 PGK1 19.82 0.093 76.7      
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E4 WHCO6 PGK1 Unknown 19.71 0.093 76.7       
F4 WHCO6 PGK1 Unknown 19.63 0.093 76.7       
D11 WITSCA10N PGK1 Unknown 21.17 0.109 76.7       
E11 WITSCA10N PGK1 Unknown 21.32 0.109 76.4       
F11 WITSCA10N PGK1 Unknown Undetermined 70.2       
D9 WITSCA2 PGK1 Unknown 20.39 0.174 76.7       
E9 WITSCA2 PGK1 Unknown 20.21 0.174 76.7       
F9 WITSCA2 PGK1 Unknown 20.56 0.174 76.7       
D10 WITSCA9 PGK1 Unknown 19.56 0.144 76.7       
E10 WITSCA9 PGK1 Unknown 19.82 0.144 76.7       
F10 WITSCA9 PGK1 Unknown 19.8 0.144 76.7       
D12  PGK1 NTC Undetermined        
Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm  Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm 
D6 MCF7 EPHA3 Unknown 33.92 0.505 80.8  D1 WHCO1_A EPHA3 Unknown 30.8 0.225 80.7 
E6 MCF7 EPHA3 Unknown 32.99 0.505 80.8  E1 WHCO1_A EPHA3 Unknown 30.66 0.225 80.7 
F6 MCF7 EPHA3 Unknown 33.1 0.505 80.8  F1 WHCO1_A EPHA3 Unknown 31.1 0.225 80.7 
D7 OC7BT EPHA3 Unknown 35.39 0.699 80.8  D2 WHCO3_A EPHA3 Unknown 34.92 0.258 80.7 
E7 OC7BT EPHA3 Unknown 34 0.699 80.8  E2 WHCO3_A EPHA3 Unknown 34.64 0.258 80.7 
F7 OC7BT EPHA3 Unknown 34.57 0.699 80.8  F2 WHCO3_A EPHA3 Unknown 35.16 0.258 80.7 
D8 OC8BT EPHA3 Unknown 32.67 0.317 80.8  D3 WHCO5_A EPHA3 Unknown 39.98 0.475 69.5 
E8 OC8BT EPHA3 Unknown 32.28 0.317 80.8  E3 WHCO5_A EPHA3 Unknown 39.03 0.475 69.5 
F8 OC8BT EPHA3 Unknown 32.91 0.317 80.4  F3 WHCO5_A EPHA3 Unknown 39.58 0.475 69.5 
D5 SNO EPHA3 Unknown 36.33 0.392 80.8  D4 WITS35N EPHA3 Unknown 31.86 0.132 81 
E5 SNO EPHA3 Unknown 35.74 0.392 80.8  E4 WITS35N EPHA3 Unknown 31.6 0.132 81 
F5 SNO EPHA3 Unknown 36.48 0.392 80.8  F4 WITS35N EPHA3 Unknown 31.69 0.132 81 
D1 WHCO1 EPHA3 Unknown 31.24 1.703 80.4  D5 WITS36N EPHA3 Unknown 34.13 0.63 80.7 
E1 WHCO1 EPHA3 Unknown 32.01 1.703 80.4  E5 WITS36N EPHA3 Unknown 35.26 0.63 81 
F1 WHCO1 EPHA3 Unknown 34.5 1.703 80  F5 WITS36N EPHA3 Unknown 35.17 0.63 81 
D2 WHCO3 EPHA3 Unknown 35.52 0.027 80.4  D6 WITS37N EPHA3 Unknown 32.95 0.561 81 
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E2 WHCO3 EPHA3 Unknown 35.47 0.027 80.4  E6 WITS37N EPHA3 Unknown 32.29 0.561 81 
F2 WHCO3 EPHA3 Unknown 35.52 0.027 80.4  F6 WITS37N EPHA3 Unknown 33.41 0.561 81 
D3 WHCO5 EPHA3 Unknown Undetermined 66  D7 WITS39N EPHA3 Unknown 32.18 0.136 81 
E3 WHCO5 EPHA3 Unknown Undetermined 69.2  E7 WITS39N EPHA3 Unknown 31.94 0.136 81 
F3 WHCO5 EPHA3 Unknown Undetermined 80  F7 WITS39N EPHA3 Unknown 31.94 0.136 81 
D4 WHCO6 EPHA3 Unknown 34.57 0.139 80.4  D8 WITS40N EPHA3 Unknown 33.36 0.076 81 
E4 WHCO6 EPHA3 Unknown 34.45 0.139 80.4  E8 WITS40N EPHA3 Unknown 33.23 0.076 81 
F4 WHCO6 EPHA3 Unknown 34.29 0.139 80  F8 WITS40N EPHA3 Unknown 33.22 0.076 80.7 
D11 WITSCA10N EPHA3 Unknown 38.68 0.901 80.8  C12  EPHA3 NTC Undetermined  
E11 WITSCA10N EPHA3 Unknown 39.95 0.901 80.4  A1 WHCO1_A YWHAZ Unknown 16.24 0.117 76.7 
F11 WITSCA10N EPHA3 Unknown Undetermined 68.9  B1 WHCO1_A YWHAZ Unknown 16.03 0.117 77.1 
D9 WITSCA2 EPHA3 Unknown 34.08 0.413 80.8  C1 WHCO1_A YWHAZ Unknown 16.04 0.117 77.1 
E9 WITSCA2 EPHA3 Unknown 33.35 0.413 80.8  A2 WHCO3_A YWHAZ Unknown 16.03 0.051 77.1 
F9 WITSCA2 EPHA3 Unknown 33.38 0.413 80.8  B2 WHCO3_A YWHAZ Unknown 15.93 0.051 77.1 
D10 WITSCA9 EPHA3 Unknown 33.91 1.15 80.8  C2 WHCO3_A YWHAZ Unknown 15.98 0.051 77.1 
E10 WITSCA9 EPHA3 Unknown 34.25 1.15 80.8  A3 WHCO5_A YWHAZ Unknown 15.22 0.074 76.7 
F10 WITSCA9 EPHA3 Unknown 36.05 1.15 80.4  B3 WHCO5_A YWHAZ Unknown 15.12 0.074 77.1 
D12  EPHA3 NTC Undetermined   C3 WHCO5_A YWHAZ Unknown 15.07 0.074 77.4 
A6 MCF7 YWHAZ Unknown 16.34 0.048 77.2  A4 WITS35N YWHAZ Unknown 15.32 0.053 77.1 
B6 MCF7 YWHAZ Unknown 16.26 0.048 77.5  B4 WITS35N YWHAZ Unknown 15.22 0.053 77.4 
C6 MCF7 YWHAZ Unknown 16.25 0.048 77.5  C4 WITS35N YWHAZ Unknown 15.25 0.053 77.4 
A7 OC7BT YWHAZ Unknown 17.28 0.208 77.2  A5 WITS36N YWHAZ Unknown 16.15 0.103 77.1 
B7 OC7BT YWHAZ Unknown 17.14 0.208 77.2  B5 WITS36N YWHAZ Unknown 15.95 0.103 77.4 
C7 OC7BT YWHAZ Unknown 17.55 0.208 77.5  C5 WITS36N YWHAZ Unknown 16.04 0.103 77.4 
A8 OC8BT YWHAZ Unknown 18.48 0.271 77.2  A6 WITS37N YWHAZ Unknown 15.98 0.073 77.1 
B8 OC8BT YWHAZ Unknown 18.02 0.271 77.5  B6 WITS37N YWHAZ Unknown 15.85 0.073 77.4 
C8 OC8BT YWHAZ Unknown 18.01 0.271 77.5  C6 WITS37N YWHAZ Unknown 15.85 0.073 77.4 
A5 SNO YWHAZ Unknown 16.48 0.163 77.2  A7 WITS39N YWHAZ Unknown 15.52 0.012 77.4 
B5 SNO YWHAZ Unknown 16.19 0.163 77.5  B7 WITS39N YWHAZ Unknown 15.49 0.012 77.4 
 242 | P a g e  
 
C5 SNO YWHAZ Unknown 16.2 0.163 77.5  C7 WITS39N YWHAZ Unknown 15.51 0.012 77.8 
A1 WHCO1 YWHAZ Unknown 16.16 0.069 76.8  A8 WITS40N YWHAZ Unknown 15.85 0.054 77.1 
B1 WHCO1 YWHAZ Unknown 16.07 0.069 76.8  B8 WITS40N YWHAZ Unknown 15.77 0.054 77.4 
C1 WHCO1 YWHAZ Unknown 16.02 0.069 77.2  C8 WITS40N YWHAZ Unknown 15.75 0.054 77.4 
A2 WHCO3 YWHAZ Unknown 16.23 0.131 76.8  A12  YWHAZ NTC Undetermined  
B2 WHCO3 YWHAZ Unknown 15.98 0.131 77.2         
C2 WHCO3 YWHAZ Unknown 16.04 0.131 77.2         
A3 WHCO5 YWHAZ Unknown 15.57 0.218 76.8         
B3 WHCO5 YWHAZ Unknown 15.24 0.218 76.8         
C3 WHCO5 YWHAZ Unknown 15.16 0.218 77.2         
A4 WHCO6 YWHAZ Unknown 16.34 0.156 76.8         
B4 WHCO6 YWHAZ Unknown 16.52 0.156 77.2         
C4 WHCO6 YWHAZ Unknown 16.21 0.156 77.9         
A11 WITSCA10N YWHAZ Unknown 15.99 0.103 76.8         
B11 WITSCA10N YWHAZ Unknown 15.79 0.103 77.2         
C11 WITSCA10N YWHAZ Unknown 15.85 0.103 77.2         
A9 WITSCA2 YWHAZ Unknown 16 0.014 77.2         
B9 WITSCA2 YWHAZ Unknown 16 0.014 77.2         
C9 WITSCA2 YWHAZ Unknown 16.03 0.014 77.5         
A10 WITSCA9 YWHAZ Unknown 16.06 0.062 77.2         
B10 WITSCA9 YWHAZ Unknown 16.01 0.062 77.2         
C10 WITSCA9 YWHAZ Unknown 16.13 0.062 77.2         
A12  YWHAZ NTC Undetermined          
Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm  Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm 
A6 MCF7 CCND1 Unknown 31.71 1.392 83.8  A1 WHCO1_A CCND1 Unknown 34.48 0.07 82.8 
B6 MCF7 CCND1 Unknown 29.17 1.392 84.2  B1 WHCO1_A CCND1 Unknown 34.42 0.07 83.1 
C6 MCF7 CCND1 Unknown 29.45 1.392 84.2  C1 WHCO1_A CCND1 Unknown 34.56 0.07 83.5 
A7 OC7BT CCND1 Unknown 33.49 0.929 83.8  A2 WHCO3_A CCND1 Unknown 32.81 1.415 82.8 
B7 OC7BT CCND1 Unknown Undetermined 67.6  B2 WHCO3_A CCND1 Unknown 30.44 1.415 83.1 
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C7 OC7BT CCND1 Unknown 34.8 0.929 83.8  C2 WHCO3_A CCND1 Unknown 32.98 1.415 83.5 
A8 OC8BT CCND1 Unknown 36.21 1.072 83.5  A3 WHCO5_A CCND1 Unknown 32.59 0.288 83.1 
B8 OC8BT CCND1 Unknown 35.08 1.072 83.8  B3 WHCO5_A CCND1 Unknown 33.1 0.288 83.5 
C8 OC8BT CCND1 Unknown 34.07 1.072 84.2  C3 WHCO5_A CCND1 Unknown 33.07 0.288 83.5 
A5 SNO CCND1 Unknown 31.45 0.329 83.5  A4 WITS35N CCND1 Unknown 35.76 0.264 83.1 
B5 SNO CCND1 Unknown 30.85 0.329 83.8  B4 WITS35N CCND1 Unknown 36.07 0.264 83.9 
C5 SNO CCND1 Unknown 31.38 0.329 83.8  C4 WITS35N CCND1 Unknown 36.28 0.264 83.5 
A1 WHCO1 CCND1 Unknown 34.02 0.696 83.5  A5 WITS36N CCND1 Unknown 34.56 0.923 78.4 
B1 WHCO1 CCND1 Unknown 35.09 0.696 83.5  B5 WITS36N CCND1 Unknown 36.4 0.923 77.7 
C1 WHCO1 CCND1 Unknown 33.79 0.696 83.1  C5 WITS36N CCND1 Unknown 35.59 0.923 83.9 
A2 WHCO3 CCND1 Unknown 33.56 0.032 83.1  A6 WITS37N CCND1 Unknown 34 0.937 83.5 
B2 WHCO3 CCND1 Unknown 33.5 0.032 83.1  B6 WITS37N CCND1 Unknown 35.43 0.937 83.9 
C2 WHCO3 CCND1 Unknown 33.52 0.032 83.5  C6 WITS37N CCND1 Unknown 33.66 0.937 83.9 
A3 WHCO5 CCND1 Unknown 33.11 0.466 83.1  A7 WITS39N CCND1 Unknown 33.46 0.21 83.5 
B3 WHCO5 CCND1 Unknown 32.61 0.466 83.5  B7 WITS39N CCND1 Unknown 33.43 0.21 83.5 
C3 WHCO5 CCND1 Unknown 32.18 0.466 83.5  C7 WITS39N CCND1 Unknown 33.81 0.21 83.9 
A4 WHCO6 CCND1 Unknown 32.82 0.772 83.5  A8 WITS40N CCND1 Unknown 35.25 0.645 83.1 
B4 WHCO6 CCND1 Unknown 32.71 0.772 83.8  B8 WITS40N CCND1 Unknown 34.59 0.645 83.9 
C4 WHCO6 CCND1 Unknown 31.43 0.772 83.8  C8 WITS40N CCND1 Unknown 35.88 0.645 84.2 
A11 WITSCA10N CCND1 Unknown 35.18 0.105 83.5  A12  CCND1 NTC Undetermined  
B11 WITSCA10N CCND1 Unknown 35.06 0.105 83.8  D1 WHCO1_A MYC Unknown 18.05 0.102 84.2 
C11 WITSCA10N CCND1 Unknown 35.27 0.105 84.2  E1 WHCO1_A MYC Unknown 18.08 0.102 84.2 
A9 WITSCA2 CCND1 Unknown 33.49 0.147 83.5  F1 WHCO1_A MYC Unknown 18.24 0.102 84.2 
B9 WITSCA2 CCND1 Unknown 33.2 0.147 83.8  D2 WHCO3_A MYC Unknown 18.04 0.268 84.2 
C9 WITSCA2 CCND1 Unknown 33.35 0.147 83.8  E2 WHCO3_A MYC Unknown 18.54 0.268 84.6 
A10 WITSCA9 CCND1 Unknown 34.19 0.14 83.8  F2 WHCO3_A MYC Unknown 18.11 0.268 84.2 
B10 WITSCA9 CCND1 Unknown 34.29 0.14 83.8  D3 WHCO5_A MYC Unknown 17.13 0.109 84.2 
C10 WITSCA9 CCND1 Unknown 34.01 0.14 83.5  E3 WHCO5_A MYC Unknown 17.23 0.109 84.6 
A12  CCND1 NTC Undetermined   F3 WHCO5_A MYC Unknown 17.35 0.109 84.6 
 244 | P a g e  
 
D6 MCF7 MYC Unknown 19.05 0.116 85  D4 WITS35N MYC Unknown 18.63 0.081 84.6 
E6 MCF7 MYC Unknown 19.21 0.116 85  E4 WITS35N MYC Unknown 18.51 0.081 84.6 
F6 MCF7 MYC Unknown 18.99 0.116 85  F4 WITS35N MYC Unknown 18.48 0.081 84.6 
D7 OC7BT MYC Unknown 21.43 0.162 85  D5 WITS36N MYC Unknown 21.14 0.097 84.6 
E7 OC7BT MYC Unknown 21.22 0.162 84.6  E5 WITS36N MYC Unknown 20.96 0.097 84.6 
F7 OC7BT MYC Unknown 21.11 0.162 85  F5 WITS36N MYC Unknown 20.99 0.097 84.6 
D8 OC8BT MYC Unknown 20.65 0.053 84.6  D6 WITS37N MYC Unknown 20.05 1.101 84.6 
E8 OC8BT MYC Unknown 20.75 0.053 85  E6 WITS37N MYC Unknown 21.79 1.101 84.6 
F8 OC8BT MYC Unknown 20.7 0.053 84.6  F6 WITS37N MYC Unknown 19.75 1.101 84.6 
D5 SNO MYC Unknown 18.7 0.061 85  D7 WITS39N MYC Unknown 18.8 0.588 84.6 
E5 SNO MYC Unknown 18.8 0.061 85  E7 WITS39N MYC Unknown 19.14 0.588 84.9 
F5 SNO MYC Unknown 18.69 0.061 84.6  F7 WITS39N MYC Unknown 19.95 0.588 84.6 
D1 WHCO1 MYC Unknown 18.13 0.087 84.6  D8 WITS40N MYC Unknown 20.87 0.104 84.6 
E1 WHCO1 MYC Unknown 17.98 0.087 84.2  E8 WITS40N MYC Unknown 20.68 0.104 84.6 
F1 WHCO1 MYC Unknown 18.13 0.087 84.2  F8 WITS40N MYC Unknown 20.86 0.104 84.6 
D2 WHCO3 MYC Unknown 17.84 0.088 84.6  C12  MYC NTC Undetermined 79.5 
E2 WHCO3 MYC Unknown 17.86 0.088 84.6         
F2 WHCO3 MYC Unknown 18 0.088 84.2         
D3 WHCO5 MYC Unknown 17.07 0.041 84.6         
E3 WHCO5 MYC Unknown 17.15 0.041 84.6         
F3 WHCO5 MYC Unknown 17.1 0.041 84.6         
D4 WHCO6 MYC Unknown 20.05 0.047 85         
E4 WHCO6 MYC Unknown 19.97 0.047 84.6         
F4 WHCO6 MYC Unknown 19.97 0.047 84.6         
D11 WITSCA10N MYC Unknown 20.01 0.661 84.6         
E11 WITSCA10N MYC Unknown 20.05 0.661 84.6         
F11 WITSCA10N MYC Unknown 21.18 0.661 84.2         
D9 WITSCA2 MYC Unknown 18.57 0.037 84.6         
E9 WITSCA2 MYC Unknown 18.56 0.037 84.6         
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F9 WITSCA2 MYC Unknown 18.63 0.037 84.6         
D10 WITSCA9 MYC Unknown 20.09 0.052 84.6         
E10 WITSCA9 MYC Unknown 20.13 0.052 84.6         
F10 WITSCA9 MYC Unknown 20.2 0.052 84.2         
C12  MYC NTC Undetermined          
 
Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm  Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm 
A6 MCF7 FGF3 Unknown 37.23 1.018 77.5  A1 WHCO1_A FGF3 Unknown 38.96 0.85 77.2 
B6 MCF7 FGF3 Unknown 37.67 1.018 77.5  B1 WHCO1_A FGF3 Unknown 37.75 0.85 73.9 
C6 MCF7 FGF3 Unknown 35.73 1.018 77.9  C1 WHCO1_A FGF3 Unknown Undetermined 68.4 
A7 OC7BT FGF3 Unknown 39.18 2.079 71.4  A2 WHCO3_A FGF3 Unknown 37.49 0.358 71.7 
B7 OC7BT FGF3 Unknown Undetermined 73.2  B2 WHCO3_A FGF3 Unknown 36.9 0.358 77.6 
C7 OC7BT FGF3 Unknown 36.24 2.079 72.5  C2 WHCO3_A FGF3 Unknown 37.55 0.358 77.6 
A8 OC8BT FGF3 Unknown 37.36 0.603 71.7  A3 WHCO5_A FGF3 Unknown 37.78 1.818 77.2 
B8 OC8BT FGF3 Unknown 36.71 0.603 71.7  B3 WHCO5_A FGF3 Unknown 35.65 1.818 77.6 
C8 OC8BT FGF3 Unknown 36.15 0.603 72.1  C3 WHCO5_A FGF3 Unknown 34.16 1.818 75.4 
A5 SNO FGF3 Unknown 34.88 0.36 73.2  A4 WITS35N FGF3 Unknown 37.72 0.455 72.1 
B5 SNO FGF3 Unknown 34.58 0.36 77.5  B4 WITS35N FGF3 Unknown 37.08 0.455 71.7 
C5 SNO FGF3 Unknown 34.17 0.36 77.9  C4 WITS35N FGF3 Unknown Undetermined 68.4 
A1 WHCO1 FGF3 Unknown 37.69 0.87 72.9  A5 WITS36N FGF3 Unknown 36.7 0.878 73.5 
B1 WHCO1 FGF3 Unknown Undetermined 71  B5 WITS36N FGF3 Unknown 34.98 0.878 75.4 
C1 WHCO1 FGF3 Unknown 38.92 0.87 72.1  C5 WITS36N FGF3 Unknown 36.15 0.878 77.9 
A2 WHCO3 FGF3 Unknown 35.68 1.007 71.7  A6 WITS37N FGF3 Unknown 36.41 0.804 73.5 
B2 WHCO3 FGF3 Unknown 36.52 1.007 73.6  B6 WITS37N FGF3 Unknown 37.64 0.804 77.6 
C2 WHCO3 FGF3 Unknown 37.68 1.007 74.3  C6 WITS37N FGF3 Unknown 37.93 0.804 77.9 
A3 WHCO5 FGF3 Unknown 38.85 0.468 77.2  A7 WITS39N FGF3 Unknown 37.54 0.615 72.8 
B3 WHCO5 FGF3 Unknown 37.94 0.468 77.5  B7 WITS39N FGF3 Unknown 36.37 0.615 77.6 
C3 WHCO5 FGF3 Unknown 38.59 0.468 77.5  C7 WITS39N FGF3 Unknown 37.28 0.615 77.9 
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A4 WHCO6 FGF3 Unknown 35.79 0.179 79.8  A8 WITS40N FGF3 Unknown 37.77 1.265 71.7 
B4 WHCO6 FGF3 Unknown 35.57 0.179 73.6  B8 WITS40N FGF3 Unknown Undetermined 87.6 
C4 WHCO6 FGF3 Unknown 35.92 0.179 77.9  C8 WITS40N FGF3 Unknown 35.99 1.265 76.8 
A11 WITSCA10N FGF3 Unknown 36.64 0.729 72.9  A12  FGF3 NTC Undetermined  
B11 WITSCA10N FGF3 Unknown 36.84 0.729 77.2  D1 WHCO1_A FGF4 Unknown 33.54 0.646 72.1 
C11 WITSCA10N FGF3 Unknown 37.99 0.729 77.5  E1 WHCO1_A FGF4 Unknown 34.83 0.646 78.7 
A9 WITSCA2 FGF3 Unknown 36.78 1.006 77.5  F1 WHCO1_A FGF4 Unknown 34.19 0.646 72.1 
B9 WITSCA2 FGF3 Unknown 36.08 1.006 71.4  D2 WHCO3_A FGF4 Unknown 35.07 0.681 78.7 
C9 WITSCA2 FGF3 Unknown 38.06 1.006 77.5  E2 WHCO3_A FGF4 Unknown 34.83 0.681 78.7 
A10 WITSCA9 FGF3 Unknown 28 0.372 77.5  F2 WHCO3_A FGF4 Unknown 33.78 0.681 78.7 
B10 WITSCA9 FGF3 Unknown 27.41 0.372 77.5  D3 WHCO5_A FGF4 Unknown 36.12 1.962 72.1 
C10 WITSCA9 FGF3 Unknown 27.31 0.372 77.9  E3 WHCO5_A FGF4 Unknown 39.32 1.962 70.6 
A12  FGF3 NTC Undetermined   F3 WHCO5_A FGF4 Unknown 35.75 1.962 74.3 
D6 MCF7 FGF4 Unknown 34.45 0.302 79  D4 WITS35N FGF4 Unknown 36.46 2.216 79 
E6 MCF7 FGF4 Unknown 34.81 0.302 79  E4 WITS35N FGF4 Unknown 35.88 2.216 73.9 
F6 MCF7 FGF4 Unknown 35.05 0.302 78.6  F4 WITS35N FGF4 Unknown 39.97 2.216 73.5 
D7 OC7BT FGF4 Unknown 34.94 0.526 73.6  D5 WITS36N FGF4 Unknown 36.19 0.581 72.1 
E7 OC7BT FGF4 Unknown 34.2 0.526 72.5  E5 WITS36N FGF4 Unknown 36.3 0.581 72.1 
F7 OC7BT FGF4 Unknown Undetermined 73.9  F5 WITS36N FGF4 Unknown 35.24 0.581 79.7 
D8 OC8BT FGF4 Unknown 33.41 0.801 72.5  D6 WITS37N FGF4 Unknown 33.87 1.521 73.9 
E8 OC8BT FGF4 Unknown 33.42 0.801 72.9  E6 WITS37N FGF4 Unknown 36.02 1.521 72.5 
F8 OC8BT FGF4 Unknown 34.8 0.801 72.9  F6 WITS37N FGF4 Unknown Undetermined 66.6 
D5 SNO FGF4 Unknown 35 0.077 78.6  D7 WITS39N FGF4 Unknown 34.51 0.645 79 
E5 SNO FGF4 Unknown 35.15 0.077 79  E7 WITS39N FGF4 Unknown 33.26 0.645 79 
F5 SNO FGF4 Unknown 35.03 0.077 78.6  F7 WITS39N FGF4 Unknown 34.18 0.645 75.8 
D1 WHCO1 FGF4 Unknown 32.79  72.1  D8 WITS40N FGF4 Unknown 35.01 1.111 75 
E1 WHCO1 FGF4 Unknown Undetermined 71.4  E8 WITS40N FGF4 Unknown 35.01 1.111 72.1 
F1 WHCO1 FGF4 Unknown Undetermined 68.5  F8 WITS40N FGF4 Unknown 36.93 1.111 74.3 
D2 WHCO3 FGF4 Unknown 34.1 0.736 71.7  C12  FGF4 NTC Undetermined 72.1 
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E2 WHCO3 FGF4 Unknown 33.6 0.736 78.6         
F2 WHCO3 FGF4 Unknown 35.05 0.736 71.7         
D3 WHCO5 FGF4 Unknown 33.42 0.485 78.6         
E3 WHCO5 FGF4 Unknown 34.23 0.485 78.6         
F3 WHCO5 FGF4 Unknown 34.28 0.485 71.7         
D4 WHCO6 FGF4 Unknown 34.13 0.369 78.6         
E4 WHCO6 FGF4 Unknown 34.39 0.369 72.5         
F4 WHCO6 FGF4 Unknown 33.67 0.369 72.1         
D11 WITSCA10N FGF4 Unknown 33.12 0.386 78.6         
E11 WITSCA10N FGF4 Unknown 33.84 0.386 78.6         
F11 WITSCA10N FGF4 Unknown 33.72 0.386 72.1         
D9 WITSCA2 FGF4 Unknown 34.71 0.693 79         
E9 WITSCA2 FGF4 Unknown 34.01 0.693 79         
F9 WITSCA2 FGF4 Unknown 33.32 0.693 79         
D10 WITSCA9 FGF4 Unknown 28.73 0.342 79         
E10 WITSCA9 FGF4 Unknown 28.71 0.342 79         
F10 WITSCA9 FGF4 Unknown 29.31 0.342 79         
D12  FGF4 NTC Undetermined          
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Well Sample 
Name 
Detector Task Ct StdDev 
Ct 
Tm 
A6 MCF7 FGF19 Unknown 34.62 0.451 79.1 
B6 MCF7 FGF19 Unknown 33.78 0.451 79.5 
C6 MCF7 FGF19 Unknown 33.92 0.451 79.5 
A5 SNO FGF19 Unknown 24.13 0.058 79.5 
B5 SNO FGF19 Unknown 24.01 0.058 79.8 
C5 SNO FGF19 Unknown 24.04 0.058 79.8 
A1 WHCO1 FGF19 Unknown 28.21 0.134 79.1 
B1 WHCO1 FGF19 Unknown 27.95 0.134 79.5 
C1 WHCO1 FGF19 Unknown 28.07 0.134 79.5 
A2 WHCO3 FGF19 Unknown 28.9 0.116 79.1 
B2 WHCO3 FGF19 Unknown 29.11 0.116 79.1 
C2 WHCO3 FGF19 Unknown 29.09 0.116 79.5 
A3 WHCO5 FGF19 Unknown 22.25 0.072 79.5 
B3 WHCO5 FGF19 Unknown 22.22 0.072 79.5 
C3 WHCO5 FGF19 Unknown 22.11 0.072 79.8 
A4 WHCO6 FGF19 Unknown 26.98 0.048 79.5 
B4 WHCO6 FGF19 Unknown 27.06 0.048 79.5 
C4 WHCO6 FGF19 Unknown 27.07 0.048 79.8 
A8 WITS35N FGF19 Unknown Undetermined 66.7 
B8 WITS35N FGF19 Unknown Undetermined 66 
C8 WITS35N FGF19 Unknown Undetermined 66 
A7 WITSCA10N FGF19 Unknown 36.75 0.965 79.1 
B7 WITSCA10N FGF19 Unknown Undetermined 67.5 
C7 WITSCA10N FGF19 Unknown 35.38 0.965 79.5 
A9  FGF19 NTC Undetermined  
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APPENDIX C 
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500K Assay 
StyI and NspI restriction digest 
In a final volume of 19.75µl, 1x NE buffer 2/3 (Nsp1 and Sty1 respectively), 1x BSA and 
0.5units of Nsp 1 or Sty 1 (New England Biolabs). 250ng of DNA is added for the reaction. 
The reaction was incubated in an Applied Biosystems 9700 thermal cycler for 2 hours at 
37°C, 65°C for 20 minutes and held at 4°C. 
Sty1 and Nsp1 ligation 
To the restriction digest in a final volume of 25µl, 1.5uM of Sty1 or Nsp1 adaptor 
(Affymetrix®), 1x T4 DNA ligase buffer and 64 units of T4 DNA ligase (New England Biolabs) 
was added. The reaction was incubated at 16°C for 3 hours, 70°C for 20 minutes and held at 
4°C. 
75µl of molecular grade water (Accugene®, Lonza) was added to the ligation reaction prior 
to PCR. 
Sty1 and Nsp 1 PCR 
6 reactions were set up per sample. In a reaction volume of 100µl, 1x Titanium Taq buffer 
(Clontech), 1M G-C Melt (Clontech), 350µM dNTP mix (Clontech), 4.5µM Primer 002 
(Affymetrix), 1x Titanium Taq DNA polymerase (Clontech) was added. 10µl of the ligation 
mix was added to each reaction. The reaction was performed on the ABI 9700 thermal 
cycler with the following, 94°C for 3 minutes, 30 cycles of 94°C for 30 seconds, 60°C for 45 
seconds, 68°C for 15 seconds and final extension for 7 minutes at 68°C.  
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3µl of PCR product was resolved on a 2% agarose (Bioline) gel run at 100V for 1 hour. The 
expected fragments range from 100 to 1100bp. FFPE samples generally amplified to around 
700bp (Figure C1). 
 
 
Figure C1. Example of the Nsp1/Sty1 PCR in FFPE samples. 
The average size amplified was up to 700bp. The red arrow 
indicates the 500bp mark of the 100bp DNA ladder 
(Fermentas O’Gene Ruler).  
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PCR purification 
The PCR products were purified by addition of 8ul of 0.1M EDTA (Ambion). Three PCR 
reactions were mixed together and loaded onto a Clontech DNA amplification clean up 
plate, which was vacuum pumped at 600 bar for approximately 2 hours until the wells were 
dry. The wells were washed three times with 50µl molecular grade water (Accugene®, 
Lonza). The PCR products were then eluted using 45µl of the Clontech RB buffer. The same 
elution was used for the second set of three PCR reactions for the same sample. The 
concentration of the PCR product was assessed by making a 100x dilution and reading on 
the Nanodrop 1000. A total of 90µg in 45µl was used for the remainder of the assay.  
Fragmentation 
In a final volume of 55µl, 1x fragmentation buffer (Affymetrix®), 0.05 units of fragmentation 
reagent (Affymetrix®). The reaction was performed on the Applied Biosystems 9700 
thermal cycler and was incubated at 37°C for 35 minutes, 95°C for 15 minutes and held at 
4°C. The product was immediately assessed for sufficient digestion by resolving 4µl of 
product on a 2% agarose gel at 100V for 40 minutes (Figure C2).  
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Figure C2. Example of the expected results for the 
fragmentation step of the 500K assay. The size should be less 
than 180bp. The red arrow indicates the 200bp mark for the 
100bp ladder. 
 
Labelling  
In a final volume of 74.5µl, added to the fragmented DNA, 1x TDT buffer (Affymetrix®), 
0.857mM labelling reagent (Affymetrix) and 1.5U of TdT (Affymetrix®) was added.  
The reaction was performed on an Applied Biosystems 9700 thermal cycler and was 
incubated at 37°C for 4 hours, 95°C for 15 minutes and held at 4°C. The samples were 
immediately mixed with hybridisation buffer and stored at -20°C until hybridisation.  
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Hybridisation 
To the labelled DNA in a final volume of 264.5µl, 0.056M MES, 5% DMSO (Sigma®), 2.5x 
Denhardt’s solution (Sigma®), 5.77mM EDTA (Ambion), 0.115mg/ml Herring Sperm DNA 
(Promega), 1x Oligo control reagent (OCR 0100, Affymetrix®), 11.5µg/ml of Cot1 Human 
DNA (Invitrogen), 0.01% Tween 20 (Pierce), 2.69M TMACL (Sigma®).  
The hybridisation cocktail was heated to 99°C for 10 minutes, placed on ice for 10 seconds, 
spun down briefly and incubated at 49°C for 1 minute. 200µl of the hybridisation cocktail 
was loaded into the Affymetrix® 250K Nsp or 250K Sty chip and incubated at 49°C for 18 
hours.  
Washing 
The washing station for Affymetrix® Genechips® is an automated system requiring the stain 
solutions and the wash buffers. The Mapping 500Kv1_450 protocol was initiated after 
priming the fluidics station with the Prime_450 protocol.  
Buffers 
1M Tris  
60,57g Tris 
(Merck) buffer 
400ml H2O 
pH8 
adjust to 500ml 
 
 
 
 
1M Na2EDTA 
93,06g EDTA 
(Merck) 
400ml H2O 
pH 8 with NaOH 
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12X MES stock 
(Store at 4 degrees 
and shield from 
light) 
 
1.25M MES 
0.89M Na+ 
70,4g MES hydrate 
(Sigma®) 
193,3g MES sodium 
salt (Sigma®) 
800ml H2O 
pH 6.5-6.7 
 
Stain buffer 
In a final volume of 1188µl, 6x SSPE (Accugene®, Lonza), 0.01% Tween 20 (Pierce) and 1x 
Denhardt’s (Sigma®) solution were added. This buffer was split into two tubes of 594µl, in 
one tube a final concentration of 10µg/ml of SAPE (Molecular Probes) was added and in the 
other, 5µg/ml of antibody (Vector laboratories). A third vial containing 830µl of array hold 
solution was added. These vials are loaded into the appropriate positions on the fluidics 
station.  
Wash buffer A  
6X SSPE, 0.01% tween 20 (Pierce) 
300ml 
20X SSPE (Accugene®, Lonza) 
1ml 10% Tween 20 
699ml H2O 
Filter through 0.2um filter 
(Nalgene) 
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Wash buffer B 
0.6%SSPE, 0.01% 
Tween20 
30ml 10XSSPE 
1ml 10% tween20 
969ml H2O 
pH8 
Filter through 0.2um 
filter 
1X array hold buffer 
100mM MES (Sigma®) 
1M Na+ 
0.01% Tween 20 
8,3ml 12X MES 
18,5ml 5M NaCl (Ambion) 
0.1ml of 10% Tween20 
73.1ml water 
Store at 4 degrees 
Shield from light 
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Array assay results 
Table C1. Results of the 500K assay for the FFPE OSCC samples 
Batch Sample Dates Nsp PCR result Nsp PCR conc Nsp Frag 
result 
Nsp Call Sty PCR 
result 
Sty PCR 
conc 
Sty Frag result Sty call 
  Nsp Sty         
a UROC16 31/03/2008-
25/03/2008 
20/02/2008-
25/03/2008 
700bp 70,391ug <180bp 73.89 700bp 125,24ug <180bp 74.57 
b UROC20 14/08/2008-
26/08/2008 
11/08/2008-
26/08/2008 
700bp 61,66ug <180bp 71.42 700bp 96,7ug <200bp 71.68 
c UROC22 13/10/2008-
16/10/2008 
20/10/2008-
23/10/2008 
700bp 139,19ug <180bp 74.37 700bp 121.56ug <180bp 74.11 
d UROC26 03/03/2008-
10/03/2008 
20/02/2008-
03/03/2008 
700bp 103,97ug <180bp 79.25 700bp 136,71ug <180bp 79.61 
e UROC29 11/03/2008-
25/03/2008 
10/03/2008-
17/03/2008 
800bp 69,79ug <180bp 69.2 700bp 95,03ug <180bp 67.59 
c UROC30 13/10/2008-
16/10/2008 
20/10/2008-
23/10/2008 
700bp 150,5ug <180bp 75.69 700bp 179,05ug <180bp 80.24 
f UROC31 12/01/2009-21-
01/2009 
20/11/2008-
27/11/2008 
700bp 62,52ug some>200bp 65.62 700bp 130,89ug <180bp 67.45 
g UROC33 4/11/2008-
10/11/2008 
10/03/2008-
17/03/2008 
700bp 142,56ug <180bp 74.41 700bp 102,,6ug <180bp 75.67 
h UROC37 18/03/2008-
25/03/2008 
10/03/2008-
17/03/2008 
700bp 76,11ug <180bp 74.94 700bp 106,34ug <180bp 71.48 
i UROC40 23/03/2009-
26/03/2009 
16/04/2009-
20/04/2009 
700bp 82,42ug <180bp 69.2 700bp 151,96ug <180bp 69.19 
g UROC42 04/11/2008-
10/11/2008 
10/03/2008-
17/03/2008 
700bp 125,99ug <200bp 71.9 700bp 103,03ug <180bp 72.86 
j UROC46 04/05/2009-
08/05/2009 
11/05/2009-
15/05/2009 
>700bp 102,76ug 200bp> 71.6 >700bp 132,87ug <200bp 74.97 
j UROC47 04/05/2009-
08/05/2009 
11/05/2009-
15/05/2009 
>700bp 156,52ug 200bp> 74.96 >700bp 147,06ug <200bp 74.58 
k UROC48 09/02/2009-
11/02/2009 
16/02/2009-
18/02/2009 
700bp 98,47ug <180bp 76.12 700bp 102,64ug <180bp 75.8 
k UROC53 09/02/2009-
11/02/2009 
16/02/2009-
18/02/2009 
700bp 78,12ug <180bp 71.47 700bp 100,79ug <180bp 73.93 
k UROC54 09/02/2009-
11/02/2009 
16/02/2009-
18/02/2009 
700bp 73,1ug <200bp 74.13 700bp 101,05ug <180bp 70.31 
k UROC55 09/02/2009-
11/02/2009 
11/05/2009-
15/05/2009 
700bp 90,16ug <200bp 74.65 >700bp 147,49ug <200bp 72.47 
l UROC59 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 68.37ug <200bp 61.84 >700bp 132.87ug <200bp 64.03 
j UROC60 04/05/2009-
08/05/2009 
11/05/2009-
15/05/2009 
>700bp 157,38ug 200bp> 71.21 >700bp 157,38ug <200bp 75.85 
j UROC62 04/05/2009-
08/05/2009 
11/05/2009-
15/05/2009 
>700bp 185,94ug 200bp> 77.21 >700bp 174,58ug <200bp 82.29 
j UROC63 04/05/2009-
08/05/2009 
11/05/2009-
15/05/2009 
>700bp 140.18ug 200bp> 76.49 >700bp 175,44ug <200bp 80.13 
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m UROC65 10/07/2009-
17/07/2009 
27/07/2009-
31/07/2009 
>700bp 167.3ug <200bp 60.37 >700bp 172.86ug <200bp 66.26 
l UROC67 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 185.33ug <200bp 75.85 >700bp 106.94ug <200bp 70.45 
l UROC69 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 147.49ug <200bp 64.96 >700bp 110.08ug <200bp 66.66 
n UROC70 02/06/2009-
05/06/2009 
08/06/2009-
11/06/2009 
>700bp 69,96ug <200bp 62.11 >700bp 148.92ug <200bp 72.86 
n UROC71 02/06/2009-
05/06/2009 
08/06/2009-
11/06/2009 
>700bp 112.53ug <200bp 68.65 >700bp 170.85ug <200bp 75.73 
n UROC84 02/06/2009-
05/06/2009 
08/06/2009-
11/06/2009 
>700bp 151.96ug <200bp 75.63 >700bp 165.84ng <200bp 83.67 
n UROC86 02/06/2009-
05/06/2009 
08/06/2009-
11/06/2009 
>700bp 118.58ug <200bp 70.37 >700bp 172ug <200bp 83.53 
m UROC87 10/07/2009-
17/07/2009 
27/07/2009-
31/07/2009 
>700bp 185.33ug <200bp 68.7 >700bp 129.56ug <200bp 78.4 
o UROC98 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 234.9ug <200bp 64.65 >700bp 165.12ug <200bp 79.68 
o UROC 103 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 236.8ug <200bp 60.35 >700bp 156.2ug <200bp 66.47 
o UROC124 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 260.3ug <200bp 65.02 >700bp 147.5ug <200bp 66.39 
o UROC125 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 197.6ug <200bp 64.13 >700bp 176.87ug <200bp 67.66 
p UROC128 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 74.16ug <200bp 70.46 >700bp 129.33ug <200bp 71.5 
p UROC130 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 99ug <200bp 66.63 >700bp 164.5ug <200bp 70.64 
p UROC131 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 77.1ug <200bp 62.24 >700bp 151.9ug <200bp 69.61 
p UROC132 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 72ug <200bp 65.2 >700bp 149.87ug <200bp 73.03 
p UROC133 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 83.75ug <200bp 62.83 >700bp 140.71ug <200bp 67.7 
p UROC142 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 120.94ug <200bp 66.44 >700bp 149.1ug <200bp 72.77 
p UROC144 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 132ug <200bp 66.75 >700bp 156.45ug <200bp 74.16 
q UROC148 24/12/2009-
31/12/2009 
24/12/2009-
31/12/2009 
>700bp 81.24ug <200bp 65.2 >700bp 127.8ug <200bp 69.33 
p UROC151 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 99.95ug <200bp 67.45 >700bp 153.98ug <200bp 70.16 
p UROC156 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 163.5ug <200bp 72.51 >700bp 190.96ug <200bp 72.48 
p UROC158 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 160.22ug <200bp 72.11 >700bp 164.79ug <200bp 72.47 
p UROC167 18/12/2009-
23/12/2009 
18/12/2009-
23/12/2009 
>700bp 141.8ug <200bp 67.04 >700bp 143.52ug <200bp 71.1 
q UROC171 24/12/2009-
31/12/2009 
24/12/2009-
31/12/2009 
>700bp 81ug <200bp 69.31 >700bp 134.62ug <200bp 73.27 
q UROC172 24/12/2009-
31/12/2009 
24/12/2009-
31/12/2009 
>700bp 115.96ug <200bp 67.63 >700bp 155.1ug <200bp 72.08 
x 1708/04 29/01/2010-
05/02/2010 
29/01/2010-
05/02/2010 
>700bp 144.67ug <200bp 73.36 >700bp 169.28ug <200bp 78.6 
x 1805/04 29/01/2010- 29/01/2010- >700bp 142.62ug <200bp 69.08 >700bp 161.92ug <200bp 72.62 
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kj05/02/2010 05/02/2010 
x 2134/04 29/01/2010-
05/02/2010 
29/01/2010-
05/02/2010 
>700bp 186.89ug <200bp 79.86 >700bp 186.98ug <200bp 82.53 
x 2136/04 29/01/2010-
05/02/2010 
29/01/2010-
05/02/2010 
>700bp 159.41ug <200bp 77.94 >700bp 210.51ug <200bp 81.68 
Average 
    
 
 
70.05 
 
 
 
73.38 
o UROC104 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 254.13ug <200bp 57.59 >700bp 146.63ug <200bp 67.41 
o UROC106 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 231.2ug <200bp 58.23 >700bp 179.74ug <200bp 66.48 
o UROC108 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 209.84ug <200bp 57.79 >700bp 178.02ug <200bp 65.46 
o UROC122 03/08/2009-
06/08/2009 
06/08/2009-
19/08/2009 
>700bp 229.7ug <200bp 58.96 >700bp 189.2ug <200bp 69.75 
The samples highlighted in turquoise were excluded from analysis due to the low call rates 
Table C2. Table of results of the 500K assay for the FFPE control samples.  
r URCONT3 29/09/2008-
08/10/2008 
16/09/2008-
08/10/2008 
700bp 71,25ug <180bp 59.42 700bp 82,69ug <180bp 65.12 
c URCONT4 13/10/2008-
16/10/2008 
16/09/2008-
25/09/2008 
700bp 71,81ug <180bp 64.56 700bp 77,65ug <180bp 65.94 
s URCONT5 22/09/2008-
29/09/2008 
16/09/2008-
25/09/2008 
700bp 116,1ug <180bp 70.16 700bp 63,6ug <180bp 70.95 
c URCONT6 13/10/2008-
16/10/2008 
16/09/2008-
08/10/2008 
700bp 115,24ug 200bp 73.52 700bp 85,7ug <180bp 73.11 
t URCONT8 27/11/2008-
04/12/2008 
04/12/2008-
10/12/2008 
700bp 141,6ug <180bp 66.27 700bp 94,77ug <180bp 71.97 
t URCONT11 27/11/2008-
04/12/2008 
04/12/2008-
10/12/2008 
700bp 131,88ug <180bp 69.27 700bp 103,50ug <180bp 70.42 
t URCONT13 27/11/2008-
04/12/2008 
04/12/2008-
22/12/2008 
700bp 171,7ug <180bp 69.97 700bp 127,28ug <180bp 63.79 
i URCONT14 23/03/2009-
26/03/2009 
16/04/2009-
20/04/2009 
700bp 118,12ug <180bp 72.85 700bp 154,32ug <180bp 71.35 
u URCONT16 05/01/2009-
08/01/2009 
17/12/2008-
22/12/2008 
700bp 116,23ug 200bp 67.45 700bp 159,23ug 200bp 62.6 
v URCONT19 19/01/2009-
21/01/2009 
02/02/2009--
4/02/2009 
700bp 135,32ug 200bp 73.28 700bp 116,7ug <200bp 78.16 
i URCONT22 23/03/2009-
26/03/2009 
16/04/2009-
20/04/2009 
700bp 82,56ug 200bp 66.74 700bp 139,06ug 200bp 62.97 
k URCONT25 09/02/2009-
11/02/2009 
16/02/2009-
19/02/2009 
700bp 86,43ug <200bp 71.19 700bp 100,79ug <200bp 69.09 
k URCONT26 09/02/2009-
11/02/2009 
16/02/2009-
19/02/2009 
700bp 92,45ug <200bp 79.45 700bp 104,92ug <200bp 81.59 
k URCONT27 09/02/2009-
11/02/2009 
16/02/2009-
19/02/2009 
700bp 88,58ug <200bp 76.41 700bp 97,91ug <200bp 80.07 
k URCONT28 09/02/2009-
11/02/2009 
16/02/2009-
19/02/2009 
700bp 95,32ug <200bp 78.6 700bp 104,92ug <200bp 78.53 
j URCONT29 04/05/2009- 11/05/2009- >700bp 137,17ug 200bp> 68.94 >700bp 148,35ug <200bp 71.71 
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08/05/2009 15/05/2009 
l URCONT32 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 177.16ug <200bp 66.14 >700bp 84.14ug ,200bp 68.09 
l URCONT33 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 175.87ug <200bp 66.45 >700bp 161.25ug <200bp 65.75 
l URCONT34 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 184.47ug <200bp 69.61 >700bp 177.16ug <200bp 67.72 
l URCONT35 18/05/2009-
22/05/2009 
25/05/2009-
29/05/2009 
700bp 188.34ug <200bp 68.07 >700bp 182.6ug <200bp 73.72 
n URCONT37 02/06/2009-
05/06/2009 
08/06/2009-
12/06/2009 
>700bp 160.69ug <200bp 67.43 >700bp 202.5ug <200bp 69.56 
n URCONT38 02/06/2009-
05/06/2009 
08/06/2009-
12/06/2009 
>700bp 193.93ug <200bp 69.14 >700bp 179.31ug <200bp 80.32 
n URCONT39 02/06/2009-
05/06/2009 
08/06/2009-
12/06/2009 
>700bp 158,84ug <200bp 70.59 >700bp 162.54ug <200bp 75.22 
g URCONT41 04/11/2008-
10/11/2008 
20/11/2008-
27/11/2008 
700bp 156,39ug <180bp 71.21 700bp 149,64ug <180bp 72.1 
g URCONT42 04/11/2008-
10/11/2008 
20/11/2008-
27/11/2008 
700bp 148,65ug <180bp 74.39 700bp 119,25ug <180bp 61.19 
n URCONT43 02/06/2009-
05/06/2009 
08/06/2009-
12/06/2009 
>700bp 176,3ug <200bp 72.76 >700bp 182.46ug <200bp 81.27 
m URCONT44 10/07/2009-
17/07/2009 
27/07/2009-
31/07/2009 
>700bp 187.65ug <200bp 66.63 >700bp 132.44ug <200bp 73.45 
m URCONT46 10/07/2009-
17/07/2009 
27/07/2009-
31/07/2009 
>700bp 159.5ug <200bp 60.24 >700bp 113.52ug <200bp 67.67 
w URCONT47 03/08/2009-
07/08/2009 
06/08/2009-
19/08/2009 
>700bp 219.3ug <200bp 69.2 >700bp 207.8ug <200bp 72.35 
w URCONT48 03/08/2009-
07/08/2009 
06/08/2009-
19/08/2009 
>700bp 229.5ug <200bp 71.18 >700bp 165.8ug <200bp 74.12 
w URCONT49 03/08/2009-
07/08/2009 
06/08/2009-
19/08/2009 
>700bp 243.7ug <200bp 79.13 >700bp 196.5ug <200bp 82.88 
w URCONT50 03/08/2009-
07/08/2009 
06/08/2009-
19/08/2009 
>700bp 224.2ug <200bp 66.47 >700bp 153.1ug <200bp 81.7 
average 
    
 
 
70.2355 
 
 
 
72.2374 
 
    
 
 
 
 
 
 
 
The sample highlighted in turquoise was excluded from the analysis. 
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